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Innate lymphoid cells (ILCs) are an emerging family of cells which have been 
well-characterised within the gut and peripheral tissues. Despite being implicated in 
shaping adaptive immune responses, relatively little is known about their function within 
lymph nodes (LNs), important sites for the generation of this type of response. The aim of 
this investigation was to characterise ILC populations within a range of different LNs, both 
at steady state and using a draining LN model to understand their role in an immune 
response. Mice in which a subset of ILC, or key functional molecules, are deficient will be 
used to better understand their function within LNs, with a focus on adaptive immune 
responses. 
My results reveal that ILCs are present in all LNs analysed, however, differences in the ILC 
composition of mucosal tissue and peripheral tissue-draining LNs indicate site-specific 
requirements for these cells. Differing dependencies on CCR7 for ILC entry into LNs were 
observed, consistent with migration of these cells into these secondary lymphoid tissues. 
Within LNs, group 3 ILCs were found to express major-histocompatibility complex class-II 
and specifically locate to sites where adaptive immune responses are initiated and 
maintained. Notably, ILCs accumulated in draining LNs following immunisation and 
whilst their roles here remain unclear they are unlikely to be involved in the priming of 
naïve CD4+ T cells. In summary, I show that subsets of ILC3 are enriched in LNs which 
drain mucosal sites and can be found to locate to crucial sites within LNs following their 
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CHAPTER 1. INTRODUCTION 
 
1.1 THE IMMUNE SYSTEM 
Our immune system protects us from agents which can cause disease, known as 
pathogens, in a variety of different ways; from maintaining the physical barriers which 
prevent pathogen entry, to efficiently eliminating pathogens should these barriers be 
breached. The vast number and variation of pathogens is reflected in the complexity of 
the immune system, which has evolved to defend us against a wide range of different 
threats. The effectiveness of the immune system is largely due to the complex interplay of 
many different immune cells which, to aid understanding, have been grouped into two 
distinct arms; the innate immune system and the adaptive.  
Cells of the innate immune system provide rapid but broad protection in the initial stages 
of immunological challenge, limiting damage to the host whilst the slower-acting adaptive 
immune system mounts a tailored, pathogen-specific defence. Although adaptive 
immunity is more evolutionarily advanced (Cooper and Alder, 2006) the innate immune 
system which pre-dates it is nonetheless highly conserved, thus highlighting the 
importance of both. Innate lymphoid cells (ILCs), a newly-emerging family of cells at the 
cutting-edge of immunological research, epitomise this interplay. Described as cells which 
‘blur’ the lines between innate and adaptive immunity (Lanier, 2013) ILCs have the ability 
to respond rapidly to immunological challenge as cells of the innate immune system, yet 
possess many of the effector functions commonly associated with adaptive immunity. 
This introduction will provide a description of key aspects of the ability of the immune 




which exclude these agents from the internal milieu, to the response of the immune 
system in the event of a breach. The differences between both arms of the immune system 
will be discussed, with an emphasis on the importance of cells of the innate immune 
system in shaping the adaptive immune response. ILCs will be introduced and their far-
reaching and crucial contributions to both innate and adaptive immune responses 
discussed.  
1.2 BARRIER SURFACES 
The first line of host defence are the physical barriers which prevent access of pathogens 
to internal tissues. The epithelial cells which form these surfaces are highly specialised, 
first and foremost to actively prevent the invasion of potentially pathogenic 
microorganisms, but also to alert cells of the innate immune system to a threat should a 
breach occur. Three crucial barrier sites are the skin, and surfaces of the respiratory and 
gastrointestinal tracts. In addition to fulfilling the functional requirements of each site, 
the epithelium at these barrier surfaces is tailored to deal with commonly encountered 
immunological challenges.  
The skin, for example, is formed of multiple layers of tightly joined or cornified cells which 
act as a robust barrier to common insults which could result in infection, such as 
wounding or insect bites (Heath and Carbone, 2013). By comparison, the barrier which 
lines the gastrointestinal tract consists of only a single layer of cells to facilitate the 
absorption of nutrients from food. Given that inflammation or infection at this site in 
healthy individuals is rare, in spite of the large number of microorganisms which colonise 
the gut, it is clear that this barrier is nonetheless highly effective (Peterson and Artis, 




tracts, are referred to as mucosal membranes due to their ability to produce mucin 
proteins. Mucus secretion helps to prevent the adherence of microorganisms to the 
epithelial cell surface, therefore restricting their ability to inflict damage and cause 
infection, as is demonstrated by the increase in intestinal inflammation and membrane 
damage in mice which lack these proteins (Van der Sluis et al., 2006). 
The exposure to and colonisation of these surfaces by a large number of microorganisms 
is unavoidable and can be of benefit to the host.  Microorganisms which reside 
symbiotically on these surfaces are known as the commensal microbiota and benefit the 
host in a number of different ways. In the gut these bacteria help to digest certain food 
molecules and facilitate absorption of nutrients by the host (Brestoff and Artis, 2013), 
whilst at all surfaces the presence of these microbes actually prevents colonisation by 
more harmful, pathogenic strains (Kamada et al., 2013). These commensal microbes can 
however cause tissue damage and spread systemically if barrier surfaces are impaired 
(Sonnenberg et al., 2012), demonstrating how important it is that these barriers are 
properly maintained and quickly healed upon damage. Despite the highly effective 
exclusion of the majority of pathogens, there are occasions when these barriers are 
breached and it falls to cells of the innate immune system to control the spread of the 
infection. Patrolling the inner side of these membranes are innate cells which are capable 
of ingesting and destroying pathogens, and an additional function of epithelial cells is to 
release immunogenic molecules upon damage to alert these cells to the threat (Heath and 




1.3 INNATE IMMUNITY 
On occasions when these barriers are breached it is vital that a protective immune 
response is rapidly initiated to restrict the growth and spread of the pathogen; and this is 
one of the functions of cells of the fast-acting innate immune system. 
Epithelial cells at barrier surfaces have been shown to be immunologically competent, and 
capable of secreting immunological molecules upon damage or infection. Upon 
recognition of pathogenic stimuli, epithelial cells in the skin have been shown to produce 
soluble signalling molecules, known as cytokines and chemokines, which recruit innate 
cells to the skin (Heath and Carbone, 2013), whilst similar is true of epithelial cells in the 
gut (Peterson and Artis, 2014). Tissue-resident mononuclear phagocytes, such as 
macrophages and dendritic cells (DCs) are amongst the first innate cells to respond. These 
cells recognise pathogens through broadly-specific receptors, known as pathogen 
recognition receptors (PRRs), that can bind elements commonly found on the surface of 
foreign organisms, known as pathogen-associated molecular patterns (PAMPs) (Akira et 
al., 2006). This interaction triggers a complex program of signalling events, which results 
in the activation of the innate cell. In addition to phagocytosing and destroying the 
pathogen these activated cells also release cytokines and chemokines, amplifying the 
response of the damaged epithelia and resulting in further innate cell recruitment 
(Mogensen, 2009).  
 Inflammation 
Cytokines are glycoproteins which can induce signalling events in those cells which 
possess a corresponding receptor, and play important roles at many different stages of an 




properties. Binding of a chemokine to its receptor induces the migration of that cell 
towards the source (Griffith et al., 2014). Release of pro-inflammatory cytokines induces 
inflammation at the site of infection. Inflammation results in the cytokine-induced 
upregulation of adhesion molecules on the endothelial cells of the blood vessels, enabling 
immune cells to leave the blood and enter the inflamed tissue; attracted to the site by the 
presence of chemokines (Garrood et al., 2006). Early in an immune response these cells 
include neutrophils and natural killer (NK) cells, which are specialised to kill pathogenic 
microorganisms and infected cells using cytotoxic mechanisms (Basset et al., 2003). The 
innate immune system therefore plays an important role in creating an environment 
which is unfavourable for the pathogen and preventing further spread, whilst also 
recruiting cells to the site which can limit pathogen growth. Sometimes, however, this 
non-specific innate response is insufficient to eliminate the pathogen entirely and it is 
necessary to engage cells of the adaptive immune system. 
 Role in activating adaptive immune responses 
In the event that a pathogen cannot be eliminated by the innate immune system alone the 
adaptive immune system must be alerted. Cells of the adaptive immune response, known 
as lymphocytes, are capable of producing effector molecules which are highly specific to 
the invading pathogen and as a result highly effective at clearing infection. Their 
activation also results in the generation of a population of memory cells, which survive 
long past the primary infection is cleared but remain poised to act should the pathogen 
be encountered again (Sprent, 1997). Despite their importance, however, lymphocytes 
are rarely found at common sites of infection. Instead, and for reasons which will become 




as the lymph nodes and spleen, and it is the responsibility of the innate immune system 
to educate cells of the adaptive immune system to the presence and nature of a threat. 
This function is carried out by antigen-presenting cells (APCs) expressing major-
histocompatibility complex (MHC), such as dendritic cells (DCs), which are known to be 
highly important in this process (Sallusto and Lanzavecchia, 1999). DCs carry both MHC 
class I (MHCI) and MHC class II (MHCII), receptors, which are capable of binding many 
different pathogenic peptides and presenting them on the cell surface (Villadangos and 
Schnorrer, 2007). In doing so, DCs are activated and instructed to transport pathogenic 
peptides to local secondary lymphoid organs where they can be presented to lymphocytes 
(Sallusto et al., 1998). The importance of APCs in this step can be highlighted by the fact 
that T lymphocytes of the adaptive immune system can only recognise antigen carried in 
the context of MHC molecules (Zinkernagel and Doherty, 1974), therefore the innate 
immune system plays an crucial role in initiating the adaptive. 
Whilst cells of the innate immune system possess receptors which are broadly-specific for 
elements commonly found on foreign microorganisms, lymphocytes recognise specific 
antigens. There are a vast number of different potential antigens and correspondingly 
many lymphocytes of different specificities. However, as lymphocytes of each specificity 
are extremely rare the chances of the dendritic cell meeting this cell are seemingly small. 
Lymph nodes and other secondary lymphoid tissues provide the solution, however, by 
providing an organised microenvironment through which lymphocytes can re-circulate 
and which confines the necessary components required for the initiation of an adaptive 
immune response to one area; thus increasing the probability of the interaction of 




2003). Lymph nodes are situated at sites where lymphatic vessels converge and are highly 
numerous in humans (Willard-Mack, 2006). Lymphatic fluid containing both antigen and 
antigen-presenting cells drains from the inflamed site of infection to the local lymph node, 
thus bringing antigenic peptides into contact with lymph node-resident cells (von Andrian 
and Mempel, 2003). Lymph nodes which drain the peripheral tissues and skin are termed 
peripheral lymph nodes, whereas those which drain the gut, airway and other mucosal 
tissues are known as mucosal lymph nodes; and the presence of local lymphoid tissue can 
be important in the generation of a targeted tissue-specific immune response (Kraal et al., 
2006).  
Naïve lymphocytes will circulate through lymph nodes at different sites via the blood and 
are thought to spend less than a day within the lymph node before moving on (von 
Andrian and Mempel, 2003), thereby providing a mechanism by which T cells of many 
different specificities can come into contact with an antigen which they recognise and 
mount a response. In one study it was reported that, in lymph nodes in the absence of 
antigen, at least five hundred different CD8+ T cells came into contact with each DC 
analysed within an hour (Bousso and Robey, 2003). 
1.4 ADAPTIVE IMMUNITY 
The adaptive immune system is comprised of T and B lymphocytes. Following their 
development in primary lymphoid tissues, naïve T and B cells enter the blood and 
recirculate through different secondary lymphoid tissue until they encounter their 
cognate antigen. Both T and B lymphocytes carry somatically rearranged antigen 
receptors, rather than the germline encoded receptors expressed by innate cells, which 




This process depends upon the proteins expressed by recombination-activating genes 1 
and 2 (RAG-1 and RAG-2 proteins), which are essential for recombinase activity, and 
expression of a somatically rearranged T cell (TCR) or B cell receptor is essential for the 
cell’s survival, which is demonstrated by the lack of all B and T lymphocytes in RAG-/- mice 
(Mombaerts et al., 1992).  
 T cells 
Multiple populations of T cells have been described. T cell populations can first be 
separated by the type of TCR that they express. The majority of T cells possess a TCR 
formed from an α-chain and a β-chain, and are therefore known as αβ T cells; whilst a 
small population expresses an alternative receptor formed from γ and δ chains (Girardi, 
2006). γδ T cells, unlike their αβ TCR+ counterparts, often reside in peripheral organs and 
at barrier surfaces (Girardi, 2006). In either case this TCR is expressed on the surface of 
cells in association with CD3, forming what is known as the TCR-CD3 complex, and both 
elements are required for antigen-induced signalling events within the T cell 
(Wucherpfennig et al., 2010). Two main groups of αβ T cells exist, CD4+ ‘helper’ T cells 
and CD8+ ‘killer’ T cells, although other non-conventional cells such as invariant natural 
killer T cells (iNKT) and NKT cells have been recognised. CD8+ T cells are restricted to 
recognising peptide presented by APCs in the context of MHCI, whilst CD4+ T cells 
recognise peptide presented in the context of MHCII. Intracellular-derived peptides are 
loaded onto MHCI molecules and, as a result, the presence of endogenous pathogens, such 
as intracellular bacteria or viruses, will often trigger a CD8+ killer T cell response. MHCII, 
by contrast, binds peptides which have been acquired by APCs from the external milieu 
(Vyas et al., 2008), although such exogenous peptides can also be presented in MHCI 




activity of T cells is important in the clearance of many infections, this investigation will 
focus primarily on the functions of CD4+ T cells.  
 CD4+ T cell activation 
CD4+ T cells continuously sample antigens presented by DCs in secondary lymphoid 
tissue. Upon coming across an antigen which they recognise the CD4+ T cell and APC form 
an immunological synapse (Monks et al., 1998); with the T cell TCR binding to 
peptide:MHCII on the surface of the APC in an interaction stabilised by the presence of 
CD4 (Madrenas et al., 1997). Although this interaction is indispensable for T cell 
activation, it alone is insufficient (Mueller et al., 1989). T cells require additional signalling 
through co-stimulatory receptors expressed by professional APCs in order to become 
activated. This secondary activation signal ensures that CD4+ T cells do not become 
activated inadvertently in the absence of infection, which could result in damaging 
immune-mediated pathologies. In the event that such inappropriate activation does occur 
T cells will become unresponsive to further stimuli, rendering them anergic (Schwartz, 
2003). Co-stimulatory molecule signalling is complex, however the most 
well-characterised interactions occur between CD28 on the T cell and ligands of the B7 
family, CD80 and CD86, on the professional APC (Chen and Flies, 2013). Recognition of 
antigen and appropriate co-stimulation results in the activation and clonal expansion of 
the T cell, and T cell proliferation is markedly reduced in mice where T cells lack CD28 
(Green et al., 1994). Activated CD4+ T helper cells can then activate other cells to become 
involved in the immune response, for example by providing co-stimulation to B cells, and 




 T helper cell subsets 
The immune system has the capacity to deal with a wide range of different pathogens, 
from intracellular bacteria and viruses to extracellular bacteria, fungi and parasites. Given 
the differences in the mechanisms of infection of these pathogens the immune system 
often has to mount a highly tailored and pathogen-specific immune response to clear 
them, and this is in part carried out by different subsets of CD4+ T helper cells. Following 
activation, T helper cells can develop different pathogen-specific effector functions, 
depending on signals which they receive following activation and the gene expression 
programs which these promote. Given that T cells are activated in secondary lymphoid 
organs and not at the site of infection, it is the job of the antigen-presenting cell to provide 
these signals; educating the T helper cell to the nature of the threat and eliciting the 
appropriate response (Walsh and Mills, 2013). For example, intracellular bacteria and 
viruses require what is commonly known as a type 1 immune response, characterised by 
phagocytic activity, whilst expulsion of extracellular parasite infections requires a type 2 
immune response. CD4+ T helper cells can be induced to acquire these effector functions 
through a process called differentiation, and differentiated cells can be assigned to four 
main subsets based on their expression of transcription factors and cytokines; T helper 1 
(Th1), Th2, Th17 and T regulatory cells (Treg) (Zhu et al., 2010). 
Th1 and Th2 cells were first discovered as populations of CD4+ T cells which could 
produce vastly different effector cytokines, yet arose from the same murine CD4+ T cell 
clone (Mosmann et al., 1986, Killar et al., 1987), a principle which could also be applied in 
parts to CD4+ T cells from humans (Umetsu et al., 1988). Two further subsets, Th17 (Park 
et al., 2005, Harrington et al., 2005) and Treg (Chen et al., 2003) cells were later identified; 




al., 2005). The phenotype of each T helper cell results from its decision to upregulate the 
expression of known master transcription factors which, with the help of activator of 
transcription (STAT) proteins, induce the expression of the molecules associated with 
each subset. 
Th1 cells express the transcription factor T-bet and the cytokines IFN-γ, IL-2 and TNF-α. 
IFN-γ expression has been shown to correlate to, and depend upon, expression of T-bet 
(Szabo et al., 2000). Th1 cells form in the presence of the cytokines IFN-γ and IL-12 and 
are important in defence against so-called type 1 immune responses; those involving 
intracellular bacteria and viruses. Th2 cells express GATA-3 (Zhu et al., 2004) and secrete 
the cytokines IL-4, IL5 and IL-13 which help in the expulsion of parasites and contribute 
to allergic inflammatory responses. The presence of TGF-β and IL-6 or IL-21 results in 
CD4+ T cell expression of the transcription factor RORγt and differentiation into Th17 cells 
(Korn et al., 2009). Th17 cells are primarily known for their ability to release the cytokine 
IL-17A and have been implicated in inflammatory immune responses to extracellular 
bacteria and fungi (Korn et al., 2009). A reciprocal relationship exists between Th17 cells 
and regulatory T cells. Similarly to Th17 cells, differentiation of naïve CD4+ T cells into 
Tregs requires signalling by TGF-β, but in this case in the absence of IL-6 and IL-21. There 
are two types of regulatory T cell: natural Tregs, which develop in the thymus, and those 
which are induced from naïve CD4+ T cells in the periphery (Liston and Gray, 2014). 
Activation and exposure of peripheral naïve CD4+ T cells to TGF-β, in the absence of IL-6 
and IL-21, results in their expression of the transcription factor FoxP3 (Chen et al., 2003) 
and differentiation into cells with immunosuppressive functions, which serve to dampen 
potentially damaging autoimmune and inflammatory immune responses. Interestingly in 




reports of plasticity between Th17 cells and Tregs. Th17 cells have been shown to 
‘transdifferentiate’ into cells with a regulatory capacity during an immune response 
(Gagliani et al., 2015), whilst there have been reports of Tregs expressing RORγt (Yang et 
al., 2015). Once the CD4+ T helper cell has acquired its specific effector functions, it can 
target the invading pathogen by modifying the effector functions of other immune cells 
and expressing homing molecules which enable it to migrate directly to the site of 
infection (Butcher and Picker, 1996, von Andrian and Mempel, 2003). 
 Innate immunity shapes adaptive immune responses 
Dendritic cells have previously been described as ‘converter stations’; cells which 
recognise input signals from pathogens and innate cells, then convert these into output 
signals which can be communicated to the adaptive immune system (Walsh and Mills, 
2013). Input signals can come from direct interaction with pathogens, through binding of 
dendritic cell PRRs to pathogenic proteins, and signalling from other cells, such as 
neutrophils, NK cells and even cells of the damaged epithelia. The output signals, in 
addition to the initial presentation of pathogenic antigens and provision of co-stimulatory 
signals, are primarily the production of APC-derived cytokines which influence the 
polarisation of naïve CD4+ T cells (Walsh and Mills, 2013). Therefore although it is the 
cytokine milieu which surrounds the CD4+ T cells in the secondary lymphoid tissue which 
ultimately dictates its differentiation, this has been influenced by the innate immune 
system and pathogen itself. 
For these reasons a better understanding of cells which make up the innate immune 
system is vital, particularly in regards to their potential as therapeutic targets. It is also 




appreciated innate cell types has garnered substantial interest. This new family of cells, 
named the innate lymphoid cells (ILCs) (Spits et al., 2013), respond rapidly to 
immunological challenge, as cells of the innate immune system, and have found to be 
enriched at barrier surfaces. However, strikingly these cells possess effector functions 
which are more commonly associated with T helper subsets and as such many have 
fittingly been branded as ‘innate helper cells’.  
1.5 INNATE LYMPHOID CELLS (ILCs) 
Innate lymphoid cells have been separated into three distinct groups based on their 
expression of transcription factors and cytokines, in a similar manner to that discussed 
above for T helper subsets (Figure 1.1). This family now includes a range of different cells, 
including those previously known, such as conventional NK cell populations and a 
previously defined population of lymphoid tissue inducer (LTi) cells. Their ability to 
rapidly respond to immunological challenge without specific interaction with cognate 
antigen marks these cells as part of the innate immune system, however their functional 
properties have up until now been associated primarily with T helper cells (Walker et al., 
2013). These cells have already been implicated in a number of important roles in the 
immune system at steady state and during disease, and these are discussed in more detail 
below. Nonetheless, as with most immune cells, if control mechanisms break down 
subsets of ILCs can be participants in immune-mediated pathologies, such as chronic 
inflammation in the gut (Buonocore et al., 2010, Geremia et al., 2011). For this reason it is 
vital that we better understand these cells, in the hope that they will provide valuable new 





A uniform nomenclature has been established (Spits et al., 2013), segregating groups of 
ILCs based on the transcription factors and cytokines that they express, in a similar 
manner to that described for T helper subsets. Although separated into three distinct 
groups, all ILCs can be characterised by their lack of expression of lineage markers which 
are associated with other cell populations—most importantly the lack of a somatically 
rearranged antigen-specific receptor (Walker et al., 2013)—and, in the most part, on their 
reliance on signalling through IL-7 for survival (Vonarbourg and Diefenbach, 2012) and 
consequent high levels of IL-7Rα. 
 Group 1 ILCs 
Group 1 ILCs, like Th1 cells, express the transcription factor T-bet and secrete IFNγ and 
TNF (Klose et al., 2014). Included within this group are conventional NK cells and a 
distinct population of cells referred to as ILC1 (Spits et al., 2013). Although often included 
in this group, conventional NK cells have recently been found to be developmentally 
distinct from ILC1 (Klose et al., 2014), and unlike other ILCs, do not depend upon GATA-3 
expression during development (Yagi et al., 2014, Serafini et al., 2014), nor IL-7 signalling 
for survival (Satoh-Takayama et al., 2010). It has therefore been proposed that those ILCs 
which express IL-7Rα and lack cytotoxic function be classed as ‘helper-like ILCs’ (Klose et 
al., 2014), thereby excluding conventional NK cells, and it is these cell types which will be 
focused on in this investigation. 
Although considered a distinct cell type, studies into the plasticity of ILCs has revealed 
that cells within a different group of ILC can, under certain circumstances, closely 




challenging (Klose et al., 2014, Spits et al., 2013) and it is not yet clear whether ILC1 
represent a distinct cell type or simply a transition state of group 3 ILCs. 
 Group 2 ILCs 
ILC2, like Th2 cells, secrete cytokines associated with a type 2 immune response, 
including IL-4, IL-5, IL-9 and IL-13 (Artis and Spits, 2015). ILC2 were first identified as 
innate sources of type 2 cytokines which did not express markers associated with 
commonly-known cell lineages (Fort et al., 2001, Hurst et al., 2002), however were better 
characterised in three, almost simultaneous, seminal publications. Cells which expressed 
type 2 cytokines but lacked lineage markers were found to be present in a number of 
different tissues, and to increase in number substantially upon administration of the type-
2-immunity inducing cytokines IL-25 and IL-33 (Neill et al., 2010, Price et al., 2010, Moro 
et al., 2010). These cells were still present in RAG-/- and RORγt-/- mice, indicating that they 
did not belong to the adaptive immune system and were not members of the already 
known population of lineage negative LTi cells, despite obvious similarities (Neill et al., 
2010, Moro et al., 2010). Similar cells which responded to IL-25 and IL-33 were also 
identified within human tissue (Mjosberg et al., 2011, Monticelli et al., 2011)  and are now 
widely known as ILC2 (Spits et al., 2013).  
Again with notable similarity to Th2 CD4+ T cells, ILC2 were shown to express high levels 
of the transcription factor GATA-3 in both mice (Hoyler et al., 2012) and humans 
(Mjosberg et al., 2012). GATA-3 has been shown to be essential for the development of not 
only ILC2 (Hoyler et al., 2012), but all subsets of helper-like ILCs (Serafini et al., 2014, Yagi 
et al., 2014), however only ILC2 require GATA-3 for homeostatic survival despite this 




Although ILC3 expressing low levels of GATA-3 do not make type 2 cytokines there is a 
report of ILC2 being able to make Th17-associated cytokines under certain circumstances 
(Huang et al., 2015), suggesting some degree of plasticity between the subsets.  
In addition to transcription factors and cytokines ILC2 can also be defined by the surface 
markers that they express. Like all helper-like ILCs they express IL-7Rα, and their 
expression of receptors for IL-25 and IL-33 is well established (Neill et al., 2010). ILC2 can 
also be identified using their high levels of the co-stimulatory molecule ICOS and the IL-2 
receptor CD25, and Sca-1 (Walker and McKenzie, 2013). Expression of KLRG-1 has also 
been reported on intestinal ILC2 and proposed to be a marker of ILC2 maturation (Hoyler 
et al., 2012) and high level expression of this molecule has been reported on a specific 
subset of ILC2, described as ‘inflammatory’ ILC2 (Huang et al., 2015).  
 Group 3 ILCs 
The final group of ILCs include those which secrete IL-17 and IL-22 and express the 
transcription factor RORγt, which is essential for their development (Eberl et al., 2004), 
and therefore in many ways resemble Th17 cells. Members of this group include the 
prototypic lymphoid tissue inducer (LTi) cell. The presence of LTi cells during embryonic 
development is essential for the development of lymph nodes and Peyer’s patches in the 
gut. In RORγt-/- mice, where the transcription factor RORγt is absent from all cells, LTi 
cells fail to develop and as a result lymph nodes and Peyer’s patches do not form (Sun et 
al., 2000, Eberl et al., 2004). 
RORγt+ ILCs can be further divided by their expression of the chemokine receptor CCR6, 
distinguishing two distinct cell lineages although both depend upon expression of RORγt 




classical LTi cells; they develop from a common lymphoid progenitor in the bone marrow, 
can be found in the fetal small intestine during embryonic development and express both 
IL-17 and IL-22. CCR6- ILC3 on the other hand can only be detected in significant numbers 
postnatally, increasing in number in the small intestine with age, in a process which 
required proliferation (Klose et al., 2013).  
Arising from this CCR6- population (Klose et al., 2013), is a subset of ILC3 which express 
the natural cytotoxicity receptor (NCR) NKp46, most commonly found on NK cells, the 
transcription factor RORt and produce IL-22. These NCR+ ILC3 develop from NCR- ILC3 
but not NK cells (Vonarbourg et al., 2010)  and their phenotype and function depends 
upon gradients of the transcription factors which they express. T-bet expression had been 
detected by NKp46+ ILC3 in the gut (Sciume et al., 2012), whilst Klose et al (2013) showed 
that expression of T-bet by CCR6- NKp46- RORt+ ILC3 enabled these cells to upregulate 
NKp46 and express the type 1 cytokine IFN. Accordingly, although CCR6- ILC3 could be 
detected in T-bet-/- mice, NCR+ ILC3 were absent (Klose et al., 2013). Upregulation of T-bet 
by ILC3 was found to be dependent upon the presence of commensal microbiota (Klose 
et al., 2013), and NCR+ ILC3 numbers were reduced in germ-free mice (Sanos et al., 2009). 
Similar IL-22 producing cells have also been identified in humans (Cella et al., 2009, 
Cupedo et al., 2009). Strikingly, studies have shown that in addition to upregulating 
expression of T-bet, CCR6- ILC3 are capable of downregulating their expression of RORγt. 
These so-called ‘ex-RORt’ ILCs can express IFN-γ and have a diminished ability to express 
IL-22, and as a result in many ways resemble ILC1 (Vonarbourg et al., 2010, Klose et al., 




1.6 FUNCTIONS OF ILCs 
Given their similarity to subsets of CD4+ T helper cells yet ability to respond rapidly as 
members of the innate immune system, there has been a great deal of interest in what 
previously unappreciated roles cells of this family could be playing in the immune system 
at steady state and during immune responses. Similar to T helper cell subsets, innate 
helper-like ILCs have been implicated in both direct and indirect immunity to infection by 
a range of different pathogens, and ILCs have been found to be enriched at barrier sites 
which are susceptible to colonisation or invasion by microorganisms.  
 Gut 
Secretion of cytokines by ILCs in the intestine has been shown to aid defence against 
bacterial and parasite colonisation. Secretion of IFN-γ by CD127+ ‘helper-like’ ILCs—
including ILC1 and those NKp46+ T-bet+ ILCs which expressed low levels of, or had 
previously expressed, RORγt— has been shown to be important in the defence against S. 
Typhimurium infection. IFN-γ produced in this context has been found to stimulate 
epithelial cells to produce mucin proteins, which prevent bacterial adherence and 
colonisation, and CD127+ ILCs were found to be the main source of this cytokine following 
infection (Klose et al., 2013). Absence of type 2 cytokines early in an immune response to 
helminth infection has been associated with impaired ability to expel parasites. Provision 
of these cytokines, most importantly IL-13, by lineage negative innate cells may 
contribute to the induction of mucus production by intestinal epithelial cells and muscle 
contractility which promotes expulsion of the worms (Oliphant et al., 2014). Secretion of 
IL-22 by ILCs was also found to be crucial in defence against infection with the 
extracellular bacterium C. rodentium in the colon. CD4+ LTi-like ILC3 were found to be key 




cells of the adaptive immune system (Sonnenberg et al., 2011). IL-22 in the context of this 
infection was shown to induce the production of antimicrobial proteins by colonic 
epithelial cells, resulting in a more effective defence during this infection (Zheng et al., 
2008). 
IL-22 was also shown to be important in maintaining intestinal homeostasis at steady 
state, after IL-22 producing ILCs were detected in the intestinal tissues of healthy mice, 
and depletion of ILCs in Rag-/- mice resulted in dissemination of an otherwise contained 
commensal bacteria species to the spleen and liver (Sonnenberg et al., 2012). In addition, 
production of IL-22 and expression of lymphotoxin (LT) by ILC3 promotes the 
fucosylation of epithelial cells in mice, disruption of which resulted in an increased 
susceptibility of mice to infection by S. Typhimurium (Goto et al., 2014).  
Besides these roles in protecting the integrity of the intestinal barrier and preventing 
pathogen colonisation, ILCs have been shown to influence other immune cells. Given the 
intestinal tissues exposure to a wide range of commensal bacterial and food antigens, in 
addition to those of harmful pathogens, it is vital that immune responses at this surface 
are highly regulated as inappropriate immune responses can result in immune-mediated 
pathologies (Pabst and Mowat, 2012). ILCs, in particular ILC3s, have been shown to 
interact with cells of the adaptive immune system to promote a tolerogenic state, and thus 
maintain this fine balance in a number of direct and indirect ways. ILC3 have been shown 
to produce colony stimulating factor (CSF) -2 in response to signals from mononuclear 
phagocytes (MNP), such as dendritic cells and macrophages, which in turn promotes MNP 
support of intestinal Tregs (Mortha et al., 2014). Although this demonstrates an indirect 




the discovery that subsets of ILC could express the molecule MHCII and process and 
present peptide; thus giving them a clear mechanism by which to interact directly with 
CD4+ T cells. MHCII was reported to be expressed on ILC2 (Neill et al., 2010) and ILC3 
(Hepworth et al., 2013), although there have been indications that expression of this 
molecule by ILC2s differs between tissues (Oliphant et al., 2014). Despite being shown to 
express functional MHCII and present peptide to CD4+ T cells in vitro, it was reported that 
ILC3 do not express the co-stimulatory molecules required to provide further signals to 
CD4+ T cells (Hepworth et al., 2013). Classically it is thought that provision of antigen 
without further stimulation through CD28 by co-stimulatory molecules on the APC results 
in T cell anergy rather than activation (Schwartz, 2003). Certainly when the function of 
MHCII on ILC3 was investigated in vivo, using mice where MHCII was specifically deleted 
on ILC3 only, CD4+ T cell responses to commensal bacteria were found to be expanded, 
supporting the notion that these cells promote tolerance to commensal bacteria in the 
intestine (Hepworth et al., 2013). It has subsequently been shown that ILC3 are capable 
of inducing T cell apoptosis in a MHCII-dependent manner (Hepworth et al., 2015), and 
therefore are likely to contribute to the deletion of commensal bacteria-specific CD4+ T 
cells in the gut. It is possible, however, that the roles performed by MHCII+ ILC3 are 
dependent upon location, following reports that ILC3 derived from the spleen can express 
CD80 and CD86 (von Burg et al., 2014). 
ILC2 can also express MHCII, and MHCII+ ILC2 have been implicated in immune responses 
to helminth infections in the gut (Oliphant et al., 2014). A type 2 immune response is most 
effective at expelling parasites and the production of type 2 cytokines by Th2 cells and 
innate cells, such as eosinophils and alternatively activated macrophages in response to 




producers of IL-13 early in immune responses to the helminth N. Brasiliensis, and ILC2-
derived IL-13 was found to contribute to the expulsion of these parasites (Neill et al., 
2010, Price et al., 2010). Further investigation revealed that the induction of IL-13 
production was in fact dependent upon cross-talk with CD4+ T cells via MHCII expressed 
on the surface of ILC2. Both murine and human ILC2 have been shown to be capable of 
presenting antigen to CD4+ T cells in an interaction which resulted in the proliferation of 
the T cells in vitro (Oliphant et al., 2014); made possible by their expression of CD80 and 
CD86, whose expression has been contentious on ILC3 (Hepworth et al., 2013, von Burg 
et al., 2014). In the context of N. Brasiliensis infection, MHCII-expression by ILC2 and 
interaction with T cells is required for efficient IL-13 induced worm expulsion (Oliphant 
et al., 2014). 
 Lung 
ILCs in the lung have been previously assigned protective roles, from ILC2 enhancing 
tissue repair following viral infection (Monticelli et al., 2011) to ILC3-derived IL-22 
limiting allergic inflammation (Taube et al., 2011), however they have also been shown to 
take a pro-inflammatory role. Group 2 ILCs were found to promote airway 
hyper-responsitivity in mice following infection with H3N1 influenza virus (Chang et al., 
2011). Their expression of type 2 related cytokines has been found to exacerbate 
pro-inflammatory responses within the lung (Barlow et al., 2012) and to influence 
adaptive immune responses in allergic inflammation through signalling to DCs. Following 
intranasal treatment with papain, ILC2-derived IL-13 was found to be important for the 
differentiation of CD4+ T cells into those with a Th2 phenotype. Further investigation 
revealed that this was through promoting trafficking of DCs to the draining LN where they 




2014). In accordance with a role in allergic inflammation in humans, patients with chronic 
rhinosinusitis have elevated numbers of ILC2 (Mjosberg et al., 2011). 
 Skin 
Recent publications have also identified group 2 and 3 ILCs in the skin. Group 2 ILCs have 
been detected in the skin of both humans and mice, and found to be enriched in number 
in lesions of patients with atopic dermatitis, where they are suspected to contribute to the 
inappropriately activated pro-inflammatory type 2 immune response (Salimi et al., 2013). 
The presence of ILC2 in the skin has also been confirmed in healthy mice (Roediger et al., 
2013), and these cells have been shown to cluster and interact with basophils during 
cutaneous inflammation (Kim et al., 2014). Group 3 ILCs in the skin, along with 
populations of γδ T cells, were found to be key producers of IL-17A, IL-17F and IL-22, 
rather than the Th17 cells with which these cytokines are commonly associated. Loss of 
expression of these cytokines in mice resulted in a reduction in the severity of an induced 
form of psoriasis, therefore providing a link between these cells and inflammatory skin 
conditions (Pantelyushin et al., 2012). Additionally, study of skin and peripheral blood of 
patients with psoriasis revealed populations of NKp44+ ILC3, the frequency of which was 
increased when compared to healthy controls (Villanova et al., 2014). 
 Secondary lymphoid tissue 
ILCs have also been detected in a range of different secondary lymphoid organs. The 
essential role of RORγt-expressing ILCs in the development of lymph nodes and Peyer’s 
patches (PPs) was established over a decade ago. Lymphoid tissue inducer cells, now 
considered a member of the group 3 ILCs, can first be detected within the embryo at 




of lymph nodes (Eberl et al., 2004). During the formation of lymph nodes provision of 
LTα1β2 signals to LTβR+ stromal cells is essential for the subsequent recruitment of 
hematopoietic cells and development of these structures (Mebius, 2003). Signalling to 
LTβR+ stromal cells results in their expression of chemokines—including CCL19, CCL21 
and CXCL13—which attract lymphocytes and adhesion molecules which then retain these 
cells within the anlagen (Mebius, 2003). LTi cells, initially characterised as cells which 
expressed CD4 but not CD3 (Kelly and Scollay, 1992), were found to be some of the first 
hematopoietic cells to enter these areas and shown to express LTα1β2 (Mebius et al., 
1997, Cupedo et al., 2002). The observation that these cells were absent from mice which 
had impairments in lymphoid tissue organogenesis, those which lacked Id2 (Yokota et al., 
1999) and later RORt (Sun et al., 2000), clearly demonstrated their importance to this 
process. LTi cells were found to be the only RORt expressing cells during mouse fetal life 
(Eberl et al., 2004) and their absence in RORt-/- mice corresponded with a lack of lymph 
nodes and PPs, but no effect on the development of the spleen (Sun et al., 2000). 
Furthermore, transfer of fetal CD4+ CD3- cells into neonatal mice which lacked Peyer’s 
patches was sufficient to induce Peyer’s patch formation (Finke et al., 2002).  
Cells with a comparable phenotype were later described within adult mouse lymph nodes 
(Kim et al., 2003) and found to play a role in repairing secondary lymphoid tissue, which 
appeared in some ways related to their lymphoid tissue inducing functions (Scandella et 
al., 2008). For example, cells which resembled LTi cells in secondary lymphoid tissues of 
mice were found to aid the repair of lymphoid tissues damaged by viral infection in a 
LTβR-dependent manner (Scandella et al., 2008). There have, however, also been a 




immune system, given the importance of secondary lymphoid tissue for adaptive immune 
responses. CD4+ CD3- cells identified in adult mice were shown to share many gene 
transcripts with neonatal CD4+CD3- cells, but additionally expressed the co-stimulatory 
molecules OX40L and CD30L (Kim et al., 2006, Kim et al., 2005), signalling by which has 
been shown to be important for the generation of CD4+ T cell-dependent memory 
antibody responses (Kim et al., 2003, Gaspal et al., 2005). Persistence of a memory CD4+ 
T cell population has been shown to be dependent upon these cells, with mice in which 
LTi cells are depleted using a bone chimera method demonstrating that LTi cells are a key 
RORt-expressing cell type required for CD4+ memory cell maintenance (Withers et al., 
2012). This study however focused only on immune responses in the spleen, with there 
being inherent difficulties in studying the absence of these cells in lymph nodes given the 









Figure 1.1 Comparison of T helper subsets and ILCs 
Figure showing simplistically some of the similarities and shared effector functions of T helper cells and 
ILCs, with a focus on the roles of these cells in infection (Zhu et al., 2010, Artis and Spits, 2015). 
Transcription factors and signature cytokines which each cell type can express are shown. ILC subsets 
shown are restricted to so-called helper-like ILCs. ILC3 here focuses on those RORγt+ ILCs which express 





1.7 AIMS OF THIS INVESTIGATION 
The overall aim of this investigation was to characterise subsets of ILCs in secondary 
lymphoid tissue with a particular focus on lymph nodes. Investigations up until this point 
have primarily focused on the role of these cells in peripheral tissues and at barrier sites, 
with comparatively less known about their function in adult lymph nodes. Nonetheless, 
these cells are increasingly being implicated in influencing adaptive immune responses, 
the mounting of which takes place primarily within secondary lymphoid tissue, therefore 
it is vital that we understand the behaviour of ILCs better at these sites.  
In this investigation we sought to: 
1. Characterise ILC populations within a range of different lymph nodes and 
investigate whether differences can be detected between those which drain 
different sites. 
2. Investigate the behaviour of ILC populations in draining lymph nodes following 
immunisation, with an emphasis on determining whether they could influence an 
immune response. 
3. Begin to understand the mechanisms by which these cells enter lymph nodes in 
the first place to determine whether or not they are consistent to trafficking from 
mucosal and peripheral tissues, and to provide an insight into their possible roles 




CHAPTER 2. MATERIALS AND METHODS 
 
2.1 MICE 
Mice were used in accordance with Home Office guidelines and maintained at the 
 Wildtype (WT) mice were 
either bred and maintained in the or sourced from an external supplier (Harlan or 
Charles River), whilst all transgenic mice were bred and maintained in the 
Externally sourced WT mice were female, but derived mice used were of both 
genders. Efforts were made to ensure that mice used were age and sex-matched within 
experiments, and -derived transgenic mice were compared to derived 
controls. All mice used in this investigation were on a C57BL/6 background and can be 
found in Table 2.1. 







CD45.1 WT  
C57BL/6 CD45.2 WT  or external 
suppliers 
C57BL/6 x BoyJ CD45.1 
CD45.2 
WT  
Ccr7-/- CD45.2 Deficiency in expression of the 
chemokine receptor CCR7. Results in 
impaired ability of cells to respond to 
the chemokines CCL19 and CCL21. 
A kind gift from 
Prof. A Rot, 
University of 
York. 
Cd80-/-Cd86-/- CD45.2 No expression of co-stimulatory 
ligands CD80 or CD86. Mice are 
unable to provide co-stimulation to T 
cells via these ligands resulting in an 









OTII CD45.2 OTII mice with high numbers of CD4+ 
T cells specific for OVA323-339 
(Barnden et al., 1998). 
OTII mice 
a kind gift from 
Prof. W Heath 
and Prof. F 
Carbone. 
Rag-/- CD45.2 Impaired ability for lymphocytes to 
undergo somatic recombination and 
consequent failure to survive. No 
mature T or B lymphocytes 
(Mombaerts et al., 1992). 
 
Rag-/- x OTII CD45.1 
and/or 
CD45.2 
OTII mice with high numbers of CD4+ 
T cells specific for OVA323-339 
(Barnden et al., 1998) were crossed 
onto a Rag-/- background to generate 
mice with OTII T cells but no other 
lymphocytes. 
OTII mice 
a kind gift from 
Prof. W Heath 
and Prof. F 
Carbone. 
Rag-/- x SM1 CD45.1 
and/or 
CD45.2 
SM1 mice with high numbers of CD4+ 
T cells specific for a peptide of 
flagellin, (427-441)-I-Ab (McSorley et 
al., 2002), were crossed onto a Rag-/- 
background to generate mice with 
SM1 CD4+ T cells but no other 
lymphocytes. 
a kind gift 
from Prof. S 
McSorley. 
Rorc(γt)-/- CD45.2 Deficiency in RORγt expression 
results in impaired survival of 
thymocytes and absence of cell types 
which require this transcription 
factor for development. This includes 
LTi cells and populations of RORγt+ T 
cells. Absence of LTi cells abrogates 
the formation of LNs or Peyer’s 
patches in these mice (Sun et al., 
2000). 
a kind gift 
from Prof. D 
Littman. 
Rorc(γt) cre x R
osa26 eYFP 
CD45.2 Fate mapping mice in which 
expression of Cre recombinase in 
cells which express Rorc(γt), 
resulting in the removal of a floxed 
STOP sequence and expression of 
eYFP by those cells.  
Rosa26 eYFP 
mice a kind gift 
from  
 
Zap70-/- CD45.2 Deficiency in expression of the 
protein tyrosine kinase ZAP-70 
results in impaired T cell 
development and absence of CD4+ or 






2.2 MEDIUM AND REAGENTS 
 Medium 
Table 2.2 Culture medium for overnight culture of cells 
Medium and additives Final Concentration Supplier 
RPMI 1640 with 
L-glutamine 
 Gibco 
Heat inactivated fetal 
bovine serum (FBS) 
10% Sigma-Aldrich 





Table 2.3 Staining buffer for flow cytometry 
Medium and additives Final Concentration Supplier 




Heat inactivated FBS 2% Sigma-Aldrich 
 
Table 2.4 Staining solution for immunofluorescence microscopy 
Medium and additives Final Concentration Supplier 
PBS  Sigma-Aldrich 




 Gey’s solution 
Gey’s solution red blood cell lysis buffer was made within the laboratory from the 
solutions detailed below. Stock solutions A-C were made to 1L final volume with distilled 
water and autoclaved prior to use. Gey’s solution was made by mixing 10ml Solution A, 









KH2PO4 0.119g  
Na2HPO4.12H2O 1.5g 
NH4Cl 35g 
1% Phenol red 1.5ml 
 










2.3 PREPARATION OF CELL SUSPENSIONS 
 Lymph nodes 
Lymph nodes were isolated from mice and placed in small petri dishes (Nunclon, Thermo 
Scientific) with RPMI. Any fat lining the outside of the LN was removed under a 
microscope using forceps. Forceps were then used to tease the LNs apart and release the 
cells. LN tissue was then incubated, in a standing incubator for 25 minutes at 37°C, in 
RPMI with 250μg/ml Collagenase-Dispase (Roche) and 25μg/ml DNase I, before the 
reaction was stopped with 10mM EDTA (Sigma-Aldrich). Tissue was then crushed 
through a 70μm cell strainer (Falcon, Corning), resulting in a single cell suspension, and 




yields. The cell suspension was then centrifuged to form a cell pellet and facilitate removal 
of the supernatant before cells were re-suspended in appropriate medium. Centrifugation 
took place for 6 minutes at 394rcf and at 4°C, unless otherwise stated.  Preparation of cells 
for overnight culture or injection into mice took place in a flume hood using only sterile 
reagents, whilst preparation of cells for flow cytometry took place under non-sterile 
conditions. 
 Spleen 
Spleens were isolated from mice and placed in RPMI. Those spleens used for ILC analysis 
were first either teased using forceps or cut into small sections using scissors and then 
digested as outlined above, with the exception that digestion was for 30 minutes rather 
than 25. Spleen tissue was then crushed through a 70μm cell strainer to extract a single 
cell suspension. Following centrifugation, cell pellets were re-suspended in Gey’s solution 
red blood cell lysis buffer and incubated for 5 minutes on ice. 10ml of RPMI was added to 
dilute the lysis buffer prior to centrifugation. Splenocytes were re-suspended in 
appropriate medium and re-filtered prior to use. 
 Bone marrow 
Skin and muscle was removed from the legs of mice before the bones (femur and tibia) 
were transferred into small petri dishes with RPMI. Bone marrow was extracted by 
forcing RPMI through the centre of the bone using a syringe and crushed through a 70μm 
cell strainer to yield a single cell suspension. Following centrifugation bone marrow cells 




 Small intestine 
Small intestine (from the end of the stomach to the cecum) was isolated and fat and 
Peyer’s patches (PPs) removed. Tissue was cut into approximately 0.5cm sections and 
washed in HBSS (Sigma-Aldrich) with 2% FBS. Between each step the liquid was filtered 
through nylon mesh to retrieve the tissue. HBSS and HBSS with 2mM EDTA was pre-
warmed in a 37°C water bath. Tissue was placed in warm HBSS with 2mM EDTA and 
incubated in a 37°C shaking incubator for 20 minutes. Following the removal of liquid, 
tissue was manually shaken for 10 seconds in HBSS before the previous incubation in 
HBSS with 2mM EDTA was repeated. Tissue was washed three times by manually shaking 
in HBSS before being placed in culture media plus 1mg/ml Collagenase VIII (Sigma-
Aldrich) in a shaking incubator at 37°C for 15 minutes, shaking manually after the first 10 
minutes had passed. Cells were passed through 100μm and 70μm cell strainers, and 
strainers rinsed with staining buffer. The resulting cell suspension was centrifuged, re-
suspended in staining buffer and placed on ice. 
2.4 CELL CULTURE 
Cells were cultured overnight at 37°C in 1ml culture media (Table 2.2) in a 12 well plate 
in a final volume of 1ml. Pam3CSK4 (Invivogen) TLR1/2 agonist was added to selected 
samples at a final concentration of 1μg/ml, whilst IL-7 (Peprotech) was added to others 
at a final concentration of 100ng/ml. The following day cells were retrieved and analysed 
by flow cytometry as outlined below. 
2.5 FLOW CYTOMETRY 
All antibodies used for flow cytometric analysis in this investigation are listed in Tables 




APC eFluor 780 viability dye (1:1000, eBioscience) in PBS for 20 minutes on ice prior to 
antibody staining. Surface antibody staining was carried out in 96-well plates (Thermo 
Scientific) in 50μl or 100μl staining buffer (Table 2.3) for 25-30 minutes on ice, unless 
otherwise stated. CXCR5 staining was carried out at room temperature for 1 hour, and 
antibodies to CCR7 were incubated with cells for 30 minutes at 37°C. Antibodies to lineage 
markers were either included individually or collectively with the same fluorochrome. 96-
well plates were centrifuged at 394rcf for 2 minutes to pellet cells, unless otherwise 
stated. Following each incubation step 100-150μl staining buffer was added before 
centrifugation. Cell pellets were then washed with 200μl staining buffer and centrifuged 
prior to next staining step. Biotinylated antibodies were typically incubated with cells in 
an additional staining step prior to the addition of the main antibody cocktail, which 
would then include a fluorochrome-conjugated streptavidin. 
Intracellular staining was carried out in those experiments where transcription factors 
were analysed. Cells were stained with surface antibodies before being fixed and 
permeabilised using the FoxP3 fixation and permeabilisation buffers (eBioscience), with 
the exception of experiments where YFP was present within cells, where 
Cytofix/Cytoperm Plus (BD Biosciences) was used instead. Both kits were used in 
accordance with manufacturer’s instructions. Cells were incubated in 100μl of fixation 
buffer for at least 30 minutes on ice prior to addition of 100μl of permeabilisation buffer 
and centrifugation. Cells were washed twice more in 200μl permeabilisation buffer prior 
to intracellular labelling. Antibodies to intracellular antigens were then incubated with 
cells, in 50-100μl of appropriate buffer, for 25-30 minutes on ice. To remove unbound 
antibody following incubation, 100μl of permeabilisation buffer was added and the cells 




before plates were centrifuged and cells re-suspended in 200-300μl staining buffer for 
analysis. 
Appropriate isotype controls, cells from knockout (-/-) mice or fluorescence minus one 
controls were used where required to identify negative populations. Single fluorochrome 
controls were used to set fluorochrome compensation parameters, and these were 
typically WT splenocytes labelled alongside experimental samples. The amount of cells 
labelled depended upon the tissue and cell types being analysed. Prior to analysis 
Spherotech Accucount blank particles (Spherotech) were added to enable calculation of 
cell frequencies.  
Flow cytometric analysis was performed on a Fortessa X-20 or LSRII analyser (BD 
Biosciences), with data analysed using FlowJo (Tree Star). During analysis, pre-gating on 
forward and side scatter of cells enabled the exclusion of dead cells and debris. Individual 
mLN numbers were calculated by dividing total cells by 5 to account for multiple 
constituent LNs, unless otherwise stated. 
Table 2.8 Antibodies used during flow cytometry 
Specificity 
(anti-) 
Clone Conjugate Working 
dilution 
Supplier 
γδ TCR UC7-13D5 FITC 1:100 eBioscience 
B220 RA3-6B2 FITC 
PECy7 
















CCR7 4B12 PECy7 1:100 eBioscience 
CD3 145-2C11 FITC 
PECy7 


















Clone Conjugate Working 
dilution 
Supplier 















CD11b M1/70 FITC 




















CD25 PC61 BV 650 1:200 Biolegend 









CD45.1 A20 BV 421 
PE 













CD62L MCL-14 PE 1:400 eBioscience 
CD80 16-10AI BV 605 1:100 BioLegend 
CD86 GL1 APC 1:100 eBioscience 
CD103 2E7 PE 1:200 eBioscience 
CXCR5 2G8 Biotin 1:25 BD Biosciences 
FoxP3 FJK-16s FITC 1:100 eBioscience 
GATA-3 TWAJ PerCP eFluor 710 1:50 eBioscience 






ICOS 15F9 PerCP eFluor 710 1:100 eBioscience 









Ki-67  SolA15 PECy7 1:300 eBioscience 









RORγt AFKJS-9 PE 1:50 Bioscience 
T-bet  eBio4B10 Alexa eFluor 660 1:25 eBioscience 





Table 2.9 Streptavidin used to detect biotinylated antibodies 
Streptavidin (SA) Supplier 
SA-Alexa fluor 647 Invitrogen 
SA-PerCP efluor 710 eBioscience 
 
2.6 CHEMOKINE CAPTURE ASSAY 
Biotinylated CCL19 was pre-incubated with streptavidin-647 (SA-647) at room 
temperature and in the dark for 45 minutes prior to the start of the assay. WT and CCR7-/- 
mLN cells were incubated with 90ng of pre-conjugated CCL19 at a final concentration of 
1.8ng/μl in a 96-well plate for 1 hour at 37°C. Secondary antibody controls were 
incubated with SA-647 only. Samples were stained for cell surface markers and analysed 
on the flow cytometer. 
2.7 TRANSMIGRATION ASSAY 
100μl RPMI containing 2 x106 cells from WT or CCR7-/- mLN were loaded into transwell 
inserts (Corning Transwell Permeable Supports, 3421, Sigma-Aldrich; 6.5mm diameter, 
pore size of 5μm). Inserts were placed into wells containing RPMI with 2% FBS +/- 20nM 
CCL21. Plates were incubated at 37°C for 3 hours, before the addition of 5.5mM EDTA to 
the bottom well and transfer of plate to ice for 10 minutes (Mackley et al., 2015). Migrated 
(output) cells and those in the insert (input) were analysed by flow cytometry. Samples 
were analysed in triplicate, with the exception of CCR7-/- controls which were analysed in 
duplicate, and average values displayed on graphs. Percentages of each cell type that had 
migrated are as a proportion of the total of each cell type retrieved from both input and 
output wells, as shown in the equation below:  
% 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 = (
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑜𝑢𝑡𝑝𝑢𝑡
[𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑜𝑢𝑡𝑝𝑢𝑡 + 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑖𝑛𝑝𝑢𝑡]





2.8 IMMUNOFLUORESCENCE MICROSCOPY 
 Sectioning of frozen tissues 
Tissues for immunofluorescence microscopy analysis were rapidly frozen on dry ice and 
stored at -80°C. Lymph nodes were mounted in optimal cutting temperature (OCT) 
compound prior to freezing to aid cutting. 6μm tissues were cut using a cryostat and 
mounted onto 4 spot glass slides (Hendley-Essex). Dry tissue sections were fixed in cold 
acetone (Baker) at 4°C for 20 minutes, air dried for at least 10 minutes and stored at -20°C 
prior to use.  
 Immunolabelling of tissue 
Slides were air dried for at least 30 minutes before being placed in a PBS (Sigma-Aldrich) 
bath for 10 minutes to hydrate tissue. Staining solution was made from 1% bovine serum 
albumin (BSA) in PBS, as detailed in Table 2.4. Sections were incubated with 75μl 10% 
horse serum in staining solution for 15 minutes to block non-specific protein binding 
sites, before this solution was aspirated from slides. Primary antibodies mixes, made up 
in staining solution, were incubated with tissue for 1 hour at room temperature in a dark, 
humidified chamber. Subsequent staining steps were carried out for only 30 minutes, and 
slides washed in PBS for 10 minutes in between each. 
Detection of the transcription factors RORγt and GATA-3 required multiple signal 
amplification steps. Purified rat antibodies against RORγt or GATA-3 (primary) were 
detected using donkey anti-rat-IgG FITC (secondary), then rabbit anti-FITC-AF488 
(tertiary) and finally donkey anti-rabbit-IgG-AF488 (quaternary), as detailed in Tables 




quaternary antibodies. To prevent broad binding of secondary anti-rat antibodies to all 
antibodies derived from rat hosts, rat antibodies other than RORγt or GATA-3 were 
included after the donkey anti-rat-IgG FITC amplification stage, and a 10-15 minute 
blocking step in 10% rat serum introduced to prevent unwanted binding. Prior to use, 
secondary, tertiary and quaternary antibodies were cross-absorbed in a final volume of 
100μl 10% mouse serum for 30 minutes, then diluted with staining solution to reach the 
required final concentration. Biotinylated antibodies were detected using streptavidin-
conjugated fluorochromes. Following the completion of staining steps sections were 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) and mounted with ProLong 
Gold (Invitrogen). Clear nail varnish was used to seal slides which were left to dry in the 
dark overnight at room temperature, then stored at 4°C until analysis. 
 Analysis of slides 
Slides were analysed on a Zeiss 780 Zen microscope (Zeiss). Tilescanned images were 
automatically stitched by the Zen software (Zeiss) following acquisition. Percentage of 
RORγt+ IL-7Rαhi cells within interfollicular areas which were CD3- ILC3 was quantified 





Table 2.10 Primary antibodies for immunofluorescence microscopy 
Specificity 
(anti-) 











CD31 390 Biotin 1:200 eBioscience 
CD169 3D6.112 FITC 1:800 AbD Serotec 
F4/80 BM8 Alexa Fluor 647 1:50 eBioscience 
GATA-3 TWAJ N/A 1:25 eBioscience 
ICOS C398.4A Alexa Fluor 647 1:25 BioLegend 
IgM  Rhodamine Red 1:200 Jackson 
ImmunoResearch 
IL-7Rα A7R34 eFluor 660 1:25 eBioscience 
KLRG-1 2F1 APC 1:50 eBioscience 
RANKL IK22/5 Biotin 1:50 eBioscience 
RORγt AFKJS-9 N/A 1:25 eBioscience 
MadCAM-1 MECA-367 Biotin 1:100 eBioscience 
 
Table 2.11 Additional antibodies and streptavidin for immunofluorescence microscopy 
Antibody Type Working 
dilution 
Supplier 
Streptavidin-AF555 Secondary 1:500 Life Technologies 
Donkey anti-rat-IgG-FITC Secondary 1:150 Jackson 
ImmunoResearch 
Rabbit anti-FITC-AF488 Tertiary 1:200 Life Technologies 
Donkey anti-rabbit-IgG-AF488 Quarternary 1:200 Life Technologies 
 
2.9 IN VIVO EXPERIMENTS 
 Bone marrow chimeras 
Host mice were given Baytril antibiotic in drinking water by staff for several days 
prior to irradiation, and this treatment was continued for at least a week following bone 
marrow transfer. Bone marrow was prepared from donor mice, as previously described 
and with aseptic techniques, then filtered and re-suspended in sterile PBS for injection. 4-
5 million bone marrow cells were transferred in total, and mice left for sufficient time for 




RORγt+/-:WT and RORγt+/-:RORγt-/- chimeras were lethally irradiated with 2 x 450rad 
irradiation on consecutive days before receiving either WT or RORγt-/- bone marrow 
intravenously (i.v). Approximately 3-4 weeks post-transfer, RORγt+/-:RORγt-/- chimeras 
were treated with two 1mg doses of anti-CD90.2 antibody (generated at University of 
Birmingham) intraperitoneally (i.p), and mice analysed approximately three weeks later. 
WT:WT and WT:RORγt-/- chimeras were generated from WT hosts which received 2 x 
600rad irradiation on consecutive days prior to transfer of WT or RORγt-/- bone marrow 
i.v. WT:RORγt-/- mice were further treated with two 1mg doses of anti-CD90.2 antibody 
i.p, whilst WT:WT chimeras received 1mg control rat IgG (Sigma-Aldrich) and mice were 
analysed approximately 6-12 weeks post-antibody treatment. CCR7-/-:WT and 
CCR7-/-:RORγt-/- chimeras were lethally irradiated with 2 x 600rad irradiation on 
consecutive days prior to intravenous bone marrow transfer and analysed approximately 
5-9 weeks later. 
Mixed bone marrow chimera hosts were lethally irradiated with 2 x 600rad irradiation 
on consecutive days before a 1:1 mix of CD45.1+ WT and either CD45.2+ WT (WT:WT) or 
CD45.2+ CCR7-/- (WT:CCR7-/-) bone marrow was transferred intravenously. The mixed 
bone marrow was analysed by flow cytometry to ensure that the ratio of transferred cells 
was approximately 1:1. Mice were analysed approximately 6-8 weeks post-bone marrow 
transfer. Analysis of mixed bone marrow chimeras generated in CD45.1+CD45.2+ WT 
hosts required the exclusion of irradiation resistant host cells at the time of tissue 
analysis. Percentage of each cell population (X) which were CD45.1+ or CD45.2+ was 





% 𝑜𝑓 𝑋 = (
𝐶𝐷45.1+𝐶𝐷45.2−𝑋 𝑜𝑟 𝐶𝐷45.1−𝐶𝐷45.2+𝑋
[𝑇𝑜𝑡𝑎𝑙 𝑋 − 𝐶𝐷45.1+𝐶𝐷45.2+𝑋]
) 𝑥 100 
 
 Adoptive transfer of TCR transgenic T cells 
Cells for transfer were isolated from selected LNs and spleen from RAG-/- SM1, RAG-/- OTII 
or OTII mice. Cells were prepared under sterile conditions and were not enzymatically 
digested. A small sample of cells was analysed by flow cytometry prior to transfer to 
calculate the percentage of total cells which were either SM1 or OTII T cells, and therefore 
to ensure the accurate and consistent transfer of either 104 or 105 TCR transgenic CD4+ T 
cells to each mouse. Cells were re-suspended in sterile PBS and filtered prior to 
intravenous injection into the tail vein of experimental mice. The day following adoptive 
transfer, mice were immunised with the appropriate cognate antigen as described below. 
 Immunisation 
Mice were immunised in the front or hind paw pad with 106 actA-deficient L. 
monocytogenes expressing FliC427-441 peptide (Lm-FliC, a kind gift from Dr. Sing Sing Way), 
the target antigen of SM1 T cells (McSorley et al., 2002). Lm-FliC was grown from frozen 
stocks on Luria-Bertani (LB) chloramphenicol-treated agar plates at 37°C overnight. 
Chloramphenicol-selective agar plates were made within the laboratory to a final 
chloramphenicol concentration of 20μg/ml agar. To prepare for injection, a single colony 
of Lm-FliC was grown overnight in a shaking 37°C incubator in LB broth supplemented 
with 20μg/ml chloramphenicol. The following day bacteria was subcultured and grown 
under the same conditions until the OD600=0.1, as calculated using a spectrophotometer. 




then cell pellets washed twice with sterile PBS. The OD600 of the washed bacteria was re-
calculated and Lm-FliC was diluted in sterile PBS to a final concentration of 106 Lm-FliC 
per 20μl sterile PBS for injection. 
Mice were immunised in the front paw pad with 10-20μg of aluminium hydroxide 
precipitated (alum ppt) FliC peptide or NP-OVA protein, or with 100μg alum-ppt FliC 
peptide i.p. To alum ppt antigen 500μg of FliC peptide or NP-OVA protein was diluted in 
PBS to a final volume of 150μl and added to 150μl of 9% Aluminium sulphate. For alum 
ppt FliC experiments 7μl of 10M sodium hydroxide (NaOH) was added to this solution, 
and in the case of NP-OVA precipitation NaOH was added dropwise until the correct pH, 
represented by a yellow colouring, was achieved (between 7.5-9μl NaOH). The solution 
was mixed and incubated at room temperature for 30 minutes, before being thoroughly 
washed 3 times with 500μl of sterile PBS. The alum precipitated antigen was then diluted 
to the required concentration in sterile PBS for injection. A final volume of 20μl alum-ppt 
antigen or 100μl alum-ppt antigen in PBS was injected in the paw pads or i.p respectively.  
2.10 STATISTICAL ANALYSIS 
Numerical data was analysed using Microsoft Excel (Microsoft) and graphs were 
generated using GraphPad Prism 6 (GraphPad). Statistical significance was determined 
using Mann-Whitney non-parametric, two-tailed tests and significance set at P<0.05, 







CHAPTER 3. CHARACTERISING ILCS IN LYMPH NODES 
 
3.1 INTRODUCTION 
Although well characterised in non-lymphoid tissues, in particular the gut where ILCs are 
enriched, comparatively little is known about ILCs within secondary lymphoid tissues, 
such as lymph nodes (LNs). The detection of group 3 ILCs within regions of lymph nodes 
which are important sites of interaction during immune responses and the sites of 
lymphocyte recirculation is indicative of an important role (Withers et al., 2012). Given 
that previous investigations within our research group have focused on the role of 
members of this family within the spleen (Withers et al., 2012), this investigation will 
focus primarily on subsets of ILCs found in lymph nodes. 
Lymph nodes provide an environment within which interactions between cells of the 
adaptive immune system and antigen-presenting cells (APCs) are facilitated.  Antigen and 
activated APCs enter the lymph at the site of infection and are transported through a 
system of lymphatic vessels to the local lymph node, known as the draining lymph node 
(dLN) (Braun et al., 2011). Here APCs presenting antigenic peptides are kept in close 
proximity to naïve lymphocytes, facilitating the initiation of a primary adaptive immune 
response. Lymph nodes are highly organised, segregated structures which provide 
separate areas for B and T lymphocytes. Each lymph node is surrounded by a capsule 
beneath which lies the sub-capsular sinus, where lymph from the peripheral organs 
enters. Within these layers, but lining the lymph node exterior sit the B cell follicles, whilst 
T cells reside deeper within an area known as the paracortex (Willard-Mack, 2006). The 
location of these two types of lymphocytes is dictated by their interaction with 
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chemokines secreted by distinct stromal cell populations that form the framework of each 
area. B cells express CXCR5 that binds the chemokine CXCL13, which is highly expressed 
within the B cell follicles (Ansel et al., 2000), whilst T cells express CCR7, which binds to 
the chemokines CCL19 and CCL21 and attracts T cells to the paracortical zone (Worbs et 
al., 2007). CD4+ T cells, however, upon activation will downregulate expression of CCR7 
and upregulate CXCR5, thus facilitating their movement to the interface between the B 
cell follicles and T cell area, the B-T interface. Some activated CD4+ T cells will then enter 
the follicle as T follicular helper cells (Ansel et al., 1999, Ma et al., 2012). In order to sample 
as many antigens as possible, naïve lymphocytes will continuously recirculate through 
lymphoid tissues until they encounter their cognate antigen. Entry of these naïve 
lymphocytes into the lymph node is through high endothelial venules (HEVs) located in 
the paracortical zones and interfollicular areas, whilst cells will leave through the efferent 
lymph (von Andrian and Mempel, 2003). 
It is within the regions between LN follicles and near the B-T interface that 
RORγt-expressing LTi cells have previously been documented in mouse mesenteric LNs 
(Withers et al., 2012). Their resulting proximity to recirculating naïve and memory 
lymphocytes in part led to the hypothesis that LTi cells might support CD4+ T cell 
responses. Although not found to be important for primary CD4+ T cell responses within 
the spleen, the presence of LTi cells within this tissue was found to be important for the 
survival of populations of memory CD4+ T cells (Withers et al., 2012). 
The roles of ILCs in lymph nodes has not been widely explored. ILCs have been studied 
within the mesenteric LN, in part due to its ease of isolation and size. Whether or not any 




identified these cells within tissues such as the skin and lung in addition to the gut, we 
hypothesised that the differences in immune requirements at each site might be reflected 
in the cells which reside in local draining lymph nodes. Therefore this chapter will 
investigate the presence and phenotype of different subsets of ILCs in a range of different 
peripheral and mucosal tissue draining lymph nodes at steady state.  
3.2 IDENTIFICATION OF ILCS IN LYMPH NODES 
 All groups of ILC reside within lymph nodes 
As has been previously reported, a distinct population of ILCs which lacked common 
lineage (Lin) defining markers which would mark them out as T cells, B cells or DCs, and 
expressed high levels of the receptor for IL-7 (IL-7Rα) could be detected within the small 
intestine (SI) of WT mice by flow cytometry (Figure 3.1a). This population was also 
evident within mesenteric LNs (mLN) which drain tissues of the gut, albeit in lower 
numbers than seen in the comparatively ILC-enriched SI (Figure 3.1a,d). In focusing on 
those Lin- cells which expressed IL-7Rα, we excluded populations of conventional NK cells 
commonly associated with cytotoxic activity. Thus throughout this investigation the ILCs 
analysed were those which depend upon IL-7 for survival and are described in recent 
publications as ‘helper’ ILCs (Artis and Spits, 2015).  
As has been described in the literature, different subsets of ILCs could be distinguished 
from this population based on their expression of the transcription factors GATA-3, RORγt 
and T-bet (Figure 3.1a-c), which have previously been associated with CD4+ T cell subsets. 
As such, it was crucial that T cells could confidently be excluded from our Lin- IL-7Rα+ 
gate, and steps were taken to ensure that this was the case. By excluding those cells which 




Figure 3.1 All subsets of ILC can be detected in the mLN  
Cells were isolated from naïve WT mouse small intestine lamina propria 
(SI) as specified in methods. mLNs were taken alongside and cells 
isolated as normal. Both SI and mLN samples were analysed using 
Live/Dead viability dye and anti-CD45 antibody in addition to normal 
markers. Samples were analysed by flow cytometry and absolute 
numbers calculated. 
All bars shown on graphs represent the median value. Data 
representative of (a-c) or pooled from (d) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on subsets of Lin- IL-7Rα+ ILCs in WT SI 
(top) and mLN (bottom). R-G- is RORγt- GATA-3- cells. Lin is CD3/CD5 
B220/CD11b/CD11c. 
b) FACS plots showing T-bet intracellular staining on RORγt-GATA-3- 
(R-G-) ILCs in SI and mLN tissue, as gated in (a). R-G- T-bet+ cells 
labelled as ILC1. 
c) Histogram showing T-bet expression by R-G- (blue line) ILCs 
compared to GATA-3+ ILC2 (filled grey) from WT mLN, as defined in 
(a). Y axis is normalised to mode. 
d) Graph showing the total number of Lin- IL-7Rα+ ILCs in whole WT 
mLN tissue (here not taking into account individual constituent LNs) 









conjunction with the T cell receptor and therefore completely absent on ILCs—and CD5, 
populations of T cells and ILCs could be kept sufficiently distinct to distinguish between 
using flow cytometry (Figure 3.1a). As an additional precaution antibodies against CD3 
were also used intracellularly to detect CD3 expression within cells (CD3-epsilon 
intracellular, CD3i), thereby preventing contamination of the Lin- IL-7Rα+ ILC gate with 
any T cells which expressed low levels of surface CD3; although such cells were generally 
found to constitute only a minor population (Figure 3.1a). Cells which expressed CD11c, 
B220 and CD11b were also excluded in keeping with a gating strategy defined previously 
within our group, and therefore excluding cells of known lineages which could possibly 
fall within this IL-7Rα+ cell gate. 
In both the SI and mLN of WT mice three distinct populations of ILCs could be identified 
by their expression of key transcription factors. Following fixation and permeabilisation, 
isolated cells were incubated with antibodies against intracellular expression of GATA-3, 
RORγt and T-bet (Figure 3.1a-c). Those cells which expressed high levels of GATA-3 but 
not RORγt could be identified as the GATA-3 expressing group 2 ILCs (ILC2), whilst those 
which expressed RORγt could be broadly identified as group 3 ILCs (ILC3). In the mLN 
those ILCs which did not express either GATA-3 or RORγt were largely T-bet+, and this 
was especially apparent when compared to T-bet- GATA-3+ ILC2 (Figure 3.1b,c), and these 
cells were identified as group 1 ILCs (ILC1). The use of transcription factor expression, 
coupled with key surface markers, to identify these cells proved an effective method of 
detection; with surface markers alone not always definitive and cytokine expression likely 




Analysis of the phenotype of these ILC subsets revealed that ILCs in the mLN in many ways 
resembled those which had been reported at other sites (Walker et al., 2013). NKp46, a 
natural cytotoxicity receptor (NCR), has been documented on ‘helper-like’ ILC1 but not 
ILC2, and accordingly is expressed by the majority of ILC1 in mLN whilst ILC2 are NKp46- 
(Figure 3.2a). NKp46 expression has also been reported on a subset of ILC3 which lack 
expression of CCR6 (Klose et al., 2013) and although this population could be identified 
within the mLN (Figure 3.2a), it constituted only a minor proportion of total RORγt+ ILCs. 
Instead, the majority were NKp46- and, in keeping with previous publications (Klose et 
al., 2013), expressed CCR6. Throughout this investigation those ILC3 which express 
NKp46 will be referred to NCR+ ILC3, whilst those which do not will be identified as 
LTi-like ILC3. The expression of CCR6 could be detected on those ILCs which expressed 
RORγt only (Figure 3.2a), thus identifying this chemokine receptor as a useful surrogate 
marker for the identification of ILC3 when intracellular staining is not possible. The 
expression of CD4 by ILCs was restricted primarily to group 3 ILCs, with LTi-like ILC3 
found to be heterogeneous for this molecule and no expression detected on those ILC3 
which lacked CCR6. (Figure 3.2a). Major-histocompatibility complex II (MHCII) 
expression by both ILC2 and ILC3 has been reported (Neill et al., 2010, Hepworth et al., 
2013), generating interest in the potential of these cells to act as antigen-presenting cells 
(APCs). Within the mLN very little MHCII expression could be detected by ILC1s and 
ILC2s, but it was found to be expressed by a proportion of ILC3, once again primarily 
limited to those which expressed CCR6 (Figure 3.2a).  
Given the phenotype data outlined above, it is highly likely that this investigation is 
focusing on the ILC populations which have been reported before. Analysis of cells which 




Figure 3.2 ILC subsets phenotypically resemble those previously 
reported. 
Cells isolated from mLNs of naïve WT mice as specified in methods. 
Samples were analysed by flow cytometry. Live/Dead viability dye and 
anti-CD45 antibody only used where specified. 
a) FACS plots showing the expression of known phenotypic cell surface 
markers on subsets of ILC from WT mLN, gated as in Figure 3.1a 
(including viability dye and CD45). ILC1 are RORγt- GATA-3- T-bet+, 
ILC2 are RORγt- GATA-3+, ILC3 are RORγt+. Data is representative of 
at least 6 WT mice. 
b) Pie chart showing the percentage of lymphocytes (gated on 
FSC/SSC) from WT mLN which are viable and CD45(.2)+ (white). 
Data pooled from 6 WT mice from 2 independent experiments.  
c) FACS plots showing gating of lineage markers on IL-7Rα+ RORγt+  
(top) or IL-7Rα+ GATA-3+ (bottom) cells in mLN, at transcription 
factor expression levels ordinarily used to define subsets of ILCs. 
Cells pre-gated on FSC and SSC. Viability dye and CD45 expression 
not analysed as very little cell death detected in LN samples as shown 










revealed that those lineage marker-expressing cells with an ILC-like phenotype were 
primarily T cells (Figure 3.2c); therefore our inclusion of antibodies to CD3i wherever 
possible is a valid further precaution. Additionally, analysis of mLN cells incubated with a 
viability dye and antibodies against CD45 revealed that >95% of cells isolated from the 
mLN were live hematopoietic cells (Figure 3.2b). Our ability to extract cells from LNs with 
minimal cell death therefore meant that these markers were not included in the majority 
of experiments within this investigation, with the exception being when mLN tissue was 
compared to the SI. 
 ILC3 are enriched in mucosal tissue-draining LNs 
Lymph nodes can be found at a number of different sites around the body, where they 
drain lymph from local tissue. Given that the immunological challenges faced by tissues at 
different sites can differ vastly, it is likely that the composition of cells in local LNs reflects 
this. To investigate whether differences were evident in the ILC subsets present, 
populations of these cells in a range of skin-draining peripheral LNs and mucosal 
tissue-draining LNs were compared. The LNs analysed included the skin-draining 
popliteal LN (popLN), inguinal LN (iLN) and brachial LN (bLN), and the mucosal 
tissue-associated mesenteric LN (mLN) and mediastinal LN (medLN). 
All three groups of ILCs could be detected in all LNs analysed, using the gating strategy 
outlined in Figure 3.3a, unless otherwise stated. Although still the predominant 
population in skin-draining iLN and bLN, ILC3 were found to be particularly numerous in 
the mucosal tissue-draining mLN; most evident when the frequency of each subset was 
analysed per 106 lymphocytes (Figure 3.3b). The frequency of ILC3 per 106 lymphocytes 




Figure 3.3 ILC3 are enriched in LNs which drain mucosal sites 
Cells isolated from LNs of naïve WT mice as specified in methods. 
Samples were analysed by flow cytometry and absolute numbers 
calculated.  
All bars shown on graphs represent the median value. Data is 
representative of (a) or pooled (b-c) from 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on subsets of Lin- IL-7Rα+ ILCs in WT bLN 
(top) and mLN (bottom). Pre-gated on lymphocytes by FSC/SSC. 
ILC1 are RORγt- GATA-3- T-bet+ ILCs. Lin is CD3/CD5/B220/CD11c. 
b) Graph (left) showing the total number of ILC1, ILC2 and ILC3 in 
individual LNs. Total cells in mLN are divided by 5, unless otherwise 
stated, to account for multiple LNs draining mesentery. Graph (right) 
showing the frequency of each ILC subset per 106 lymphocytes 
(gated on FSC/SSC). (n=8,8,10). 
c) Graph showing the percentage of total Lin- IL-7Rα+ ILCs which are 
RORγt+ ILC3 (left) or GATA-3+ ILC2 (right) in a range of LNs. For 
popLN and medLN analysis CD11b was not excluded and LNs from 
multiple WT mice were pooled to retrieve enough cells for analysis. 
popLN; popliteal LN, iLN; inguinal LN, bLN; brachial LN, mLN; 









ILC2. Although this observation was not exclusive to the mLN, for the frequency of ILC3 
in iLN and bLNs was also statistically significantly higher than other ILC subsets, the 
frequency of ILC3 in the mLN was much higher than that found in either of these 
skin-draining LNs, and this was statistically significant (Figure 3.3b). Importantly, no 
significant difference was detected in the number or frequency of ILC3 when iLN and bLN 
were compared (Figure 3.3b), suggesting that, in this respect, these skin-draining LNs 
were similar.  
In agreement with this, the percentage of total Lin- IL-7Rα+ ILCs which expressed RORγt 
was statistically significantly higher in the mLN than in either the iLN or bLN (Figure 3.3c). 
However, when the proportion of total ILCs which were RORγt+ in iLN, bLN and mLN was 
compared to the popliteal LN (popLN) and medastinal LN (medLN) there appeared to be 
a bias towards ILC3 within those LNs known to drain mucosal surfaces. The popLN—a 
small, peripheral tissue-draining LN which drains the hind paw-pad—had the lowest 
percentage of ILC3, marginally lower than that found in skin-draining iLN and bLN. By 
contrast, the medLN—small LNs which drain the mucosal surfaces of the lung and upper 
respiratory tracts—was found to have the highest percentage of ILC3 of any LN analysed 
(Figure 3.3c), statistically significantly higher than even the mLN. The percentage of ILC2 
did not, however, differ to any notable extent in the same LNs, although was found to be 
higher in the popLN (Figure 3.3c). 
In the spleen, T-bet+ ILC1 were found to be as numerous as ILC3, whilst ILC2 only made 
up a small percentage of the total population of ILCs (Figure 3.4b). Interestingly a 
proportion of RORγt- GATA-3- ILCs were found to not express high levels of T-bet but still 




Figure 3.4 All subsets of ILC can be detected in the spleen 
Cells isolated from spleen of naïve WT mice as specified in methods. 
Samples were analysed by flow cytometry and absolute numbers 
calculated. 
All bars shown on graphs represent the median value. Statistical test 
used is Mann-Whitney non-parametric, two-tailed test. *P<0.05, 
**P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on subsets of Lin- IL-7Rα+ ILCs in WT 
spleen. Pre-gated on lymphocytes by FSC/SSC. ILC1 are RORγt- 
GATA-3- T-bet+ ILCs. Lin is CD3/CD5/B220/CD11c. Data is 
representative of 2 independent experiments. 
b) Graph (left) showing the total number of ILC1, ILC2 and ILC3 in 
whole spleen. Graph (right) showing each ILC subset as a percentage 
of the total Lin- IL-7Rα+ ILCs. Data is pooled from 2 independent 
experiments. (n=6,6,6).  
c) Graph showing the frequency of total Lin- IL-7Rα+ ILCs per 106 
lymphocytes in iLN, bLN, mLN and spleen. Data pooled from 3 (iLN, 









each ILC subset was higher within the spleen, due to its size and cellularity, the frequency 
of ILCs was determined to be similar to or lower than that found in LNs. Analysis of the 
frequency of total Lin- IL-7Rα+ ILCs per 106 lymphocytes within the iLN, bLN, mLN and 
spleen revealed that ILCs as a population of cells made up a statistically significantly 
higher proportion of total lymphocytes in the mLN than any other tissue analysed (Figure 
3.4c). 
 Ex-RORγt+ ILC3 are a minor ILC population in lymph nodes 
Defining group 1 ILCs has been complicated not only by the debate surrounding whether 
or not conventional NK cells should be included within the ILC family, but also because of 
reports that populations of ILC3 can downregulate expression of the transcription factor 
RORγt, upregulate expression of T-bet and as a result resemble ILC1; becoming so-called 
‘ex-RORγt+’ ILCs (Klose et al., 2013, Vonarbourg et al., 2010). The use of RORt cre x 
ROSA26 eYFP fate mapping mice—in which even transient expression of the transcription 
factor RORγt causes cells to permanently express a yellow fluorescent protein (YFP), thus 
enabling the fate of these cells to be mapped—allowed us to investigate to what extent 
these ex-RORγt+ cells could be detected within the ILC1 population found in LNs.  
Within the Lin- IL-7Rα+ ILC population shown in Figure 3.5a the majority of cells which 
expressed RORγt at the time of ex vivo analysis were also YFP+, thus confirming the 
successful expression of the YFP reporter protein. It was also possible to detect a 
population of cells which were YFP+ but RORγt-, confirming that there were indeed some 
ILCs which had once expressed, but since downregulated, RORγt expression. To 
investigate whether any of these RORγt- YFP+ cells could resemble ILC1s, T-bet+ cells were 




Figure 3.5 ‘Ex-RORγt+’ ILC3 are a minor population in LNs 
Cells isolated from LNs of Rorc(γt) cre x Rosa26 eYFP mice as specified 
in methods. Samples were analysed by flow cytometry. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b-d) 2 independent repeats, popLN 
and medLN pooled from multiple mice. Statistical test used is Mann-
Whitney non-parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 
and ****P<0.0001. 
a) FACS plots showing gating for ‘ex-RORγt+ ILCs’ in mLN tissue. Lin is 
CD3/CD5/B220/CD11c. 
b) Graph showing the total number of Tbet+ RORγt- YFP+ ‘ex-RORγt+’ 
ILCs, highlighted in blue in (a), per LN. (n=2,77,2).  
c) Graph showing the percentage of total Lin- IL-7Rα+ ILCs which were 
Tbet+ RORγt- YFP+. (n=2,77,2).  
d) Percentage of total Tbet+ RORγt- ILCs (ILC1) which are YFP+ ‘ex-









YFP+ but RORγt- could be identified in all LNs analysed (Figure 3.5b) and despite 
constituting only a minor percentage of total Lin- IL-7Rα+ ILCs (Figure 3.5c), were found 
to comprise between 30-45% of total ILC1 (Figure 3.5d). This suggests that a proportion 
of ILC1s detected in LNs were in fact a population of ‘ex-RORγt+’ ILC3, yet it is worth 
noting that plasticity within all subsets of ILCs is increasingly being reported (Bernink et 
al., 2015). It is therefore also possible that transient expression of RORγt by ILC1 within 
LNs is a phenomenon separate from the documented ability of ILC3 to alter their 
transcriptional profile to resemble ILC1, and highlights the difficulties associated with 
definitively defining these populations. 
 Phenotype of ILCs in different lymph nodes 
Earlier in this chapter ILC3 within the mLN were shown to be primarily CCR6+, with very 
few NKp46+ ILC3 detected. This was also true of the skin-draining iLN and bLN (Figure 
3.6a,b), with more than 80% of ILC3 in iLN, bLN and mLN expressing the chemokine 
receptor CCR6 (Figure 3.6b, median values). The proportion of ILC3 which expressed 
NKp46 was low in all LNs analysed, although a marginally lower percentage were 
detected within the mLN than iLN or bLN, and this difference was found to be statistically 
significant (Figure 3.6b). CD4 expression differed more convincingly, with a lower 
percentage of ILC3 within the mLN found to express CD4 than in the peripheral iLN and 
bLNs, and this was a statistically significant difference (Figure 3.6b). In contrast MHCII 
was expressed by a significantly higher percentage of ILC3 in the mLN than either the iLN 
or bLN (Figure 3.6b), perhaps indicative of a difference in the importance of 




Figure 3.6 Characterising the phenotype of ILC3 in LNs 
Cells isolated from LNs of naïve WT mice as specified in methods. 
Samples were analysed by flow cytometry. 
All bars shown on graphs represent the median value. Data is 
representative of (a) or pooled (b) from 2 (MHCII) or 3 independent 
experiments. Statistical test used is Mann-Whitney non-parametric, two-
tailed test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing expression of phenotype markers on RORγt+ 
ILC3s in iLN (top) and mLN (bottom). 
b) Graphs showing the percentage of total Lin- IL-7Rα+ RORγt+ ILC3 
which express CCR6, CD4, MHCII and NKp46 in iLN, bLN and mLN. 










 LN ILC populations differ in T cell-deficient mice 
Previous investigations into the functions of ILC3 populations have often been carried out 
in mice which lacked T cells, using anti-CD90 antibodies to deplete ILC3 in vivo 
(Sonnenberg et al., 2012). This was in part due to the challenges associated with 
specifically depleting these cells in vivo, given that similar molecules are expressed by 
both ILCs and T cells. Analysis of ILC populations in the LNs of T cell-deficient RAG-/- and 
ZAP-70-/- mice was therefore important to enable comparison of our observations in WT 
mice with those of previous functional studies.  
Expression of recombination-activating gene (RAG) proteins is important for the activity 
of a recombinase enzyme, which participates in the formation of a somatically rearranged 
T cell and B cell receptors. Successful rearrangement of these receptors is vital for the 
survival of T and B lymphocytes, and as a result all B and T lymphocytes are absent in 
RAG-deficient mice (Mombaerts et al., 1992). ZAP-70 is a protein tyrosine kinase, 
signalling through which is important during both T cell activation and thymic 
development. As a result, mice deficient in ZAP-70 lack αβTCR+ CD4+ and CD8+ mature T 
cells, but B cells are still present (Negishi et al., 1995). Therefore, although the 
architecture of LNs in RAG-/- mice is impaired as a result of the absence of lymphocytes, 
LNs from ZAP-70-/- mice still have detectable B cell follicles. Analysis of ILC populations 
within the mLNs of RAG-/- and ZAP-70-/- mice revealed striking differences to what had 
previously been observed in WT mice. Whilst ILC3 were the predominant ILC population 
in WT mLNs, GATA-3+ ILC2 made up the majority of total ILCs in both RAG-/- and ZAP-70-




Figure 3.7 Composition of LN ILC populations differs in T cell-
deficient mice 
Cells isolated from LNs of naïve WT, Rag-/- and ZAP70-/- mice as specified 
in methods. Samples were analysed by flow cytometry.  
All bars shown on graphs represent the median value. Data is 
representative of (a) or pooled (b-c) from at least 3 independent 
experiments. Statistical test used is Mann-Whitney non-parametric, two-
tailed test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on subsets of Lin- IL-7Rα+ ILCs in WT 
(top), Rag-/- (middle) and ZAP-70-/- (bottom) mLNs. Lin is 
CD3/CD5/B220/CD11c. Arrows demonstrating gating strategy on 
WT FACS plots (top) apply to both RAG-/- and ZAP-70-/- also. 
b) Graphs showing the total number of GATA-3+ ILC2 (left) and RORγt+ 
ILC3 (right) per individual mLN from WT, Rag-/- and Zap70-/- mice. 
Leftmost Y axis scale applies to both graphs.  
c) Graphs showing the percentage of total Lin- IL-7Rα+ ILCs which are 
GATA-3+ ILC2 (left) or RORγt+ ILC3 (right) in mLN. Leftmost Y axis 
scale applies to both graphs.  
d) Graphs showing the total number of ILC1, ILC2 and ILC3 per Rag-/- 
iLN (top) and the percentage of total ILCs which are ILC1, ILC2 or 









specific to the mLN, with the similar percentages of all ILCs detected in RAG-/- iLNs (Figure 
3.7d) more comparable to what has previously been observed in WT mice. 
3.3 LOCATION OF ILCS IN LYMPH NODES 
 Locating ILC2 and ILC3 in lymph node tissue sections 
Whilst flow cytometry as an experimental technique is useful for enumerating and 
phenotyping ILCs, identifying ILCs in LNs using immunofluorescence microscopy 
provides an insight into their location and, as a result, the cell types with which they might 
interact; information lost when tissue is disrupted for flow cytometric analysis. 
Immunofluorescence microscopy therefore provides important clues as to the functions 
of cells of interest and valuable additional information to that which has been discussed 
above. 
By refining previously established methods it was possible to identify and locate not only 
RORγt+ ILCs, as has been previously published (Withers et al., 2012), but also GATA-3+ 
ILCs within lymph node tissue. RORγt+ IL-7Rα+ cells which lacked expression of the T 
cell-marker CD3 could be identified within lymph node tissue (Figure 3.8a). Crucially 
anti-RORγt antibody staining coincided with nuclear DAPI staining, confirming that this 
was genuine intracellular transcription factor staining. In contrast, fluorescently labelled 
antibodies to both CD3 and IL-7Rα could be seen to bind to the non-nuclear portion of the 
cells (Figure 3.8a). Although CD3+ T cells also express IL-7Rα—with co-staining of these 
surface antibodies causing these cells to appear purple—those RORγt+ cells with notably 
high levels of this receptor were for the most part CD3- and therefore not T cells (Figure 
3.8a). This was consistent with earlier flow cytometry data, which showed that ILCs 




Figure 3.8 ILC3 and ILC2 can be located in LNs 
Representative immunofluorescence microscopy images of WT mLN 
tissue sections. Images in (b) are serial sections of the same 
interfollicular area in a WT mLN. Smaller images are from regions of 
interest (ROI) marked by white dashed rectangles in corresponding 
images, and manually zoomed post-capture. 
Sections all counterstained with DAPI.  
a) Tilescanned image (left) showing interfollicular area of WT mLN 
stained for expression of RORγt, CD3 and IL-7Rα. Scale bar 
represents 100μm. Smaller images (right) are of RORγt+ CD3- IL-
7Rα+ cells from ROI manually zoomed post-capture. Scale bar 
represents 10μm. 
b) Tilescanned image (left) showing interfollicular area of WT mLN 
stained for expression of RORγt, CD3 and IL-7Rα. Scale bar 
represents 100μm. Smaller images below are from marked ROI and 
scale bar represents 10μm. Tilescanned image (centre) showing 
interfollicular area of WT mLN stained for expression of GATA-3, 
CD3 and KLRG-1. Scale bar represents 100μm. Smaller images below 
are from marked ROI and scale bar represents 10μm. Tilescanned 
image (right) showing interfollicular area of WT mLN stained for 
expression of GATA-3, CD3 and ICOS. Scale bar represents 100μm. 











Using this improved method of staining these RORγt+ CD3- IL-7Rα+ ILCs were found to 
cluster in the interfollicular areas of LNs—those regions between B cell follicles and close 
to the subcapsular sinus—and at the B-T interface (Figure 3.8a) as previously reported 
(Withers et al., 2012); with B cell follicles here identified by their location and absence of 
CD3+ T cells. Strikingly, within these areas CD3- cells which expressed the transcription 
factor GATA-3 and resembled ILC2 could also be detected (Figure 3.8b). Those CD3- cells 
which expressed high levels of GATA-3 also expressed KLRG-1 (Figure 3.8b, centre) and 
ICOS (Figure 3.8b, right), two cell surface markers which have been reported to be 
expressed by ILC2 (Hoyler et al., 2012, Neill et al., 2010). Once again, close-up images of 
these cells revealed that the GATA-3 staining co-localised with the nucleus of the cells and 
that the surface expression of KLRG-1 and ICOS did not coincide with CD3 expression, 
thus confirming that these are very likely ILC2 and not GATA-3+ T cells.  
 ILC3 cluster in interfollicular areas of LNs 
Whilst innate lymphoid cells are a rare cell type in WT lymph nodes, immunofluorescence 
microscopy staining has shown group 3 ILCs to cluster within highly specific areas in all 
LNs analysed, therefore increasing the potential for even a small population of cells to 
exert effects on others.  
Large numbers of RORγt+ CD3- IL-7Rα+ ILC3s could be found to cluster in the 
interfollicular areas of lymph nodes and at the B-T interface of mLNs (Figure 3.9a). These 
clusters could be observed within many, although not all, interfollicular areas. Large 
numbers of RORγt-expressing cells could also be detected in similar areas of other lymph 




Figure 3.9 ILC3 can be detected in interfollicular regions of all LNs 
analysed 
Representative immunofluorescence microscopy images of WT LN tissue 
sections. All images are tilescanned. 
Sections all counterstained with DAPI.  
a)   Image showing interfollicular areas of WT mLN stained for 
expression of RORγt, CD3 and IL-7Rα. Scale bar represents 100μm.  
b) Image showing interfollicular areas of WT iLN stained for expression 
of RORγt, CD3 and IL-7Rα. Scale bar represents 100μm.  
c) Image showing popLN (top) and medLN (bottom) stained for 
expression of RORγt, CD3 and IL-7Rα, scale bar is 100μm. Images on 
right are zoomed in versions of numbered ROIs (highlighted by 









(Figure 3.9c), and the mucosal tissue-draining medLN (Figure 3.9c), suggesting that the 
location of these cells does not change notably between lymph nodes at different sites. 
Upon further inspection, however, it became clear that although RORγt+ CD3- IL-7Rα+ 
ILC3s could be detected in these regions in peripheral LNs, many of the RORγt-expressing 
cells present in fact expressed CD3 and were therefore RORγt+ T cells. Quantification of 
the proportion of RORγt-expressing, IL-7Rαhi cells in the interfollicular areas of these LNs 
which lacked expression of CD3 revealed that there was indeed a significant difference. 
Tissues were analysed as shown in Figure 3.10a, with interfollicular areas here defined as 
the area between the B cell follicles and extending to the central points of each follicle, 
therefore including those cells which can be found to reside at the B-T interface. 
Proportions were calculated from the total RORγt+ IL-7Rαhi cells within each defined area. 
This analysis revealed that those RORγt-expressing cells observed in the peripheral 
draining popliteal and inguinal LNs were indeed predominantly T cells (Figure 3.10b), 
although ILC3 were still present, and that this phenotype did not differ significantly 
between these two lymph nodes. In contrast, these areas in mLNs contained many RORγt+ 
ILC3 (Figure 3.10b) and relatively few RORγt-expressing T cells, a phenotype which was 
statistically significantly different to both peripheral LNs analysed. Notably, the medLN 
also had a large proportion of ILC3 within these areas, and although this phenotype was 
less defined than that seen in the mLN it was indicative of ILC3-enriched 
microenvironments existing in mucosal-draining LNs which were not found in those 
which drained the skin (Figures 3.10b). 
 ILC3 expression of chemokine receptors 
The signals which attract ILC3s to this distinct location are not known, although one 




2009). ILC3s have been reported to express mRNA for the chemokine receptors CXCR5, 
which binds the chemokine CXCL13, and CCR7 (Kim et al., 2008), which binds to CCL19 
and CCL21. Within the organised microarchitecture of LNs CXCL13 facilitates the 
segregation of B cells, which express CXCR5, into B cell follicles (Ansel et al., 2000), whilst 
signalling through CCR7 attract T cells to the paracortical, T cell-dominated zone (Worbs 
et al., 2007). Up or down-regulation of either molecule results in the movement of cells to 
the B-T interface, a phenomenon which enables B and T lymphocytes to interact following 
activation (Ansel et al., 1999). To investigate further the proposal that it is the expression 
of these receptors which dictates ILC3 location, cell-surface expression of CXCR5 and 
CCR7 was analysed under different conditions. 
Cells were cultured overnight, to allow for the testing of different conditions on 
chemokine receptor expression, before being analysed by flow cytometry. High levels of 
CXCR5 were detected on the surface of both Lin+ IL-7Rα- ‘B cells’ and Lin- IL-7Rα+ RORγt+ 
ILCs (Figure 3.11a). Approximately half of ILC3 were found to express this receptor and 
no significant difference between ILC3s from mLNs and those from a pool of peripheral 
LNs (pLNs) could be detected (Figure 3.11c). Notably CXCR5 expression was primarily 
detected on ILCs which expressed RORγt, suggesting that neither ILC1 nor ILC2 express 
this marker to any great extent under these conditions (Figure 3.11b). CCR7, in contrast, 
was detected on Lin+ CD3i+ IL-7Rα+ T cells but not on any ILC subset (Figure 3.11a-c). It 
could be possible that expression of mRNA for this molecule in ILC3s (Kim et al., 2008) 
does not result in functional cell surface expression under these circumstances, or 
alternatively that, although detectable on our positive T cell control population, the level 
of this marker on ILC subsets is below our level of detection by flow cytometry and a more 




Figure 3.10 RORγt+ T cells co-localise with ILC3 in peripheral LNs 
Representative immunofluorescence microscopy images of WT LN tissue 
sections. All scale bars are 100μm. 
Sections all counterstained with DAPI, data representative of (a) or 
pooled from 1-3 interfollicular areas from 3 WT mice. Statistical test used 
is Mann-Whitney non-parametric, two-tailed test. *P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001. 
a) Images from analysis of interfollicular areas in stated LNs (detailed 
in bottom left hand corner). Interfollicular areas were defined as 
areas between follicles and to the mid-point of B-T interface. RORγt+ 
IL-7Rαhi cells are circled, those which express CD3 in white, and 
those which are CD3- in yellow.  
b) Graph showing percentage of RORγt+ IL-7Rαhi cells within these 











expression, ILC3 in pLNs and mLNs analysed did not differ significantly. Interestingly, 
CXCR5 expression did seem to correlate with high expression of RORγt, with a RORγtlo 
population appearing CXCR5- (Figure 3.11b). Whether or not these cells locate differently 
within tissues as a result is yet to be seen, and further work would be needed to ensure 
that this population exists within directly ex vivo, un-cultured tissue. 
We also investigated whether any change in chemokine receptor expression, and 
therefore potentially location, could be induced by the introduction of TLR-ligand 
Pam3CSK4—a lipoprotein which resembles the acylated amino terminus of bacterial 
lipopolysaccharide (LPS) and has been shown to bind to TLR1 and TLR2 (Jin et al., 2007) 
—into the cell culture medium. Although this system did not differentiate between 
whether ILC3 were responding to TLR-ligands directly or indirectly (as the culture was 
set up using non-sorted lymph node cell suspension), a statistically significant reduction 
in the percentage of ILC3 which expressed CXCR5 was observed when compared to 
culture only controls. This correlated with a lower median fluorescence intensity (MFI) of 
staining on those ILC3s which were CXCR5+, indicative of downregulation of CXCR5 
expression on the surface of even those cells which remained positive. In both mLN 
(Figure 3.12a,c) and pLNs (Figure 3.12e) there was a significant reduction in the 
percentage of ILC3 which expressed CXCR5 compared to culture only controls. 
Additionally there was also a clear reduction in the intensity of CXCR5 staining on those 
ILC3s which were CXCR5+ following treatment with TLR ligands, indicative of 
downregulation of CXCR5 from the surface of even those cells which remained positive 
(Figure 3.12a,b). When the MFI of CXCR5 expression by CXCR5+ ILC3 and CXCR5+ ‘B cells’ 
was analysed under each condition there was significantly less CXCR5 detected on the 




Figure 3.11 Expression of chemokine receptors by ILCs 
Cells isolated from LNs of naïve WT mice as specified in methods. 
Peripheral LNs (pLNs) are a pool of axillary LN, brachial LN and inguinal 
LNs. All cells cultured overnight at 37°C in culture media prior to analysis 
by flow cytometry. 
All bars shown on graphs represent the median value. Data is 
representative of (a,b) or pooled (c,d) from 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing CCR7 expression by Lin+ IL-7Rα+ CD3i+ T cells, 
CXCR5 expression by Lin+ IL-7Rα- CD3i- ‘B cells’ (top) and both 
CXCR5 and CCR7 expression by Lin- IL-7Rα+ RORγt+ ILCs (bottom, 
pre-gated on Lin- IL-7Rα+ cells highlighted in red) isolated from WT 
mLN. Lin is CD3/CD5/B220/CD11c. 
b) CXCR5 and CCR7 staining on all Lin- IL-7Rα+ cells from WT mLN. 
c)  Graphs showing the percentage of RORγt+ ILC3 which express 











CXCR5 expression on CXCR5+ B cells by comparison significantly increased in treated 
samples (Figure 3.12b,d,f). It is not at this point clear whether or not this is indicative of 
ILC migration away from the B cell follicles in response to the presence of ligands which 
stimulate TLRs, and therefore a phenotype that might be seen in vivo upon immunological 
challenge. 
LTi cells have been shown to be highly dependent upon the cytokine IL-7 for support in 
adult tissue (Schmutz et al., 2009) and fittingly express high levels of the IL-7 receptor, IL-
7Rα. Lymphatic epithelial cells (LECs) within the interfollicular regions of LNs have been 
shown to produce IL-7 (Onder et al., 2012), therefore we hypothesised that the clustering 
of ILC3 in these regions reflected a requirement for vital survival signals. To examine the 
relationship between IL-7 signalling and the expression of CXCR5 on the surface of ILC3 
we added IL-7 to the culture medium and compared to culture-only controls. Binding of 
IL-7 and signalling through IL-7Rα results in the downregulation of IL-7Rα in mature T 
cells (Park et al., 2004), and this has been proposed to prevent excess consumption of this 
cytokine. In the presence of IL-7 not only did T cells downregulate expression of IL-7Rα, 
but ‘helper-like’ ILCs also (Figure 3.13a). In cultures with added IL-7 very few cells were 
found to express IL-7Rα in comparison to the culture only controls, evidence that IL-7 
signalling had indeed taken place, and the gating strategy was adapted accordingly 
(Figure 3.13a). By nature of this method there was contamination of a small population of 
IL-7Rα- RORγt+ cells within the ILC3 gate, however both culture only and treated samples 
were directly comparable. Interestingly, when both culture only and IL-7 treated mLN 
samples were compared there was no statistically significant difference in the number of 
ILC3, indicating that within this time increased levels of IL-7 did not impact survival 




Figure 3.12 ILC3 downregulate CXCR5 in presence of TLR ligands 
Cells isolated from LNs of naïve WT mice as specified in methods. 
Peripheral LNs are pool of axillary LN, brachial LN and inguinal LNs. All 
cells cultured overnight at 37°C in culture media +/- Pam3CSK4 TLR1/2 
agonist (TLRL) prior to analysis by flow cytometry. 
All bars shown on graphs represent the median value. Data is 
representative of (a,b) or pooled (c-f) from 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.  
MFI; median fluorescence intensity, TLRL; TLR ligand.  
a) FACS plots showing expression of CXCR5 by RORγt+ ILC3 from WT 
mLN following overnight culture with (bottom) or without (top) 
TLRL. Gated as shown in Figure 3.11a. 
b) Histograms showing the level of CXCR5 expression on Lin+ IL-7Rα- 
‘B cells’ (left) and Lin- IL-7Rα+ RORγt+ ILC3 (right) from WT mLN, as 
gated in Figure 3.1a. Blue line represents cells which have been 
cultured overnight with TLRL, grey filled histogram shows cells from 
culture media only controls. Y axis is normalised to mode. 
c) Percentage of RORγt+ ILC3 in mLN samples +/- TLRL which are 
CXCR5+.  
d) MFI of CXCR5 staining on CXCR5+ ILC3 (left) and CXCR5+ ‘B cells’ 
(right) from mLN samples +/- TLRL. Y axis on leftmost graph applies 
to both. 
e) Percentage of RORγt+ ILC3 in pLN samples +/- TLRL which are 
CXCR5+.  
f) MFI of CXCR5 staining on CXCR5+ ILC3 (left) and CXCR5+ ‘B cells’ 













Figure 3.13 ILC3 downregulate CXCR5 moderately in presence of IL-
7 
Cells isolated from LNs of naïve WT mice as specified in methods. 
Peripheral LNs are pool of axillary LN, brachial LN and inguinal LNs. All 
cells cultured overnight at 37°C in culture media +/- IL-7 prior to analysis 
by flow cytometry. 
All bars shown on graphs represent the median value. Data is 
representative of (a,b) or pooled (c,d) from 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating strategy for RORγt+ ILCs from WT mLN 
following overnight culture with (bottom) or without (top) IL-7. Lin 
is CD3/CD5/B220/CD11c. 
b) Graph showing the total number of ILC3 per sample following 
overnight culture of the same number of cells +/- IL-7. Cells from WT 
mLN.   
c) Graph showing the percentage of RORγt+ ILC3 which are CXCR5+ in 












experiment was not the result of ILC3 cell death. There was however a decrease in the 
percentage of ILC3 which expressed CXCR5 in both mLN and pLN cultures where IL-7 was 
present but, although statistically significant, the decrease was only moderate (Figure 
3.12c). 
 RORγt+ cell types in peripheral versus mucosal LNs 
Whilst investigating the interfollicular areas of peripheral tissue-draining LNs it was 
noted that populations of RORγt-expressing T cells could be found within these regions, 
which were not detectable within the mucosal tissue-draining mLN. To further explore 
this observation an analysis of all RORγt+ IL-7Rα+ cells within iLN, bLN and mLN was 
carried out. RORγt-expressing cells appeared to constitute a higher proportion of total 
cells in the iLN and bLN than in the mLN (Figure 3.14a), and large populations of RORγt+ 
T cells which were present in the iLN were notably absent in the mLN (Figure 3.14a,b). In 
keeping with both flow cytometry and immunofluorescence microscopy data, CD3- cells 
which resembled ILC3 made up a higher proportion of total RORγt-expressing cells in the 
mLN than in the iLN or bLN (Figure 3.14b,c), indicative of an increased importance for 
these cells at this site. RORγt-expressing cell populations in iLN and bLN tissue were 
found to be largely similar. The dominant RORγt-expressing populations in these LNs 
were a population of RORγt+ γδ T cells and a population of γδTCR- T cells which expressed 
very high levels of IL-7Rα (Figure 3.14c). The identity of this cell type was not established 
in this investigation, however both of these RORγt-expressing IL-7Rαhi T cells and γδ T 
cells were found to be largely absent in the mLN (Figure 3.14a-c). It therefore seems likely, 
although not definitively shown, that these two populations account for the differences 
detected in the interfollicular areas of peripheral LNs. A more detailed flow cytometric 




Figure 3.14 Predominant RORγt-expressing cell types differ in 
peripheral and mucosal tissue-draining LNs    
Cells isolated from LNs of naïve WT mice as specified in methods. 
Samples were analysed by flow cytometry.  
All bars shown on graphs represent the median value. Data is 
representative of (a) or pooled (b,c) from 2 (mLN) or 3 (iLN, bLN) 
independent experiments. Statistical test used is Mann-Whitney non-
parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001. 
a) FACS plots showing gating on populations of RORγt+ IL-7Rα+ cells 
(pre-gated on FSC and SSC). 
b) Graphs comparing percentage of total RORγt+ IL-7Rα+ cells which 
are named cell types in iLN (n=12) and mLN (n=8). 
c) Graphs showing the percentage of total RORγt+ IL-7Rα+ cells which 
are stated cell populations in iLN, bLN and mLN. (n=12,11,8). Y axis 










 Interfollicular regions are unaffected by the loss of RORγt+ cells 
The specific deletion of ILCs is made challenging by their similarities to other cell types, 
including T cells. The most elegant methods of deletion require sophisticated mouse 
models, however it is possible to gain an indication of the result of removing ILCs by using 
bone marrow chimera mice and antibody-mediated depletion. To analyse the importance 
of RORγt-expressing cells within the interfollicular microenvironment of LNs, we 
generated chimeric mice by lethally irradiating RORγt+/- hosts and subsequently 
reconstituting with either WT or RORγt-/- bone marrow. Enhanced depletion of ILC3s, 
which are known to be resistant to irradiation (Dudakov et al., 2012), was achieved by the 
subsequent treatment with anti-CD90 or control antibody, with CD90 expressed by all ILC 
subsets (Walker et al., 2013). Although not ILC3-specific, as this method results in the 
absence of all RORγt-expressing cell types and non-specific targeting of CD90+ cell 
populations, it did allow us to study the lack of ILC3 in a mouse where LNs are still present 
and the opportunity to explore the effect of the loss of RORγt-expressing cell types from 
the interfollicular areas where they cluster.  
Gating on cells which were Lin- IL-7Rα+ revealed that three populations of ILC could be 
detected within iLNs of RORγt+/-:WT chimeras based on expression of GATA-3 and RORγt, 
and therefore the reconstitution of our irradiated hosts had been successful (Figure 
3.15a). By comparison in RORγt+/-:RORγt-/- chimeras no population of RORγt+ ILCs could 
be detected, showing not only that these mice had been reconstituted with RORγt-/- bone 
marrow, but also that the irradiation and anti-CD90 depletion of existing ILC3s within 




Figure 3.15 Interfollicular regions of LNs appear unchanged in 
absence of RORγt-expressing cells  
Chimeras were generated by lethally irradiating RORγt+/- mice before 
hosts reconstituting with WT or RORγt-/- bone marrow cells. WT:RORγt-
/- mice were further treated with anti-CD90.2 antibody. iLNs were 
analysed by flow cytometry and mLNs by immunofluorescence 
microscopy.  
All bars shown on graphs represent the median value.  Data from 1 
independent experiment, and images (d,e) representative of mLNs from 
3 in RORγt+/-:WT and 6 RORγt+/-:RORγt-/- mice. 
a) FACS plots showing gating strategy for ILC populations in iLNs of  
RORγt+/-:WT or RORγt+/-:RORγt-/- chimeras. Lin is 
CD3/B220/CD11b/CD11c. 
b) Graph showing the number of each RORγt+ ILCs per iLN in RORγt+/-
:WT (WT) and RORγt+/-:RORγt-/- (KO) chimeras. (n=2,6). 
c) Image showing area of RORγt+/-:WT and RORγt+/-:RORγt-/- mLN 
tissue stained for expression of RORγt, CD3 and IL-7Rα. Scale bar 
represents 100μm.  
d) Image showing similar areas of mLN in RORγt+/-:WT and RORγt+/-
:RORγt-/- chimeras, stained for expression of IgM, MadCAM-1 and 
CD3. Scale bar represents 100μm.  
e) Image showing similar areas of mLN in RORγt+/-:WT and RORγt+/-
:RORγt-/- chimeras, stained for expression of F4/80 and CD169. Scale 
bar represents 100μm.  
f) Image showing similar areas of mLN in RORγt+/-:WT and RORγt+/-
:RORγt-/- chimeras, stained for expression of RANKL and IgM. Scale 









depletion a small number of RORγt+ ILCs could still be detected in mLN tissue by 
immunofluorescence microscopy, an observation which we were later able to explain by 
different rates of efficiency in removal of these cells by irradiation in mLN and peripheral 
LNs, however their number was much reduced when compared to controls (Figure 3.15c).  
The overall structure of the mLN remained similar, suggesting that the loss of RORγt-
expressing cells does not result in notable morphological changes, however there were 
notably fewer CD3+ cells within RORγt+/-:RORγt-/- lymph nodes. The reason for this is 
unknown, but could be as a result of the use of anti-CD90 antibodies which can also target 
T cells. Although chimeras were not analysed for a number of weeks following antibody 
treatment, it cannot be discounted that this could account for any effects that we observe. 
The presence HEVs, as based on expression of MadCAM-1, did not appear to be perturbed 
and detection of IgM showed the location of B cell follicles (Figure 3.15d). Macrophages 
have been reported to line the subcapsular sinus of LNs (Junt et al., 2007), and could be 
detected in this study by their expression of F4/80 and CD169, but did not appear to be 
affected by the loss of RORγt-expressing cells within these regions. Additionally, within 
the subcapsular region resides a population of marginal reticular cells (MRCs) which have 
been reported to  RANKL, otherwise known as TRANCE (Katakai et al., 2008), with no 
detectable loss of this stromal layer in the absence of RORγt-expressing cells (Figure 
3.15d). 
3.4 SUMMARY 
In depth characterisation of ILC subsets in a range of LNs has revealed differences 
between those LNs which drain mucosal tissues and those which drain peripheral tissues, 




tissue than in either the bLN or iLN, and form a higher proportion of total ILCs in both the 
medLN and mLN—LNs which drain the mucosal surfaces of the respiratory tract and gut 
respectively—than in those LNs which drain the peripheral tissues. Analysis of total 
RORγt-expressing cells within a selection of these LNs has revealed that, whilst ILC3 make 
up the highest proportion of RORγt+ IL-7Rα+ cell types in the mLN, RORγt+ T cell 
populations dominate in the iLN and bLN. This finding fits with our observation of RORγt+ 
T cells clustering in the interfollicular areas of iLNs, regions which, in the mLN, were 
primarily occupied by ILC3. These observations taken together appeared indicative of an 
increased requirement for ILC3 within those LNs which drain mucosal tissues. A higher 
percentage of ILC3 expressed MHCII in the mLN compared to either the iLN or bLN, 
perhaps indicative of an increased requirement for ILC3-expressed MHCII in this LN 
which drains the gut. 
Interestingly, the ILC composition of mLNs from T cell-deficient mice differed 
considerably from those of WT mice. Markedly fewer ILC3 were detected in mLNs from 
RAG-/- mice, which lack both mature T and B lymphocytes, despite there being similar 
numbers of each ILC subset in iLNs. A similar phenotype was apparent in ZAP-70-/- mice, 
where mature T cells are absent but B cells and LN B cell follicles are still present, 
suggesting that this phenotype was not due to the lack of organised lymphoid architecture 
and subsequent effects on ILC3. Strikingly, ILC2 were now the predominant ILC 
population in these LNs, present at much higher numbers than seen in WT controls. This 
seemed unlikely to be a broad effect on ILC development in this mice, since iLNs of RAG-/- 
mice did not show the same trend. The reason for fewer ILC3 in T cell-deficient mLNs is 
unknown, however whether or not the large numbers of ILC2 detected instead is as a 




All three groups of ILC could be detected in all WT LNs analysed, and strikingly ILC2 could 
be detected within the interfollicular areas of the mLN alongside ILC3. The location of 
ILC1 has not yet been elucidated, in part due to our focus on group 2 and group 3 ILC 
subsets, but also because of difficulties in staining for T-bet expression. Why these cells 
sit in these areas is not yet known, and we explored whether this was due to a balance of 
chemokine receptors on the cell surface. CXCR5 could be detected on the surface of ILC3, 
but not ILC2, and CCR7 was not detectable by the methods used, despite CCR7 mRNA in 
LTi cells having previously been reported (Kim et al., 2008). We determined that various 
factors could affect CXCR5 expression by ILC3 in vitro. Inclusion of a TLR1/2 agonist 
resulted in a lower percentage of ILC3 expressing CXCR5, and apparent downregulation 
of CXCR5 levels on those which remained CXCR5+. What was not clear from this study was 
whether this effect was as a result of direct signalling to ILC3, as human LTi-like ILCs have 
been reported to express TLR2 (Crellin et al., 2010), or indirect effects on other cell types. 
It would be interesting to see whether this held true in vivo; whether loss of CXCR5 
resulted in different location of ILC3, and whether this would take place in the context of 
TLR stimulation during an immune response. Also explored was the possibility that 
receiving signals by IL-7 would have an effect on expression of CXCR5. One hypothesis for 
their distinctive location within these regions was their requirement for IL-7 signalling, 
as has previously been shown for adult LTi cells (Schmutz et al., 2009). In a manner similar 
to T cells, we showed that IL-7 signalling resulted in the downregulation of IL-7Rα from 
the surface of ILCs. Although moderate changes in the level of CXCR5 expression were 
detected upon addition of IL-7 to cultures, what this reflects in vivo is not clear and 
requires further investigation. Given that CXCR5 was not detected on the surface of ILC2 




that expression of this chemokine receptor was the primary mechanism of their location 
to this region, and other factors should be considered. LTi cells have previously been 
shown to interact with stromal cells; to provide signals required for the formation of LNs 
(Mebius, 2003), and interact with fibroblastic reticular cells (FRCs) to help repair 
damaged secondary lymphoid tissue following viral infection (Scandella et al., 2008). 
Depletion of RORγt-expressing cells in chimeric mice did not have a noticeable effect on 
structural elements within the interfollicular regions of mLN within the timeframe of our 
experiments, although this was not analysed in the context of infection.  
Those experiments which looked at the number and phenotype of ILC populations in WT 
LNs at steady state were carried out in externally sourced WT mice, so as to minimise 
animal facility-specific differences and enable this experiment to be repeated by 
researchers at different institutions. One interesting observation has been that the 
differences in numbers of ILC3 between skin-draining and mesenteric LNs were less in 
WT mice which had been bred and maintained in our animal facility, perhaps suggesting 
that ILC3 numbers are influenced by microbial flora which is likely to be distinct between 
facilities. Certainly, it can be argued that the mLN represents a more ‘activated’ type of LN, 
given its location draining the gut, therefore an increased number of ILC3 might be the 
result of an ongoing immune response. On a similar note, the peripheral popLN, a LN 
which is arguably less often required to respond to an immunological challenge than the 
mLN given its location draining the hind paw, was found to have the lowest proportion of 
ILC3 of all analysed. Equally, and not mutually exclusively, the observation of ILC3 in the 
mLN could be as a result of it draining the ILC3-enriched gut tissue and both of these 




CHAPTER 4. CHARACTERISING ILCS IN DRAINING LYMPH NODES 
 
4.1 INTRODUCTION 
In light of the presence of all three groups of ILC within all lymph nodes analysed, and the 
potentially influential location of ILC2 and ILC3, we next investigated whether any 
changes in these cells could be observed in a draining lymph node (dLN) following 
immunisation. Owing to its function draining antigen from the microorganism-enriched 
gut, the mLN is likely to be continuously exposed to antigen and therefore more activated 
than those LNs found at other sites. It is therefore possible that the ILC composition of the 
mLN in fact reflects that of an ‘activated’ LN, and could perhaps be induced in a skin-
draining LN following immunisation.  
Following immunisation, antigen-presenting dendritic cells (DCs) carrying antigen can 
drain to the local lymph node via the lymph and lymphatic vessels. DCs presenting this 
antigen in the context of MHCII will then interact with naïve CD4+ T cells within this 
structure and activate an adaptive immune response. ILCs, like dendritic cells, have been 
shown to express MHCII and to process and present peptide (Neill et al., 2010, Hepworth 
et al., 2013); with this discovery changing the way in which the potential roles of ILCs are 
viewed. Certainly within lymph nodes a proportion of ILC3s express this molecule, as 
demonstrated in Chapter 3.  
Although there are still relatively few studies on the function of ILC-expressed MHCII, 
those that exist indicate that expression of MHCII by ILCs can affect an immune response 
in vastly different ways. ILC3 in the gut have been shown to contribute to the prevention 




mechanism (Hepworth et al., 2013). Mice in which MHCII had been specifically deleted 
from ILC3 (MHCIIΔILC3) but not other antigen-presenting cell types developed intestinal 
inflammation, indicating that antigen-presentation by ILC3 in the gut is important for the 
ability of the immune system to tolerate the presence of commensal microbiota. The 
authors found that MHCII+ ILC3 isolated from murine mesenteric LN did not express the 
co-stimulatory molecules CD80 and CD86 (Hepworth et al., 2013). Antigen presentation 
to T cells without further stimulation from co-stimulatory molecules has been shown to 
limit their responses (Schwartz, 2003), and fittingly ILC3s have been shown to induce the 
apoptosis of responding T cells in a MHCII-dependent manner (Hepworth et al., 2015). 
Interestingly, MHCII expression was restricted to those ILC3 that lacked NKp46 
expression (Hepworth et al., 2013), which were found in Chapter 3 of this investigation to 
be the predominant population in lymph nodes.  
Whilst ILC3 in the gut and gut-associated lymphoid tissues lack expression of co-
stimulatory molecules (Hepworth et al., 2013), some ILC3 isolated from the spleen have 
been shown to be able to modestly upregulate expression of CD80 and CD86. This was 
true of murine ex vivo splenic CD4+ NCR- ILC3 stimulated with IL-1β, but not those NCR- 
ILC3 isolated from the small intestine lamina propria (von Burg et al., 2014).  The authors 
also found that the proliferation of a specific population of CD4+ T cells two days following 
exposure to OVA-based antigens was impaired in the spleens of mice where MHCII was 
deleted from ILC3 (von Burg et al., 2014), indicating that antigen presentation by splenic 
ILC3, by contrast, promotes CD4+ T cell responses within this tissue. Mice in which LTi 
cells are deficient have also previously been shown to have normal splenic primary CD4+ 
T cell responses although long-term maintenance of memory populations was perturbed 




differences in the phenotype, and consequently function, of ILC3s at different sites reflects 
the different immunological challenges faced. 
Although CD80 and CD86 expression by group 3 ILCs needs further investigation, co-
stimulatory molecule expression has also been reported by ILC2. ILC2 expressing MHCII 
and the co-stimulatory molecules CD80 and CD86 were found to be capable of inducing T 
cell proliferation in vitro (Oliphant et al., 2014). MHCII-mediated ILC2 interaction with T 
cells was found to be important for the production of IL-13 by ILC2, and for the efficient 
expulsion of intestinal helminth N. Brasiliensis (Oliphant et al., 2014). Interestingly ILC2 
expression of MHCII appears to be site-dependent; with expression documented on ILC2 
in the lymph nodes, spleen and Peyer’s patches, but less so on ILC2 from the lung, 
peritoneal and bronchoalveolar lavages (Oliphant et al., 2014). This area of ILC biology is 
under-explored, with much still to be discovered about the role of ILCs as antigen-
presenting cells. Given that lymph nodes are recognised as important sites for the 
generation of adaptive CD4+ T cell responses we chose to investigate the antigen-
presenting potential of ILCs within these tissues. 
To investigate this we focussed on a draining lymph node immune response to 
immunisation in the skin. Analysis of an endogenous CD4+ T cell response within 
peripheral LNs of mice where ILC3 lack MHCII expression has shown a significantly 
increased number of these cells responding to immunisation compared to controls, 
consistent with ILC3-expressed MHCII being important in these tissues (Mackley et al., 
2015). We utilised a robust draining lymph node model which targeted the skin-draining 
popliteal or brachial and axillary lymph nodes, using a population of responding CD4+ T 




trafficking in response to skin painting with a chemical stimulant have shown that DCs 
arrive within the draining peripheral LN within one day, with their numbers decreasing 
within the draining LN over time (Tomura et al., 2014). We chose to investigate both the 
number and phenotype of ILCs in a draining LN at both early and late timepoints in a 
primary immune response, so as to better understand the potential roles of these cells in 
influencing an adaptive immune response. 
This chapter will firstly describe the number of each ILC subset within draining peripheral 
LNs at early and late timepoints following immunisation, with any accumulation of ILCs 
potentially indicative of a function in the immune response. It will also explore the 
expression of antigen-presenting machinery by these cells at different timepoints, 
comparing their levels of expression to those seen on DCs. Finally it will investigate 
whether or not changes in ILC number within a draining lymph node are due to 
proliferation of these cells or another mechanism, such as trafficking. 
4.2 DRAINING LYMPH NODE MODELS 
 TCR transgenic CD4+ T cell system 
In order to study the response of ILC populations to immunisation, it was important to be 
able to track the progress and magnitude of an immune response within lymph nodes. To 
do this we made use of two existing TCR transgenic CD4+ T cell populations, SM1 
(McSorley et al., 2002) or OTII cells (Barnden et al., 1998). Either SM1 or OTII cells were 
adoptively transferred into our experimental mice the day prior to immunisation, which 
allowed us to trace responding cells of a known antigen-specificity by either allotype 
markers or the expression of their specific TCR. Immunising with their known cognate 




for OTII cells—allowed us to identify an activated CD4+ T cell population and verify that 
the immunisation had been successful. Two TCR transgenic systems were adopted as a 
result of difficulties in maintaining our colony of RAG-/- SM1 mice.   
We identified SM1 T cells by their expression of CD3, CD4 and either CD45.1 or CD45.2; 
the expression of which was used to distinguish donor CD4+ T cells from allotype-marked 
hosts (Figure 4.1a). CD44 expression was used to determine those cells which had seen 
their cognate antigen following immunisation and had become activated (Figure 4.1a,b). 
Similarly, responding OTII cells could be recognised by their expression of CD3, CD4 and 
CD44 and the use of an antibody against Vβ5.1/2 TCR+ T cells, which allowed us to identify 
those CD4+ T cells which respond to OVA, the majority of which were our adoptively 
transferred OTII cells (Figure 4,1b), when allotype discrimination was not possible. In all 
cases TCR transgenic T cells were isolated from secondary lymphoid tissue of the donor 
mouse, analysed to calculate the exact number of SM1 or OTII cells to be transferred, and 
injected intravenously into hosts the day prior to immunisation to allow for circulation of 
the cells to tissues. 
 Targeting immune responses to skin-draining lymph nodes 
Introducing the cognate antigen for the TCR transgenic population being analysed 
subcutaneously into the footpad of host mice induced an immune response in the local 
draining lymph node. Immunising in the hind footpad of mice resulted in an immune 
response in the draining popliteal lymph node (popLN), located behind the knee. Strains 
of L. monocytogenes (Lm) expressing specific peptides have been used previously within 
our laboratory to induce a robust immune response (Marriott et al., 2014), and in this 




Figure 4.1 Comparison of TCR transgenic T cell gating strategies 
Draining LNs from WT mice 4 days p.i. Mice received 104 SM1 or 105 OTII 
transgenic CD4+ T cells intravenously (i.v) a day before immunisation. 
Cells were isolated from LNs as specified in methods. Samples were 
analysed by flow cytometry and representative FACS plots shown.  
a) FACS plots showing the gating strategy for CD44hi SM1 T cells in 
draining popLN 4 days p.i. in the hind paw pad with Lm-FliC. Pre-
gated on FSC and SSC. 
b) FACS plots showing the gating strategy for CD44hi OTII T cells in 
draining brachial and axillary LNs 4 days p.i in the front paw pads 









cells. At the first timepoint analysed, 4 days following immunisation with Lm-FliC, a 
population of CD44hi CD45.2+ SM1 T cells could be detected in the draining popLN, which 
was not present in the contralateral non-draining popLN (ndLN; Figure 4.2a). These cells 
were negative for CD11b, CD11c and B220, but the CD3 gate was generous to account for 
relatively low CD3 expression on SM1 T cells in this system (Figure 4.1a). Nonetheless the 
number of non-SM1 T cells which will have been included because of this is negligible, as 
demonstrated by the low numbers seen in ndLNs. SM1 CD4+ T cells could still be detected 
in the draining popliteal LN up to 12 days post-immunisation (p.i), with numbers peaking 
between day 4 and day 8 (Figure 4.2b). This response looked to be largely specific to the 
draining popliteal lymph node at early timepoints, with no significant increase in SM1 T 
cell number 4 days p.i in the draining iLN when compared to the contralateral iLN (Figure 
4.2c), whilst a highly statistically significant increase was observed in the draining popLN 
(Figure 4.2b).  
This draining LN model was also effective when applied to the front paw-pad, with the 
immune response then detectable within the draining brachial (bLN) and axillary lymph 
nodes (aLN) located beneath the arm. Paw-pad immunisation with aluminium hydroxide-
precipitated (alum-ppt) NP-OVA resulted in the expansion of CD44hi OTII cells in the 
draining lymph node when compared to mice which had been immunised instead with 
PBS (Figure 4.2d,e). This was as opposed to analysing the contralateral LN, as in the 
popLN study detailed above, and a refinement which serves as a better control and avoids 
any potential discrepancies caused by the re-circulation of cells to the contralateral lymph 
node by later timepoints. The higher number of OTII cells detected in this system is most 




Figure 4.2 Tracking CD4+ T cell responses in dLNs 
(a-c) All WT mice received 104 SM1 TCR transgenic CD4+ T cells i.v a day 
before immunisation with Lm-FliC in one hind paw pad. Draining popLNs 
(dLN) were compared to non-draining contralateral popLN controls 
(ndLN).  
(d,e) All WT mice received 105 OTII TCR transgenic CD4+ T cells 
intravenously a day before immunisation with PBS or alum ppt NP-OVA 
in both front paw pads. Brachial and axillary LNs were pooled and 
analysed. 
Samples were analysed by flow cytometry and absolute numbers per 
lymph node calculated. All bars shown on graphs represent the median 
value. Statistical test used is Mann-Whitney non-parametric, two-tailed 
test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating  on populations of adoptively transferred 
SM1 T cells 4, 6, 8 and 12 days (D4, D6, D8 and D12 respectively) p.i. 
ndLN control is also shown (top). Gating strategy is as shown in 
Figure 4.1a.  
b) Graph showing the total number of CD44hi SM1 T cells per popLN at 
stated timepoints p.i. ndLNs are pooled contralateral controls from 
across all timepoints. Data pooled from 1 (D12), 2 (D6) or 3 (D4,8) 
independent experiments. (n=30,11,8,12,4). 
c) Graph showing the total number of CD44hi SM1 T cells per iLN at 
stated timepoints p.i. ndLNs are pooled contralateral controls from 
across all timepoints. Data pooled from 1 independent experiment. 
(n=16,4,4,4,4). 
d) FACS plots showing gating on populations of CD44hi OTII T cells 
pooled from bLNs and aLNs. D1; day 1. Cells pre-gated on CD3+ CD4+ 
T cells as shown in Figure 4.1b. 
e) Graph showing the total number of CD44hi OTII cells per LN at stated 
timepoints p.i. PBS controls are pooled from across all timepoints. 










comparison to 104 naïve SM1 T cells, which made these cells easier to detect and 
characterise within small LNs—and differences in the adjuvant used. 
4.3 CHARACTERISATION OF ILC NUMBER AND PHENOTYPE IN DRAINING LNS 
 ILCs increase in number in a dLN 
Given the lack of experimental data describing ILC responses in draining LNs we sought 
to investigate this further. During the popLN immunisation timecourse outlined in Figure 
4.2 we enumerated the number of LTi-like cells present, at this time identifying them 
using only cell-surface markers. Prior to the discovery of CCR6 as an effective surface 
marker for RORγt-expressing ILCs, a subset of LTi-like cells could be identified in LNs by 
their lack of lineage markers (CD3/CD11b/CD11c/B220)—taking care to exclude any 
CD45.2 CD3lo SM1 T cells that could fall within this population—expression of IL-7Rα and 
expression of CD4 (Figure 4.3a). At the time of this study the existence of other 
populations of ILC was not widely known. Nonetheless, as neither ILC1 nor ILC2 express 
CD4 this analysis is specific for CD4+ group 3 ILCs.  Within the population of cells which 
were negative for common lineage defining markers, cells which expressed both IL-7Rα 
and CD4 could be identified (Figure 4.3a,b). Although still rare in popLNs at steady state, 
the number of these cells was increased in draining popLNs 4-8 days following 
immunisation with Lm-FliC, but appeared to begin to return to steady state levels 
between day 8 and 12 (Figure 4.3b,c). 
The observation that these cell types increased in number during an immune response 
led us to optimise this model further, analysing ILC subsets in draining LNs beneath the 
arm rather than in the leg by immunising in the front paw pad. This was in part due to the 




Figure 4.3 CD4+ LTi-like ILC3 accumulate in draining popLNs 
All WT mice received 104 SM1 TCR transgenic CD4+ T cells i.v a day before 
immunisation with Lm-FliC in one hind paw pad. Draining popLNs (dLN) 
were compared to non-draining contralateral popLN controls (ndLN). 
Samples were analysed by flow cytometry and absolute numbers per 
lymph node calculated.  
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from 1 (D12), 2 (D6) or 3 (D4,8) 
independent experiments. Statistical test used is Mann-Whitney non-
parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001. 
a) Gating strategy showing populations of CD4+ LTi-like ILC3 in 
contralateral non-draining popLN (top) and draining popLN 4 days 
p.i (bottom). 
b) FACS plots showing CD4+ LTi-like ILC3 across stated timepoints, pre-
gated as shown in (a). 
c) Graph showing the total number of CD4+ LTi-like ILC3 per popLN at 
stated timepoints p.i. ndLNs are pooled contralateral controls from 









because ILC characterisation studies outlined in Chapter 3 have shown the popLN to have 
relatively few ILC3. The adjuvant used at the time of immunisation was also adapted. Pilot 
data shown in Figure 4.4, using a more sophisticated method of gating ILCs (Figure 4.4a), 
revealed that alum-ppt FliC peptide induced a larger expansion of both SM1 T cell and ILC 
populations in dLNs than FliC peptide expressed by L. monocytogenes (Figure 4.4b-d). 
Numbers of total Lin- IL-7Rα+ ILCs were statistically significantly increased in those mice 
which had been immunised with alum-ppt FliC when compared to those immunised with 
Lm-FliC 8 days p.i (Figure 4.4b). This corresponded to a statistically significant increase 
in numbers of ILC1 and ILC3 (Figure 4.4c). Immunisation with alum-ppt FliC also resulted 
in a greater expansion of SM1 T cells than Lm-FliC (Figure 4.4d) and as a result alum was 
used as an adjuvant in the experiments detailed below. 
 An optimised draining lymph node model 
Having observed an increase in ILC number following immunisation we sought to 
characterise ILCs in draining LNs further by phenotyping each subset at early and late 
timepoints during an immune response; in particular to investigate their potential to act 
as APCs. To achieve this our optimised draining lymph node model was used. WT mice 
were immunised in the front paw pads, and the immune response analysed in the draining 
brachial and axillary LNs. OTII CD4+ T cells were used in this particular study as a result 
of difficulties in maintaining the RAG-/- SM1 mouse colony, however both TCR transgenic 
systems have been found to be effective as a readout of the magnitude of the immune 
response. Mice were therefore immunised with NP-OVA to target the adoptively 





Figure 4.4 Comparison of the magnitude of response to different 
adjuvants 
All WT mice received 105 SM1 TCR transgenic CD4+ T cells i.v a day 
before immunisation with Lm-FliC in one front paw pad and alum-ppt 
FliC in the other. Draining bLNs were compared to mice in which both 
paw pads were immunised with PBS, 8 days p.i. Samples were analysed 
by flow cytometry and absolute numbers per LN calculated.  
All bars shown on graphs represent the median value. Data 
representative of 1 independent pilot experiment. Statistical test used is 
Mann-Whitney non-parametric, two-tailed test. *P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001. 
a) Gating strategy showing populations of ILCs in PBS control LN. Lin is 
CD3/CD5/B220/CD11c. 
b) Graph showing the total number of Lin- IL-7Rα+ ILCs per LN 8 days 
following immunisation with PBS, Lm-FliC (Lm) or alum-ppt FliC 
(Alum). (n=3,4,4). 
c) Graphs showing the number of ILC1, ILC2 and ILC3 per LN 8 days p.i 
with PBD (white triangles), Lm-FliC (grey triangles) or alum-ppt FliC 
(black triangles). ILC1 are defined as RORγt- GATA-3- ILCs. (n=3,4,4). 
d) Total number of CD44hi SM1 T cells per LN 8 days following 
immunisation with PBS, Lm-FliC (Lm) or alum-ppt FliC (Alum). 
(n=3,4,4). 










 ILCs as antigen-presenting cells 
All three groups of ILC could be detected in a pool of brachial and axillary LNs from mice 
taken one day (approximately 20-22hrs) following immunisation with either PBS or 
alum-ppt NP-OVA. Three groups of ILCs could be identified from a population of lineage 
(CD3/CD5/B220/CD11b/CD11c) negative IL-7Rα+ cells, based on their expression of 
GATA-3 (ILC2), RORγt (ILC3) or absence of both transcription factors (ILC1; Figure 4.5a). 
Cells identified as ILC3 were then further split into those which were NKp46- (LTi-like 
ILC3) and those which were NKp46+ MHCII- (NCR+ ILC3). One day p.i the total number of 
Lin- IL-7Rα+ ILCs per LN were found to be increased in comparison to control LNs (Figure 
4.5b), with statistically significant increases detected specifically in the number of ILC2 
and LTi-like ILC3 populations (Figure 4.5c). To understand whether this increase in 
number was indicative of ILCs playing a role early in immune responses we next sought 
to characterise the phenotype of these cells at this timepoint. 
As it has been reported that some ILC2 and ILC3 express MHCII and are capable of 
presenting antigen to CD4+ T cells (Oliphant et al., 2014, Hepworth et al., 2013, von Burg 
et al., 2014) we thought it relevant to investigate whether, in the context of a peripheral 
LN immune response, ILCs resembled professional APCs in their expression of MHCII and 
the co-stimulatory molecules CD80 and CD86. In order to make this comparison 
populations of DCs detected during our response were phenotyped. Two distinct 
populations of MHCII+ CD11c+ CD3- B220- DCs could be detected in draining LNs of both 
PBS and alum-ppt NP-OVA treated mice 1 day p.i (Figure 4.6a), and these DC populations 




Figure 4.5 Numbers of dLN ILC2 and LTi-like ILC3 moderately 
increase early in an immune response 
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. Lin- IL-7Rα+ RORγt+ ILC3s 
were further split into those which express NKp46 at a level comparable 
to ILC1 (NCR+ MHCII- ILC3) and those which do not (LTi-like ILC3), whilst 
ILC1 are defined as Lin- IL-7Rα+ RORγt- GATA-3- cells. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b,c) 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on populations of ILCs in pooled bLN and 
aLNs 1 day p.i with alum-ppt NP-OVA (D1). Lin is 
CD3/CD5/B220/CD11b/CD11c. 
b) Graph showing the total number of Lin- IL-7Rα+ ILCs per LN in PBS 
control mice (white triangles) or 1 day p.i with alum-ppt NP-OVA 
(grey triangles). (n=9,10). 
c) Graph showing the number of ILC1, ILC2, LTi-like ILC3 or NCR+ ILC3 













Figure 4.6 Characterising DCs early in an immune response 
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. CD11c+ cells were split 
into those which expressed intermediate levels of MHCII (MHCII+) and 
those whose levels were high (MHCIIhi). iLN, bLN and aLNs from non-
immunised CD80-/-CD86-/- mice were used to control for expression of 
CD80 and CD86. 
All bars shown on graphs represent the median value. Data 
representative of (a,c,e) or pooled from (b,d,f-h) 3 independent 
experiments. Statistical test used is Mann-Whitney non-parametric, two-
tailed test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on CD11c+ MHCII+ DCs in bLN and aLN 1 
day p.i with alum-ppt NP-OVA.  
b) Graph showing the total number of MHCII+ and MHCIIhi DCs per LN 
1 day following immunisation with PBS or alum-ppt NP-OVA (D1). 
c) FACS plot showing expression of phenotypic markers CD11b and 
CD103 on CD11c+ MHCIIhi DCs as gated in (a). 
d) Graph showing the percentage of MHCIIhi DCs which express CD103 
or CD11b 1 day p.i with PBS or alum-ppt NP-OVA (D1). 
e) FACS plots showing the expression of CD80 and CD86 on WT MHCIIhi 
DCs (left) from bLN and aLN 1 day p.i with alum-ppt NP-OVA, 
compared to MHCIIhi DCs from naïve CD80-/-CD86-/- mice (right), as 
gated in (a). 
f) Graphs showing percentage of MHCIIhi DCs which are CD80+ and/or 
CD86+ (co-stim+) in  bLN and aLN 1 day p.i with PBS or alum-ppt NP-
OVA (D1) and compared to CD80-/-CD86-/- controls. 
g) Graph showing percentage of MHCIIhi DCs which are CD86+ in  bLN 
and aLN 1 day p.i with PBS or alum-ppt NP-OVA (D1) and compared 
to CD80-/-CD86-/- controls. 
h) Graph showing the percentage of MHCIIhi DCs which are CD80+ and 
CD86+ in  bLN and aLNs 1 day p.i with PBS or alum-ppt NP-OVA (D1) 










high levels of MHCII may include skin-derived DCs, whilst those which have intermediate 
expression of MHCII and higher expression of CD11c have previously been described as 
LN-resident DCs (Tomura et al., 2014). Analysis of the number of each DC population per 
LN revealed that although the median number of both populations increased following 
immunisation, only the increase in MHCII+ DCs was statistically significant at this 
timepoint (Figure 4.6b).  The phenotype of the MHCIIhi DC population in dLNs was also 
found not to change significantly between PBS and alum-ppt NP-OVA treated mice, with 
the cells found to be primarily CD11b+, and only a small population expressing CD103 
(Figure 4.6c,d). Interestingly, although ILCs are generally considered a rare population in 
LNs, DC populations are also relatively rare within LNs at this timepoint, therefore it is 
feasible that ILCs could play a role in antigen-presentation provided they possess the 
molecules required. Analysis of DC populations also provided a positive control for 
expression of the co-stimulatory molecules CD80 and CD86, whilst comparison to LNs 
from CD80-/-CD86-/- mice served as an effective negative control (Figure 4.6e). Analysis 
revealed that >80% of MHCIIhi DCs expressed CD80 and/or CD86 (co-stim+) in dLNs from 
both PBS control and alum-ppt NP-OVA treated mice (Figure 4.6f), but although a higher 
percentage of MHCIIhi DCs expressed both molecules simultaneously in those mice 
immunised with alum-ppt NP-OVA both this, and their expression of CD86 alone, was not 
statistically significantly increased (Figure 4.6 f-h). 
MHCII expression was analysed on populations of ILC1, ILC2 and LTi-like ILC3, with NCR+ 
ILC3 here partly defined by their absence of MHCII and therefore excluded. Expression of 
MHCII to some extent could be seen by all ILC subsets, however most notably on ILC2 and 
LTi-like ILC3 (Figure 4.7a-c). For each ILC subset, the percentage of cells that expressed 




Figure 4.7 A proportion of ILC2 and LTi-like ILC3 express MHCII in 
draining LNs   
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. ILC1 are defined as RORγt- 
GATA-3- ILCs. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b,c) 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing expression of MHCII on ILC2 (left, GATA-3+) and 
LTi-like ILC3 (right, RORγt+ NKp46-) in bLN and aLNs 1 day p.i with 
PBS (top) or alum-ppt NP-OVA (bottom). Cells shown are pre-gated 
on Lin- IL-7Rα+ ILCs.  
b) Graph showing the total number of ILC1, ILC2 and LTi-like ILC3 
which express MHCII per LN. (n=9,10). 










(Figure 4.7c), however the number of LTi-like ILC3 which expressed the molecule was 
moderately increased in dLNs, and this was statistically significant (Figure 4.7b). Analysis 
of co-stimulatory molecule expression by MHCII+ ILCs revealed some expression of CD80 
and CD86 by both ILC2 and LTi-like ILC3 (Figure 4.8a). Approximately 50% of MHCII+ 
ILC2 (Figure 4.8b) and 30-35% of MHCII+ LTi-like ILC3 (Figure 4.8c) expressed CD80 
and/or CD86 (described as co-stim+) in a pool of bLN and aLN, and this did not differ 
significantly between dLNs from PBS control and alum-ppt NP-OVA immunised mice. 
When expression of each molecule was investigated in more detail, MHCII+ ILC2 were 
found to express primarily CD86 (Figure 4.8d), whilst LTi-like ILC3 showed no apparent 
bias (Figure 4.8e).  
Although from Figure 4.8(a-e) it might be possible to conclude that a proportion of MHCII+ 
ILC2 and LTi-like ILC3 look comparable to professional antigen-presenting cells in their 
expression of MHCII and co-stimulatory molecules, DCs express much higher levels of 
these molecules than LTi-like ILC3. Comparison of levels of both CD80 and CD86, in terms 
of intensity of fluorescence detected, on MHCII+ LTi-like ILC3 and MHCIIhi DCs revealed a 
much bigger difference between staining levels on DCs when compared to those in 
CD80-/-CD86-/- controls than on LTi-like ILC3 (Figure 4.8f ). Therefore, although there are 
CD80 and/or CD86 expressing MHCII+ ILCs within these LNs, their scarcity and low level 
of expression of key co-stimulatory molecules suggests that their role as APCs naïve CD4+ 
T cell proliferation would be minor in comparison to DCs. 
 Phenotyping ILCs at later timepoints in an immune reponse 
Given our previous observation, in Figures 4.3 and 4.4, of ILC number increasing at later 




Figure 4.8 Characterising co-stimulatory molecule expression by 
ILCs early in an immune response    
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i, as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. Non-immunised CD80-/-
CD86-/- mice were used to control for expression of CD80 and CD86. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b-e) 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing expression of CD80 and CD86 by MHCII+ ILC2 
(top) and MHCII+ LTi-like ILC3 (bottom) in LNs 1 day p.i with PBS or 
alum-ppt NP-OVA (D1) and compared to naïve CD80-/-CD86-/- mice. 
b) Graph showing the percentage of MHCII+ ILC2 which express CD80 
and/or CD86 (co-stim+) in naïve CD80-/-CD86-/- (black triangles) or 
1 day p.i with PBS (white triangles) or alum-ppt NP-OVA (D1, grey 
triangles). 
c) Graph showing the percentage of MHCII+ LTi-like ILC3 which express 
CD80 and/or CD86 (co-stim+) in naïve CD80-/-CD86-/- or 1 day p.i 
with PBS or alum-ppt NP-OVA (D1). 
d) Graph showing the percentage of MHCII+ ILC2 which express CD80, 
CD80 or both molecules 1 day p.i with PBS or alum-ppt NP-OVA (D1).  
e) Graph showing the percentage of MHCII+ LTi-like ILC3 which express 
CD80, CD80 or both molecules 1 day p.i with PBS or Alum ppt NP-
OVA (D1).  
f) Histograms showing expression of CD80 and CD86 on MHCIIhi 
CD11c+ DCs (left) and MHCII+ LTi-like ILC3 (right) 1 day p.i with PBS 
or alum-ppt NP-OVA. Naïve CD80-/-CD86-/- control shown alongside 









 phenotype, in a manner similar to that discussed above, both 4 and 8 days p.i. Each subset 
was once again identified as lineage (CD3/CD5/B220/CD11b/CD11c) negative cells 
which expressed high levels of IL-7Rα, and then further distinguished by expression of 
transcription factors and other surface markers (Figure 4.9a). Surprisingly, although total 
number of ILCs did increase at day 4 (D4) p.i with alum-ppt NP-OVA, this was not 
determined to be statistically significant from PBS controls in this study, whilst the 
increase in total ILCs by day 8 (D8) was found to be highly statistically significant (Figure 
4.9b). This draining LN model has consistently revealed a biological trend towards 
increases in the number of ILCs in a dLN, however in this particular study only the 
increase in NCR+ ILC3 was found to be statistically significant 4 days p.i. (Figure 4.9c); 
nonetheless the trend remained the same, with moderate increases in the median number 
of ILC2 and LTi-like ILC3. By day 8, however, all subsets had statistically significantly 
increased in comparison to PBS controls (Figure 4.9c), with LTi-like ILC3 marginally the 
most abundant ILC per LN at this timepoint. 
Four days p.i there was no significant difference in the number of each ILC subset which 
expressed MHCII in dLNs from PBS controls and alum-ppt NP-OVA immunised mice, and 
similarly to at D1 timepoints no difference in the overall percentages were observed 
(Figure 4.10a,b). Although 8 days following immunisation there was a significant increase 
in the number of LTi-like ILC3 which were MHCII+ in dLNs compared to PBS controls 
(Figure 4.10c) this appeared to correspond to an overall decrease in the total percentage 
of LTi-like ILC3 which expressed this molecule (Figure 4.10d). As with early in an immune 
response a proportion of MHCII+ ILC2s expressed CD80 and/or CD86 (co-stim+) at both 
D4 and D8 timepoints, and although there was an increase in the median percentage of 




Figure 4.9 Numbers of dLN ILCs increase more substantially at later 
timepoints in an immune response    
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i, as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. Lin- IL-7Rα+ RORγt+ ILC3 
subset further split into those which express NKp46 at a level 
comparable to ILC1 (NCR+ MHCII- ILC3) and those which do not (LTi-like 
ILC3), whilst ILC1 are defined as Lin- IL-7Rα+ RORγt- GATA-3- cells. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b,c) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on populations of ILCs in bLN and aLNs 4 
(centre) or 8 days (bottom) days p.i. with alum-ppt NP-OVA and 
compared to PBS control (top). Cells are pre-gated on CD11c- cells 
and Lin is CD3/CD5/B220. 
b) Graph showing the total number of Lin- IL-7Rα+ ILCs per LN in PBS 
control mice (white triangles) or 4 and 8 days p.i with alum-ppt NP-
OVA (D4, D8; grey triangles). PBS controls are pooled from both D4 
and D8 timepoints. (n=10,6,6). 
c) Graph showing the number of ILC1, ILC2, LTi-like ILC3 or NCR+ ILC3 
per LN in PBS (P) controls, 4 days or 8 days p.i with alum-ppt NP-










Figure 4.10  A proportion of ILC2 and LTi-like ILC3 express MHCII in 
draining LNs at later timepoints in an immune response 
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i, as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. ILC1 are defined as RORγt- 
GATA-3- ILCs. 
All bars shown on graphs represent the median value. Data pooled from 
2 independent experiments. Statistical test used is Mann-Whitney non-
parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001. 
a) Graph showing the total number of ILC1, ILC2 and LTi-like ILC3 
which express MHCII per LN 4 days p.i with PBS or alum-ppt NP-OVA 
(D4). (n=5,6). 
b) Graph showing the percentage of ILC1, ILC2 and LTi-like ILC3 which 
express MHCII 4 days p.i with PBS or alum-ppt NP-OVA (D4). (n=5,6). 
c) Graph showing the total number of ILC1, ILC2 and LTi-like ILC3 
which express MHCII per LN 8 days p.i with PBS or alum-ppt NP-OVA 
(D8). (n=5,6). 
d) Graph showing the percentage of ILC1, ILC2 and LTi-like ILC3 which 









 (Figure 4.11a), nor was there any significant increase in the percentage of MHCII+ LTi-
like ILC3 which expressed either molecule (Figure 4.11b). As seen previously at day 1 p.i 
there was no obvious bias of MHCII+ LTi-like ILC3 towards expression of CD80, CD86 or 
both molecules (Figure 4.11d), however in contrast to the phenotype seen at day 1 MHCII+ 
ILC2 at day 4 and day 8 timepoints did not appear to express very much CD86, expressing 
instead CD80 (Figure 4.11c). As this was also true of PBS controls, this difference was 
unlikely to be due to the immunisation, perhaps instead indicating subtle differences 
between ILCs in male mice (D1 timepoint) versus female (D4 and D8) or other factors 
unknown. It is important however to take into account that if the number of MHCII+ co-
stim+ ILC2 or LTi-like ILC3 are analysed as a percentage of the total ILC2 or LTi-like ILC3 
in a LN at either timepoint, as opposed to just those which are MHCII+, this is only a very 
small percentage of total ILCs (Figure 4.11e,f). 
 Ability of ILCs to proliferate following immunisation 
These data so far have shown a modest increase in ILC number at early timepoints in an 
immune response, followed by a more substantial accumulation by day 8 p.i. To determine 
the mechanism of this increase expression of the proliferation marker Ki67 was analysed 
to determine whether evidence of increased ILC proliferation could account for the 
increase seen. A proportion of ILC1 and ILC2 could be seen to express Ki67—a marker of 
cell cycling and proliferation—at steady state (Figure 4.12a,b), in contrast to LTi-like ILC3 
which uniformly lacked Ki67 expression. NCR+ ILC3 Ki67 expression was more varied 
than in other subsets, probably reflecting some expression of Ki67 by these cells but also 
that the number of this ILC3 subset is so low in lymph nodes that, perhaps for this reason, 
this analysis is more variable. Although there were some significant changes in the 




Figure 4.11 Characterisation of co-stimulatory molecule expression 
by ILC2 and LTi-like ILC3    
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i, as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. Non-immunised CD80-/-
CD86-/- mice were used to control for expression of CD80 and CD86. 
All bars shown on graphs represent the median value. Data pooled from 
2 independent experiments. Statistical test used is Mann-Whitney non-
parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001. 
a) Graph showing the percentage of MHCII+ ILC2 which express CD80 
and/or CD86 (co-stim+) in naïve CD80-/-CD86-/- (black triangles) or 
4 (left) or 8 (right) days p.i with PBS (white triangles) or alum-ppt 
NP-OVA (D4, D8; grey triangles). 
b) Graph showing the percentage of MHCII+ LTi-like ILC3 which express 
CD80 and/or CD86 (co-stim+) in naïve CD80-/-CD86-/- or 4 (left) or 8 
(right) days p.i with PBS or alum-ppt NP-OVA (D4, D8). 
c) Graph showing the percentage of MHCII+ ILC2 which express CD80, 
CD80 or both molecules 4 (left) or 8 (right) days p.i with PBS or 
alum-ppt NP-OVA (D4, D8). 
d) Graph showing the percentage of MHCII+ LTi-like ILC3 which express 
CD80, CD80 or both molecules 4 (left) or 8 (right) days p.i with PBS 
or alum-ppt NP-OVA (D4, D8). 
e) Graph showing the percentage of total ILC2 which express CD80 
and/or CD86 (co-stim+) in naïve CD80-/-CD86-/- or 4 (left) or 8 (right) 
days p.i with PBS or alum-ppt NP-OVA (D4, D8). 
f) Graph showing the percentage of total LTi-like ILC3 which express 
CD80 and/or CD86 (co-stim+) in naïve CD80-/-CD86-/- or 4 (left) or 8 










Figure 4.12 ILCs do not proliferate substantially in draining LNs 
All WT mice received 105 OTII TCR transgenic CD4+ T cells intravenously 
a day before immunisation with PBS or alum-ppt NP-OVA in both front 
paw pads. Cells were isolated and pooled from bLN and aLNs 1 day p.i, as 
detailed in methods. Samples were analysed by flow cytometry and 
absolute numbers per lymph node calculated. Lin- IL-7Rα+ RORγt+ ILC3 
subset further split into those which express NKp46 at a level 
comparable to ILC1 (NCR+ MHCII- ILC3) and those which do not (LTi-like 
ILC3), whilst ILC1 are defined as Lin- IL-7Rα+ RORγt- GATA-3- cells. 
All bars shown on graphs represent the median value. Data 
representative of (a,c) or pooled from (b,d) 2 (D4, D8) or 3 (D1) 
independent experiments. Statistical test used is Mann-Whitney non-
parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001. 
a) FACS plots showing Ki67 expression by ILC subsets in PBS controls 
and 1 day p.i with alum-ppt NP-OVA (D1).  
b) Graphs showing the percentage of each subset of ILC which were 
Ki67+ 1, 4 and 8 days p.i with either PBS (P) or alum-ppt NP-OVA (D1, 
D4, D8). Y axis scale on the leftmost graph applies to all. 
(n=9,10,5,6,5,6). 
c) FACS plots showing Ki67 expression by MHCII- (blue) and MHCII+ 
(red) ILC2 in PBS control mice. 
d) Graph showing the percentage of MHCII- and MHCII+ ILC2 which 
express Ki67 in bLN and aLNs of PBS control mice pooled from 










percentage Ki67+ ILC1 increased at day 8 p.i with alum-ppt NP-OVA (Figure 4.12b) and 
the percentage of Ki67+ significantly decreased at day 1 p.i when compared to PBS 
controls (Figure 4.12b)—Ki67 expression by ILCs in draining lymph nodes appears 
largely comparable to those analysed at steady state, certainly not increased to an extent 
which would explain the increase in ILC number.  
Strikingly further analysis of MHCII- and MHCII+ ILC2 populations in PBS control brachial 
and axillary lymph nodes revealed that those ILC2 which expressed MHCII also expressed 
significantly more Ki67 (Figure 4.12c,d), perhaps implying fundamental differences 
between these two ILC2 populations. 
 ILCs do not accumulate in dLNs of CD80-/-CD86-/- mice. 
To further investigate the potential pathways regulating ILC accumulation in the draining 
LN, we used CD80-/-CD86-/- mice to provide some further insight into the mechanisms 
involved in ILC increase in LNs. CD80-/-CD86-/- mice were used to study the effects of 
immunisation on ILCs in a system where the ability of T cells to respond was impaired. In 
these mice all cell types lack the expression of the co-stimulatory molecules CD80 and 
CD86, one result being that antigen-presenting cells are unable to provide co-stimulatory 
signals to T cells through interaction with CD28 (Green et al., 1994). In the absence of this 
signal T cells are unable to become activated and proliferate even in the presence of their 
cognate antigen, and therefore both T cell responses and T cell-dependent processes are 
affected. These mice proved useful in analysing the effect of a T cell response on the 
response of ILCs to immunisation. Analysis of the ILC composition of brachial and axillary 
LNs taken from PBS control mice revealed that the number of ILC1, ILC2, LTi-like ILC3 




4.13a,b). The absence of CD80 and CD86 did not therefore have any effect on the number 
of ILCs present in LNs at steady state. 
To verify the abrogation of T cell activation within these mice, OTII TCR transgenic CD4+ 
T cells were transferred intravenously into WT and CD80-/-CD86-/- mice, which were 
immunised the following day with either PBS or alum-ppt NP-OVA. Analysis of total OTII 
cell number per LN 4 days p.i revealed that whilst there had been an increase in OTII cell 
number in the lymph nodes of alum-ppt NP-OVA immunised WT mice compared with PBS 
controls, there had been no such increase in CD80-/-CD86-/- mice (Figure 4.13c,d). This 
was consistent with an impairment in T cell activation and proliferation resulting from 
the inability of APCs to provide ‘signal 2’, and supported by the fact that OTII cells within 
immunised CD80-/-CD86-/- mice had lower levels of Ki67 than those in immunised WT 
mice (Figure 4.13d). 
Analysis of ILC1, ILC2, LTi-like ILC3 and NCR+ ILC3 populations in WT mice revealed that 
all had increased in number when compared to PBS controls (Figure 4.13e), consistent 
with earlier biological trends. By comparison, in CD80-/-CD86-/- mice, despite the numbers 
of ILCs at resting state not being significantly different to those in WT mice, there had 
been no significant increase in number following immunisation (Figure 4.13e); and when 
numbers of ILC1, LTi-like ILC3 and NCR+ ILC3 in alum-ppt NP-Ova immunised WT and 
CD80-/-CD86-/- LNs were compared they were found to differ statistically significantly at 
day 4. 
4.4 SUMMARY 
Characterisation of the response of ILC populations to immunisation has revealed that 




Figure 4.13 ILCs do not accumulate in dLNs of mice which lack CD80 
and CD86  
WT mice compared to CD80-/-CD86-/- mice.  All mice received 105 OTII 
transgenic CD4+ T cells intravenously a day before immunisation with 
either PBS (control) or alum-ppt NP-OVA in both front paw pads. All mice 
were taken at 4 days p.i and a cell suspension made from brachial and 
axillary LNs as specified in methods. Samples were analysed by flow 
cytometry and absolute numbers per lymph node calculated. Lin- IL-7Rα+ 
RORγt+ ILC3 subset further split into those which express NKp46 at a 
level comparable to ILC1 (NCR+ ILC3) and those which do not (LTi-like 
ILC3), whilst ILC1 are defined as Lin- IL-7Rα+ RORγt- GATA-3- cells. 
All bars shown on graphs represent the median value. Data 
representative of (a,c) or pooled from (b,d,e) 3 independent 
experiments. Statistical test used is Mann-Whitney non-parametric, two-
tailed test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating  ILC populations in WT and CD80-/-CD86-
/- LNs 4 days p.i with PBS or alum-ppt NP-OVA. Cells were pre-gated 
on Lin- (CD3/CD5/B220/CD11b/CD11c, CD3i-) IL-7Rα+ ILCs. 
b) Graph showing the total number of each ILC subset per LN in WT 
(white) and CD80-/-CD86-/- (grey) PBS control mice. (n=6,8). 
c) FACS plots showing gating on CD44hi OTII cells in WT (top) and 
CD80-/-CD86-/- (bottom) mice 4 days p.i with PBS or alum-ppt NP-
OVA (D4). Cells are pre-gated on CD3+ CD4+ T cells and Vβ5.1/2 TCR 
is used for OTII cell detection. 
d) Graph (top) showing the total number of CD44hi OTII cells per LN in 
WT (white) and CD80-/-CD86-/- (grey) mice 4 days p.i with PBS or 
alum-ppt NP-OVA (D4) and the percentage of CD44hi OTII cells which 
are Ki67+ (bottom). (n=6,8,8,9). 
e) Graphs showing the total number of each subset of ILC per LN in WT 
(white) and CD80-/-CD86-/- (grey) mice 4 days p.i with PBS or alum-











some expression of MHCII and co-stimulatory molecules, seem unlikely to function like 
DCs as inducers of primary CD4+ T cell responses. 
Using an optimised draining LN model we were able to analyse changes in ILC number 
and phenotype across a timecourse, focusing first on early timepoints in an immune 
response. DCs have been shown to accumulate within a draining peripheral LN by 1 day 
post immunological stimulation of the skin (Tomura et al., 2014) and in this investigation 
we show an increase in the total number of ILCs at this timepoint, as well as specific 
increases in populations of ILC2 and LTi-like ILC3.  
MHCII expression has previously been detected on ILC3 (Hepworth et al., 2013) and ILC2 
(Oliphant et al., 2014) isolated from the mLN. We show here that a proportion of ILC2 and 
LTi-like ILC3 within pooled brachial and axillary LNs express MHCII, although there was 
no convincing evidence that these cells upregulated expression of this molecule following 
immunisation. A proportion of MHCII+ ILC2 and LTi-like ILC3 were also found to express 
low levels of CD80 and/or CD86, thus theoretically making them capable of presenting 
antigen to naïve CD4+ T cells and providing the signals required for activation at early 
timepoints following immunisation. The rarity of these cells, coupled with comparably 
lower levels of expression of co-stimulatory molecules than DC makes it seem unlikely 
that ILCs contribute to this process in any meaningful way. 
All populations of ILCs had increased more substantially by day 8 of the immune response. 
Although LTi-like ILC3 had accumulated significantly by this timepoint, it is not clear that 
the ILC compartment began to resemble that observed in mucosal draining LNs. ILC2 have 
previously been reported to accumulate in draining medLNs following intranasal 




in this study ILC2 increase was mild in comparison to the increase of other ILC subsets. 
This was in spite of the use of alum as an adjuvant in the latter part of this study for its 
capacity to induce a stronger immune response to antigen in our draining LN model, and 
this adjuvant is widely known to induce robust type 2 immune responses (Lindblad, 
2004). It would therefore be of interest to investigate the ability of different immunisation 
methods to induce ILC accumulation within these LNs, in addition to a better 
understanding of the mechanism by which these cells accumulate in the first place.  
Analysis of Ki67 expression by ILC subsets across this timecourse revealed little 
difference in proliferation between ILCs in PBS control LNs and those from mice 
immunised with alum-ppt NP-OVA. ILC2 were generally more proliferative than either 
ILC1 or LTi-like ILC3, but this did not appear to be related to the ongoing immune 
response. Proliferation of this subset has previously been documented in response to IL-2 
in spleens of RAG-/- mice (Roediger et al., 2013) and ILC2s have been shown to respond to 
the production of this cytokine by T cells (Oliphant et al., 2014), however this does not 
seem to be the case in the immune response documented here despite the presence of 
activated T cells in alum-ppt NP-OVA treated mice. Interestingly a higher proportion of 
MHCII+ ILC2 express Ki67 than their MHCII- counterparts in PBS controls, although it is 
not clear why this should be the case at steady state and may be indicative of differences 
between these two subsets of ILC2. 
An absence of an ongoing T cell response did however appear to affect accumulation of 
ILCs within draining LNs. No accumulation of any ILC subset could be detected in CD80-/-
CD86-/- mice. Although low levels of CD80 and CD86 can be detected on the surface of ILCs 




themselves which causes this phenotype. One possible explanation is the lack of a T cell-
dependent immune response within CD80-/-CD86-/- draining LNs. In these mice APCs are 
unable to provide the necessary co-stimulatory signals following antigen presentation, 
and as a result T cells do not become activated. It is possible that signals resulting from T 
cell expansion and activation subsequently facilitate the accumulation of ILCs. Whether 
or not this is a direct effect of T cell activation, or due to impairments of other elements of 
the immune response in these mice is yet to be seen. 
Overall, there is no evidence that ILCs change their phenotype to become potent 
professional antigen-presenting cells or increase in number substantially in the skin-
draining LN immune responses investigated in this study. Although it can be argued that 
the number and phenotype of DC populations within this study similarly did not change 
notably early in an immune response, these cells are fundamentally better at this function 
than populations of ILCs. All subsets of ILCs had accumulated most noticeably at later 
timepoints in the immune response, but it is not clear that this increase in ILC numbers is 
indicative of a role in skin-draining immune responses or just as a result of LN 
enlargement and shutdown. To address this, sophisticated genetic mouse models of ILC 
depletion will need to be used, and although these exist for the deletion of populations of 
ILC2 (Oliphant et al., 2014) and the specific deletion of MHCII on ILC3 (Hepworth et al., 




CHAPTER 5. DETERMINING THE MECHANISM OF ILC ENTRY INTO LNS 
 
5.1 INTRODUCTION 
My analysis of changes in ILC populations in peripheral LNs responding to immunisation 
revealed that ILCs increase in number in a draining LN in a manner independent of cell 
proliferation. Rather, this may instead reflect an ability of these cells to migrate and enter 
lymph nodes from distant tissues. Trafficking of certain immune cells from the peripheral 
and mucosal tissues to the local draining LNs has been well-established, as are many of 
the mechanisms which underlie this process. 
Entry of cells into secondary lymphoid tissue such as spleen and lymph nodes can be 
through the blood or in the case of lymph nodes also via the afferent lymph. Naïve 
lymphocytes migrate through many different lymph nodes, entering from the blood at 
high endothelial venules (HEVs) and leaving through the efferent lymph, which eventually 
filters back into the blood via the thoracic duct (von Andrian and Mempel, 2003, Gowans 
and Knight, 1964). By comparison, immune cells which patrol the peripheral tissues gain 
entry to the lymph nodes through the lymph, entering lymphatic vessels in the tissues 
which then transport them to the local lymph node through the afferent lymphatics. Both 
of these mechanisms of entry rely on the expression of distinct chemokine receptors and 
molecules which facilitate cell entry through the HEVs or lymphatics. 
The chemokine receptor CCR7 has previously been described in this investigation for its 
role in dictating cell movement within the organised structure of the lymph nodes; 
however it also plays a vital role in enabling cells to migrate to, and enter these structures 




lymph nodes and attract cells expressing CCR7 from the blood or tissues. Well-known cell 
types which express CCR7 are naïve T cells and dendritic cells (DCs) (Forster et al., 2008). 
Naïve T cells enter the lymph nodes through HEVs in a CCR7-dependent manner. Lymph 
nodes from mice which lack expression of CCR7 are depleted of T cells (Forster et al., 
1999). CCR7-/- T cells are impaired in their ability to enter LNs yet are present in the 
spleen, demonstrating the different homing requirements of these secondary lymphoid 
tissues (Forster et al., 1999). T cells which have been recruited into tissues are also 
capable of entering LNs through the afferent lymphatics, in a process which is similarly 
dependent on CCR7 (Debes et al., 2005, Bromley et al., 2005). DCs upregulate CCR7 upon 
activation (Sallusto et al., 1998), expression of which facilitates their migration to the local 
draining LN. Given that DCs reside in peripheral tissues, their entry into LNs is thought to 
be primarily through the afferent lymphatics. Whilst the number of DCs in peripheral 
organs of CCR7-/- mice is similar to WT, CCR7-/- DCs are impaired in their ability to home 
to lymphoid tissues in response to challenge (Forster et al., 1999).  
Expression of CCR7 mRNA has previously been reported by adult LTi cells, although no 
role had been ascribed to its expression. CCR7 mRNA was detected in both adult and 
embryonic splenic LTi cells from T cell-deficient mice (Kim et al., 2008) and more recently 
expression of CCR7 was detected on the surface of NKp46- ILC3 in the small intestine by 
flow cytometry (Klose et al., 2013). Given that CCR7 expression has been shown to be 
integral to the trafficking of cells into these structures we hypothesised that expression of 
this molecule by ILCs could enable them to enter LNs and provide evidence of their ability 




In this chapter I will investigate whether or not ILC entry into LNs is consistent with 
trafficking from peripheral and mucosal tissues. Focusing on group 3 ILCs, I explore the 
role of CCR7 on ILCs in a range of different lymph nodes at steady state and in skin-
draining LNs following immunisation. Finally I will investigate whether or not the 
presence of group 3 ILCs in lymph nodes is important for a primary CD4+ T cell immune 
response. 
5.2 ROLE OF CCR7 SIGNALLING 
 ILC requirement for CCR7 for entry into LNs differs between tissues 
To determine whether or not the presence of ILC subsets within lymph nodes was 
dependent upon CCR7 we compared the number of ILC1, ILC2, LTi-like ILC3 and NCR+ 
ILC3 in the spleen, mLN and iLNs of WT and CCR7-/- mice. Lymph nodes in CCR7-/- mice 
have previously been described as having fewer of naïve T cells (Forster et al., 1999), due 
to impaired entry of T cells into these structures in the absence of CCR7 signalling. In 
keeping with this, we observed substantially lower numbers of CD4+ T cells within mLNs 
from CCR7-/- mice, and which differed statistically significantly from WT controls (Figure 
5.1a).  
Within all secondary lymphoid tissue analysed from CCR7-/- mice it was possible to detect 
the three main groups of ILC, based on their expression on GATA-3, RORγt or T-bet 
(Figure 5.1b-e). Analysis of CCR7-/- spleens revealed no significant difference in the total 
number of ILC1, ILC2 or LTi-like ILC3 in the absence of CCR7 when compared to WT 
controls. The number of NCR+ ILC3 was however lower in CCR7-/- spleen when compared 
to WT and, although a mild phenotype, this was found to be statistically significant (Figure 




into this secondary lymphoid tissue is less dependent upon CCR7 than entry into lymph 
nodes; with CCR7-/- T cells having previously been shown to be present in the spleen 
despite being fewer in LNs (Forster et al., 1999). Importantly, this result indicated that 
any differences observed in the ILC composition of CCR7-/- mouse LNs should not be 
attributed solely to the impaired ability of any subset to develop in the absence of CCR7. 
Within the mLN of CCR7-/- mice there were found to be lower numbers of LTi-like ILC3 
than detected in WT controls, and this difference was statistically significant (Figure 
5.1d). This phenotype was specific to LTi-like ILC3 since numbers of ILC1, ILC2 and NCR+ 
ILC3 were not affected within this tissue. By contrast statistically significantly lower 
numbers of all ILC subsets were detected in CCR7-/- iLNs when compared to WT iLN 
controls, although the greatest difference was still found in the LTi-like ILC3 population 
(Figure 5.1e). This observation was particularly relevant in light of earlier data suggesting 
inherent differences between the ILC composition of mucosal-tissue draining and 
peripheral tissue-draining LNs. These data suggested that whilst within the mLN LTi-like 
ILC3 alone require CCR7 signalling to be functional in order to achieve the numbers 
observed in WT controls, in the iLN this applied to all subsets; raising interesting 
questions about the differing requirements for ILCs to enter lymph nodes at different 
sites. 
 CCR6+ ILC3 express functional CCR7  
Although these data indicated a reliance of certain ILCs on CCR7 signalling, the use of 
CCR7-/- mice does not allow for differentiation between cell-intrinsic or cell-extrinsic 
requirement for this receptor. Despite reports of CCR7 mRNA expression by LTi cells (Kim 




Figure 5.1 Characterisation of ILCs in CCR7-/- mice 
Tissues from naïve WT mice compared to CCR7-/- mice. Cells were 
isolated from iLN, mLN and spleen as specified in methods. Samples were 
analysed by flow cytometry and absolute numbers per LN calculated. 
Numbers shown represent the number of cells per individual LN or 
whole spleen. Lin- IL-7Rα+ RORγt+ ILC3 subset further split into those 
which express NKp46 at a level comparable to ILC1 (NCR+ ILC3) and 
those which do not (LTi-like ILC3), whilst ILC1 are defined as Lin- IL-7Rα+ 
RORγt- GATA-3- Tbet+ cells. 
All bars shown on graphs represent the median value. Data 
representative of (b) or pooled from (a,c-e) 3 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) Graph showing the total number of CD3i+ CD4+ T cells in individual 
mLN from WT or CCR7-/- mice. (n=7,9). 
b) FACS plots showing gating on ILC populations in mLN from WT and 
CCR7-/- mice. Cells pre-gated on FSC/SSC. GATA-3- RORγt- cells 
further gated on T-bet. Lin is CD3/CD5/B220/CD11b/CD11c. 
c) Total number of ILC1, ILC2, NCR+ ILC3 (NKp46+) and LTi-like ILC3 
(NKp46-) per spleen of WT (white triangles) and CCR7-/- (grey 
triangles) mice. (n=7,9). 
d) Total number of ILC1, ILC2, NCR+ ILC3 (NKp46+) and LTi-like ILC3 
(NKp46-) per individual mLN of WT (white triangles) and CCR7-/- 
(grey triangles) mice. (n=7,9). 
e) Total number of ILC1, ILC2, NCR+ ILC3 (NKp46+) and LTi-like ILC3 
(NKp46-) per iLN of WT (white triangles) and CCR7-/- (grey 











with conventional staining methods, such as fluorescently-tagged antibodies against 
CCR7 and analysis by flow cytometry (Figure 3.11). An alternative method of labelling 
CCR7-expressing cells was therefore attempted. A chemokine capture assay was utilised 
(Ford et al., 2013), where fluorescently labelled CCL19, a chemokine shown to bind 
specifically to CCR7, was incubated with cells from mLN and chemokine uptake by CCR7-
expressing cells later assessed using flow cytometry. Gating on CD4+ T cells, our positive 
control, showed that the majority were positive for the CCL19-bound fluorochrome 
(Figure 5.2a,b), thus indicating that these cells had bound and most likely endocytosed 
CCL19 and providing validation of the method. Crucially very little fluorescence was 
detected within CD4+ T cells which lacked CCR7, therefore detection of the fluorescently-
tagged chemokine was specifically as a result of it binding to CCR7 (Figure 5.2b). Given 
that the biotinylated CCL19 was incubated with fluorescently-tagged streptavidin (SA-
647) prior to this assay, a further control where SA-647 was present without chemokine 
was also assessed. Despite serving as a better indicator of functional cell surface CCR7 
expression, no convincing level of fluorescently-tagged CCL19 could be detected within 
the population of CCR6+ ILC3 in this pilot study (Figure 5.2b), here using surface markers 
to detect ILC populations.  
Although possible to conclude from this that expression of CCR7 mRNA within these cells 
does not result in functional expression on the cell surface, it may also be that these 
methods, whilst effective in detecting CCR7 on CD4+ T cells, are not sensitive enough to 
detect it at the level expressed by ILC3. This led us to utilise a different approach. Using a 
transwell migration assay system we were able to isolate those cells which were capable 




Figure 5.2 CCR7 not detected on ILC3 using chemokine capture 
assay   
Chemokine capture assay using cells from naive WT and CCR7-/- mice. 
WT Cells were isolated and pooled from a range of LNs, including mLN, 
iLN, aLN and bLN as specified in methods, then divided into four samples 
when stained. Cells were incubated with CCL19-647 or SA-647 alone. 
ILCs were identified using only surface markers and cells were not fixed. 
Samples were analysed by flow cytometry. Cells from CCR7-/- mice were 
used as a control. 
Pilot data which is representative of 2 WT mice under these 
experimental conditions.  
a) FACS plots showing gating on CD4+ T cells (top, pre-gated on 
FSC/SSC) or Lin- IL-7Rα+ ILCs (bottom, pre-gated on FSC/SSC) from 
WT LNs.  Lin is CD5/B220/CD11b/CD11c. 
b) FACS plots showing detection of CCL19-647 on WT CD4+ T cells (top) 











This assay therefore could reveal those cells which express even low levels of CCR7, whilst 
additionally providing evidence that expression of CCR7 is functional.  
Within our system an ‘input’ well containing cells isolated from WT mLN was immersed 
in a solution of RPMI 2% FBS and 20nM CCL21, separated by a membrane which 
prevented the passive transfer of cells from the input well to that containing the 
chemokine solution yet allowed those cells which expressed CCR7 to actively migrate 
through in the direction of the chemoattractive gradient. The ability of both CCL19 and 
CCL21 to induce cell migration using this assay was assessed in a pilot study and found to 
be comparable, therefore CCL21 alone was chosen for use in final experiments, and a 
concentration of 20nM CCL21 was found to be sufficient to induce cell migration. The use 
of a whole LN suspension allowed the capacity of multiple cell types to migrate toward 
CCL21 to be assessed. Using the gating strategy outlined in Figure 5.3(a), CD4+ T cells, B 
cells, DCs, ILC2 and ILC3 could be identified, and it should here be noted that in this study 
ILCs expressing low levels of CD11b—lower than that detected on IL-7Rα- counterparts—
were included, as it is not clear that these cells cannot acquire low levels of this molecule 
from interactions with other cell types (Gray et al., 2012). 
The proportion of each specified cell type which had migrated from the input well, and 
could as a result be detected within the well containing chemokine (‘output’), could then 
be calculated as a percentage of the total number of each cell type retrieved from both 
input and output wells, as detailed in the methods. RPMI 2% FBS only ‘no chemokine’ 
controls were used to assess non-chemokine specific migration of cells across the 
transwell membrane, whilst additionally comparing the ability of CCR7-/- cells to migrate 




Figure 5.3 A proportion of ILC3 migrate in response to a ligand of 
CCR7    
Chemokine transmigration assay using cells from naive WT and CCR7-/- 
mice. 2 x 106 WT or CCR7-/- cells isolated from mLN were used in each 
well, as specified in methods and CCL21 used at a concentration of 20nM. 
ILCs were identified using only surface markers and cells were not fixed. 
Samples were analysed by flow cytometry.  
Data is representative of (a) or pooled (b) from 2 independent 
experiments. Bars show median value. Statistical test used is Mann-
Whitney non-parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 
and ****P<0.0001. 
a) FACS plots showing gating on CD3+ CD4+ T cells, CD3- B220- CD11c+ 
‘DCs’ and CD3- B220- CD11c- CD5- CD11blo, IL-7Rα+ ILCs retrieved 
from input (top) and output (bottom) wells (pre-gated on FSC/SSC). 
ILCs are further split into CCR6- ICOS+ ILC2 and CCR6+ ILC3. 
b) Graphs showing the percentage of stated cell types from WT mLN 
(white triangles) or CCR7-/- mLN (grey triangles) which have 
migrated during this assay, calculated from the total cells retrieved 
from both wells, as specified in methods. Each sample was analysed 
in triplicate (WT) or duplicate (CCR7-/-) and graphs display average 
values. WT + no chemokine controls (black triangles) and CCR7-/- + 
20nM CCL21 controls (grey triangles) are shown alongside. Cell 












due to CCL21 binding to CCR7. Each experimental sample was analysed in either duplicate 
(CCR7-/-) or triplicate (WT no chemokine control, WT + 20nM CCL21), and average values 
are shown in Figure 5.3(b).  
Following incubation CD4+ T cells were detected within the output well, with 
approximately 70% of CD4+ T cells having migrated to the well containing CCL21 within 
this time (Figure 5.3a,b). Given that we have previously detected evidence of CCR7 
expression on the surface of CD4+ T cells (Figure 5.2b) this was expected and confirmed 
the validity of the approach. Importantly, very few CD4+ T cells, or indeed any other cell 
types analysed, were retrieved from the output well in the no-chemokine controls or in 
samples where all cells lacked expression of CCR7 (Figure 5.3b), thereby confirming that 
the migration seen was as a result of CCL21 binding to CCR7. By comparison <2% of B 
cells had migrated in this time, supporting the concept that although B cells are capable 
of expressing CCR7 (Reif et al., 2002) they are less dependent upon this molecule than T 
cells (Figure 5.3a,b). A proportion of the CD3- B220- CD11c+ putative dendritic cell and 
Lin- IL-7Rα+ CCR6+ ILC3 population had also migrated into the output well in response to 
CCL21. Approximately 30% of putative dendritic cells could be found within the output 
well following incubation, along with approximately 8% of ILC3. Although the percentage 
of migrating ILC3 was low in comparison to CD4+ T cells and putative DCs, the proportion 
was statistically significant when compared to the no-chemokine control (Figure 5.3a,b) 
and no migration was detected by ILC3 lacking CCR7, therefore demonstrating that a 
proportion of ILC3 were capable of migrating toward CCL21 in a CCR7-dependent 
manner. The proportion of Lin- IL-7Rαhi CCR6- ICOS+ ILC2 within the output well, 




chemokine control (Figure 5.3b), in keeping with prior observations of no ILC2 
dependency for CCR7 within the mLN (Figure 5.1d). 
 CCR7-dependency of LTi-like ILC3 is in part cell intrinsic 
These data indicate that CCR7 is functionally expressed on at least a proportion of CCR6+ 
ILC3 within the mLN. To determine whether the lower numbers of LTi-like ILC3 isolated 
from CCR7-/- lymph nodes resulted from the loss of direct signalling through CCR7 on the 
surface of LTi-like ILC3 themselves or cell extrinsic effects resulting from the loss of CCR7 
signalling on other cell types, a mixed bone marrow chimera (BMC) approach was used. 
These chimeric mice, generated to have equal amounts of WT and CCR7-/- bone marrow, 
enabled a direct comparison of the ability of both CCR7+/+ and CCR7-/- cells to re-populate 
secondary lymphoid tissue following the depletion of host cells using irradiation. This 
approach therefore provided an environment where CCR7 signalling was on some cells 
functional and any defect in the ability of CCR7-/- LTi-like ILC3 to enter lymphoid tissue 
regardless would indicate their requirement for direct cell-intrinsic CCR7 signalling. To 
generate WT:CCR7-/- mixed BMCs equal amounts of WT (CD45.1+) and CCR7-/- (CD45.2+) 
bone marrow was introduced into WT host mice, which had been lethally irradiated. For 
comparison, WT:WT control mice were generated using equal amounts of WT (CD45.1+) 
and WT (CD45.2+) bone marrow. Six to eight weeks following irradiation mice were culled 
and analysed, which allowed sufficient time for lymphoid cells to re-populate the 
secondary lymphoid tissue. The ability of both CCR7+/+ and CCR7-/- cells to enter spleen 
and lymph nodes was then analysed, with their expression of either CD45.1 or CD45.2 




Figure 5.4 Experiments in mixed bone marrow chimeras (BMCs) 
suggest that LTi-like ILC3 CCR7-dependency is in part cell-intrinsic 
Chimeras were generated by lethally irradiating WT (CD45.1+) mice and 
reconstituting with a 1:1 ratio of either WT CD45.1+ and WT CD45.2+ 
bone marrow (WT:WT) or WT CD45.1+ and CCR7-/- CD45.2+ bone 
marrow (WT:KO). iLN, mLN and spleen were taken for analysis and cells 
isolated as specified in methods. Samples were analysed by flow 
cytometry and absolute numbers per lymph node calculated. 
All bars shown on graphs represent the median value.  Dotted line shows 
50%. Data representative of (a-b) or pooled from (c) 2 (spleen) or 3 (iLN 
and mLN) independent experiments. Statistical test used is Mann-
Whitney non-parametric, two-tailed test. *P<0.05, **P<0.01, ***P<0.001 
and ****P<0.0001. 
a) FACS plots showing gating strategy for CD4+ T cells and LTi-like ILC3. 
Lin is CD3/CD5/B220/CD11b/CD11c. 
b) FACS plots showing CD45.1 and CD45.2 expression by CD4+ T cells 
(left) and LTi-like ILC3 (right) in WT:WT and WT:KO mLNs. 
c) Graphs showing the percentage of CD4+ T cells (top) or LTi-like ILC3 
(bottom) from iLN, mLN and spleen which are CD45.1+ (white 












Analysis of WT:WT chimeric inguinal and mesenteric LN tissue revealed that 
approximately 50% of the total CD4+ T cell population had originated from each donor, 
the anticipated result given that both sets of WT cells should be identical in their ability 
to enter lymph nodes (Figure 5.4c). By contrast, the majority of CD4+ T cells isolated from 
WT:CCR7-/- lymph nodes had originated from the WT (CD45.1+) donor, thereby indicating 
that CCR7-/- CD4+ T cells were unable to enter these tissues in the absence of cell-intrinsic 
CCR7 signalling (Figure 5.4b,c); consistent with the ability of CCR7-sufficient CD4+ T cells 
to migrate towards ligands of CCR7 (Figure 5.3b). Certainly, if compared to CD45.2+ CD4+ 
T cells from WT:WT chimeras, CD45.2+ CCR7-/- CD4+ T cells made up a statistically 
significantly lower percentage of the total population than would be expected were there 
no effect of CCR7 deficiency on this cell type (Figure 5.4c). Similar analysis of this 
population in the spleen revealed that whilst there was still a statistically significantly 
lower percentage of CCR7-/- CD4+ T cells than their equivalent in WT:WT mice, the 
phenotype was less exaggerated, consistent with the idea that T cell entry into this tissue 
is less dependent upon CCR7 (Forster et al., 1999) (Figure 5.4c) and demonstrating that 
thymic emigration of T cells was not completely abrogated in these mice in the absence of 
CCR7 (Ueno et al., 2004). Naïve T cell entry to LNs has been found to be primarily through 
HEVs (Forster et al., 2008), therefore it seems likely that these results primarily reflect 
entry of naïve CD4+ T cells from the blood rather than the lymph and it is worth noting 
here that the approach outlined above cannot definitively distinguish between the two. 
Like CD4+ T cells, CD45.2+ CCR7-/- LTi-like ILC3 within WT:CCR7-/- inguinal and 
mesenteric LNs made up a statistically significantly lower percentage of the total LTi-like 
ILC3 population than their CD45.2+ WT counterparts in WT:WT controls (Figure 5.4b,c), 




apparent that the inability of CCR7-/- LTi-like ILC3 to re-populate the tissue in numbers 
comparable to WT LTi-like ILC3 was not ameliorated by the presence of CCR7-sufficient 
cells, thereby indicating that LTi-like ILC3 require cell-intrinsic CCR7 signalling for entry 
into iLNs (Figure 5.4c). In mLNs, however, this is less clear. The difference between the 
percentage of cells that had originated from CD45.2+ donors in WT:WT and WT:CCR7-/- 
mice, although statistically significant, was less pronounced than in the iLN, and appeared 
to be partially masked by a skewing of the population towards that of CD45.1+ origin, not 
observed when looking at other cell types or in other tissues.  
Given that, in general, the contribution of CD45.1+ and CD45.2+ donor bone marrow had 
been consistently evenly proportioned during these experiments it seemed unlikely that 
this ‘skewing’ arose from problems with the bone marrow injected. It was, however, 
possible that this could be due to the persistence of CD45.1+ host LTi-like ILC3 despite 
irradiation. LTi cells have previously been reported to display some resistance to 
irradiation techniques (Dudakov et al., 2012), and previously we have had to employ 
additional methods, such as antibody-mediated depletion, to eliminate RORγt+ ILCs from 
murine hosts entirely. To investigate this phenomenon mixed BMCs, similar to those 
outlined above, were generated in CD45.1+CD45.2+ WT host mice, thereby allowing the 
identification of not only donor CD45.1+ and CD45.2+ cell populations, but also those 
CD45.1+CD45.2+ cells which have persisted from the host. Analysis of these new chimeras 
revealed that a number of LTi-like ILC3 within the mLN, but not the iLN or spleen, were 
indeed resistant to lethal doses of irradiation. Comparison of the origin of RORγt+ ILC3 
from iLN, mLN and spleen in these new WT:WT chimeras showed that whilst in the iLN 
and spleen CD45.1+CD45.2+ persisting ILC3 made up less than 20% of total RORγt+ ILC3, 




to irradiation was found to be specific to these mLN-resident LTi-like ILC3, with only low 
percentages of CD45.1+CD45.2+ host CD4+ T cells, ILC2 or NCR+ ILC3 detected in any 
tissues analysed (Figure 5.5a,c).  
This provided an explanation as to why, in the mixed BMC approach shown in Figure 5.4, 
a skewing of the bone marrow towards that of the host was detectable only in populations 
of LTi-like ILC3, and only in the mLN. To avoid this complication, the experiment outlined 
in Figure 5.4 was repeated using CD45.1+ CD45.2+ WT hosts, with any CD45.1+CD45.2+ 
host cells detected subtracted from the overall cell type population before percentages 
were calculated, thereby removing any bias from this persisting host population. Bone 
marrow from these new chimeras, isolated at the time of harvesting and tissue analysis, 
was also analysed to ensure that WT:WT and WT:CCR7-/- chimeras were comparable. This 
analysis revealed that CD45.2+ bone marrow constituted 40-45% of the total bone 
marrow (here not excluding host cells, which were a minor population), with no 
significant difference between WT:WT and WT:CCR7-/- chimeras (Figure 5.6a,b). 
Gating of allotype-marked populations in WT:WT and WT:CCR7-/- chimeras was as shown 
in Figure 5.6(c). Analysis of CD4+ T cells revealed a similar result to that seen previously, 
with CCR7-/- CD4+ T cells statistically significantly impaired in their ability to enter all 
secondary lymphoid tissue, but most notably the inguinal and mesenteric LNs. LTi-like 
ILC3 were once again found to be dependent upon cell-intrinsic CCR7 signalling for entry 
into iLN, with significantly fewer CD45.2+ (CCR7-/-) LTi-like ILC3 detected than in WT:WT 




Figure 5.5 LTi-like ILC3 in the mLN of chimeric mice display 
resistance to irradiation 
Chimeras were generated by lethally irradiating WT (CD45.1+CD45.2+) 
mice and reconstituting with a 1:1 ratio of WT CD45.1+ and WT CD45.2+ 
bone marrow (WT:WT). Cells isolated from iLN, mLN and spleen (spln) 
as specified in methods. Samples were analysed by flow cytometry. 
All bars shown on graphs represent the median value. Data 
representative of (a-b) or pooled from (c) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing the gating strategy for CD4+ T cells, ILC2, LTi-
like ILC3 and NCR+ ILC3 from WT:WT mLN. Both gating strategies 
for ILCs (top) and CD4+ T cells (bottom) are pre-gated on FSC/SSC. 
Lin is CD3/CD5/B220/CD11b/CD11c. 
b) FACS plots showing CD45.1 and CD45.2 staining on all RORγt+ ILC3 
in iLN, mLN and spleen from WT:WT chimeras. CD45.1+ WT donor, 
CD45.2+ WT donor and CD45.1+CD45.2+ WT host populations are 
shown. 
c) Graphs showing the percentage of each specified cell population 












Figure 5.6 A refined mixed BMC model can be used to exclude 
persisting host cells  
Chimeras were generated by lethally irradiating WT (CD45.1+CD45.2+) 
mice and reconstituting with a 1:1 ratio of either WT CD45.1+ and WT 
CD45.2+ bone marrow (WT:WT) or WT CD45.1+ and CCR7-/- CD45.2+ 
bone marrow (WT:KO). Cells were isolated from mLN and bone marrow 
as specified in methods. Samples were analysed by flow cytometry. 
Data representative of (a,c) or pooled from (b) 2 independent 
experiments. Statistical test used is Mann-Whitney non-parametric, two-
tailed test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing CD45.1 and CD45.2 staining on bone marrow 
cells from WT:WT and WT:KO chimeras, pre-gated on FSC/SSC.  
b) Percentage of cells (gated on FSC/SSC) from bone marrow of WT:WT 
and WT:KO chimeras which are CD45.2+ CD45.1-. Dotted line shows 
50%, bars represent median values. (n=7,7). 
c) FACS plots showing CD45.1 and CD45.2 staining on CD4+ T cells, 
ILC2, LTi-like ILC3 and NCR+ ILC3, as gated in Figure 5.5a, from 
WT:WT and WT:KO mLNs. CD45.1+ WT donor, CD45.2+ WT donor 










Figure 5.7 Experiments in refined mixed BMCs are consistent with 
LTi-like ILC3 CCR7-dependency being in part cell-intrinsic 
Chimeras were generated by lethally irradiating WT (CD45.1+CD45.2+) 
mice and reconstituting with a 1:1 ratio of either WT CD45.1+ and WT 
CD45.2+ bone marrow (WT:WT) or WT CD45.1+ and CCR7-/- CD45.2+ 
bone marrow (WT:KO). Cells were isolated from iLN, mLN and spleen 
(spln) as specified in methods. Samples were analysed by flow 
cytometry. 
All bars shown on graphs represent the median value. Data pooled from 
2 independent experiments. Dotted line shows 50%. Statistical test used 
is Mann-Whitney non-parametric, two-tailed test. *P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001. 
a)   Percentage of CD4+ T cells, LTi-like ILC3, NCR+ ILC3 and ILC2 from 
iLN, mLN and spleen of WT:WT and WT:KO chimeras which are 
CD45.1+ (white triangles) or CD45.2+ (grey triangles). 
CD45.1+CD45.2+ host cell populations were excluded from analysis 









the exclusion of persisting host cells, revealing that, although significant, the difference 
between the ability of CD45.2+ WT LTi-like ILC3 and CD45.2+ CCR7-/- LTi-like ILC3 was 
indeed less exaggerated in this tissue if compared to iLN (Figure 5.7a). This may therefore 
indicate a partial reliance on cell-intrinsic CCR7 signalling for LTi-like ILC3 to re-populate 
the mLN, but also some effect of CCR7-dependent cell-extrinsic factors. 
The ability of CD45.2+ CCR7-/- NCR+ ILC3 to enter inguinal and mesenteric LNs of mixed 
BMCs was impaired compared to their CD45.2+ WT counterparts (Figure 5.7a), although 
the phenotype was most pronounced in the iLN. Lower numbers of NCR+ ILC3 had 
previously been detected in the iLN and spleen of CCR7-/- mice when compared to WT 
controls, but not in the mLN (Figure 5.1c,d). CCR7-/- NCR+ ILC3 in fact made up a 
significantly higher proportion of NCR+ ILC3 within the spleen of WT:CCR7-/- mixed BMCs 
than CD45.2+ WT NCR+ ILC3 from WT:WT controls (Figure 5.7a), although the reason for 
this is difficult to elucidate from this data alone. The ILC2 populations within these LNs 
were biased towards CD45.2+ donors in both WT:WT and WT:CCR7-/- mice (Figure 5.7a) 
and although the reason for this was unknown it was consistently seen across all mixed 
BMC experiments. Comparison of CD45.2+ ILC2 from WT:WT and WT:CCR7-/- mice 
revealed that, although statistically significant, CCR7-/- ILC2 were only mildly impaired in 
their ability to re-populate host mLN and spleen in mixed BMCs, but more so in the iLN 
(Figure 5.7a), tissue in which data in straight CCR7-/- mice had previously indicated that 
ILC2 depend upon CCR7 (Figure 5.1e). Nonetheless it is not clear that either NCR+ ILC3 or 
ILC2 are completely dependent upon cell-intrinsic CCR7 signalling and cannot be 




 Numbers of LTi-like ILC3 are normal in the small intestine of CCR7-/- mice. 
With the knowledge that LTi-like ILC3 entry into secondary lymphoid tissue is impaired 
in the absence of CCR7 signalling, we hypothesised that these cells might accumulate in 
non-lymphoid tissues of CCR7-/- mice. To investigate this, the number of LTi-like ILC3 
within the small intestine lamina propria (SILP) of WT and CCR7-/- mice was analysed. 
Within the SILP of both WT and CCR7-/- mice a large population of lineage- (CD3 CD5 B220 
CD11b CD11c, CD3i-) IL-7Rα+ ILCs could be detected. From this population all three 
groups of ILC could be detected based on their expression of GATA-3 (ILC2), RORγt (ILC3) 
(Figure 5.8a,b) or T-bet (ILC1). In both WT and CCR7-/- SILP RORγt+ ILC3s constitute the 
majority of ILCs, with ILC1 a relatively minor population within this tissue (Figure 5.8b). 
Using CCR6 in addition to RORγt as a marker of LTi-like ILC3, and thus allowing direct 
comparison between the predominant ILC3 population found in the mLN and similar cells 
in the gut, the total number of LTi-like ILC3 per individual mLN or whole SILP was 
analysed. As previously observed the number of LTi-like ILC3 in the mLN of CCR7-/- mice 
is lower than that seen in WT (Figure 5.8c), however there was no statistically significant 
difference in the number isolated from WT and CCR7-/- SILP (Figure 5.8c). There does not, 
therefore, appear to be a significant accumulation of CCR7-/- LTi-like ILC3 in this tissue 
despite their impaired ability to enter the draining lymph node. Given the large number 
of these cells within the SI (Figure 5.8d), it seems possible that it is below the sensitivity 
of the assay to detect such slight fluctuations as these. When other ILC populations in the 
SILP of WT and CCR7-/- mice were analysed alongside ILC3 (here comparing all RORγt+ 
ILCs), it emerged that there was no statistically significant difference in the number of any 
population in this tissue in the absence of CCR7 (Figure 5.8e), although such differences 




Figure 5.8 Similar numbers of ILCs detected in the SI of WT and 
CCR7-/- mice   
Cells were isolated from naïve WT and CCR7-/- small intestine lamina 
propria (SI) as specified in methods. mLNs were taken alongside and 
cells isolated as normal. Both SI and mLN samples were analysed using 
Live/Dead viability dye and anti-CD45 antibody in addition to normal 
markers. Samples were analysed by flow cytometry and absolute 
numbers calculated. 
All bars shown on graphs represent the median value. Data 
representative of (a-b) or pooled from (c-d) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on viability dye negative (live), CD45+ 
cells in WT SI. 
b) FACS plots showing gating on subsets of ILCs in WT and CCR7-/- SI. 
Lin- IL-7Rα+ CD3i+ cells are excluded but gating not shown. Lin is 
CD3/CD5/B220/CD11b/CD11c. 
c) Graphs showing the total number of LTi-like ILC3 (CCR6+ NKp46-) 
per individual mLN (left) or in whole SI (right) in WT (white 
triangles) and CCR7-/- (grey triangles) mice. (n=6,6). 
d) Graph showing the total number of RORγt+ ILC3s in WT mLN (whole 
tissue) or WT SI (whole tissue). (n=6,6). 
e) Graph showing the total number of ILC1, ILC2 and all RORγt+ ILC3 in 
WT (white triangles) and CCR7-/- (grey triangles) SI. ILC1 are defined 










5.3 INVESTIGATING THE MECHANISM OF ILC ACCUMULATION IN DRAINING LNS 
 ILCs do not accumulate in draining LNs in the absence of CCR7 
CCR7 signalling has previously been described as necessary for timely immune responses 
to immunological challenge (Forster et al., 1999), in part because of its requirement by 
antigen-presenting cells to home from the site of infection to the local draining LN. ILCs 
have been well-characterised in the skin however it is not definitively known whether 
these cells can traffic from this site to secondary lymphoid tissue. We have previously 
shown that certain ILCs within skin-draining LNs express low levels of markers generally 
associated with APCs, accumulate within draining lymph nodes following immunisation 
in a manner which does not involve proliferation and that, like APCs, ILCs depend upon 
CCR7 signalling for entry into peripheral tissue-draining lymph nodes. We therefore 
hypothesised that the increased number of ILCs detected within draining brachial and 
axillary LNs could be due to ILCs trafficking from the site of immunisation in a 
CCR7-dependent manner.   
To investigate whether the increase in numbers of ILCs seen in draining LNs is dependent 
upon CCR7, WT and CCR7-/- mice were immunised in both front paw-pads with either 
alum-precipitated (alum-ppt) antigen or PBS, and cells analysed within the draining 
brachial and axillary LNs 4 days p.i. The adoptive transfer of TCR transgenic CD4+ T cells 
prior to immunisation, allowed us to track the magnitude and progress of the immune 
response within the draining LN. Although all T cells transferred were from TCR 
transgenic strains of mice, adoptively transferred CD4+ T cells used in the initial 




experimental repeat were OTII, activated using alum-ppt NP-Ova. This was due to 
problems arising in the maintenance of the RAG-/- SM1 colony and each individual repeat 
is specified in Figure 5.9(c). As this had no apparent impact on the numbers of ILCs 
between experimental repeats, here the results are combined (Figure 5.9e). In WT 
draining LNs 4 days p.i the number of CD44hi TCR transgenic CD4+ T cells can be seen to 
increase compared to PBS controls, consistent with the activation and expansion of these 
cells (Figure 5.9a,c). In alum-ppt antigen immunised LNs from CCR7-/- mice at this 
timepoint, however, there was no statistically significant increase in TCR transgenic T cell 
number in comparison to PBS controls, and significantly fewer TCR transgenic CD4+ T 
cells than seen in WT alum-ppt antigen dLNs (Figure 5.9a,c). Given that the adoptively 
transferred TCR transgenic T cells are CCR7-sufficient it is unlikely that this difference is 
due to the inability of donor T cells to enter the lymph nodes of CCR7-/- mice, rather is 
more likely to reflect the inability of CCR7-/- APCs to traffic into the draining LN and 
activate the TCR transgenic T cells following immunisation.  
Analysis of the numbers of each ILC subset in PBS controls revealed that, as seen 
previously in peripheral tissue-draining iLN tissue (Figure 5.1e), there are significantly 
lower numbers of all subsets of ILCs in brachial and axillary LNs of CCR7-/- mice than WT 
(Figure 5.9d). Four days following immunisation the numbers of all ILC subsets could be 
seen to increase in comparison to PBS controls, statistically significantly so with the 
exception of ILC2 (Figure 5.9b,e). By contrast no significant difference in the number of 
any ILC subset could be detected in CCR7-/- dLNs (Figure 5.9b,e), which could be taken to 
indicate that the increase observed in WT draining LNs was a CCR7-dependent 
phenomenon. Certainly, in comparison to WT dLNs 4 days p.i with alum-ppt antigen there 




Figure 5.9  ILCs do not accumulate in draining LNs of CCR7-/- mice  
Comparison of WT and CCR7-/- mice.  Mice in one experimental repeat 
received 105 OTII TCR transgenic CD4+ T cells intravenously a day before 
immunisation with either PBS or alum-ppt NP-OVA in both front paw 
pads, whilst mice in an independent repeat received 105 SM1 TCR 
transgenic CD4+ T cells and either PBS or alum-ppt FliC peptide in both 
front paw pads.  Tissues were taken 4 days p.i (D4) and a cell suspension 
made from brachial and axillary LNs as specified in methods. Samples 
were analysed by flow cytometry and absolute numbers per lymph node 
calculate. Lin- IL-7Rα+ RORγt+ ILC3 subset further split into those which 
express NKp46 at a level comparable to ILC1 (NCR+ ILC3) and those 
which do not (LTi-like ILC3), whilst ILC1 are defined as Lin- IL-7Rα+ 
RORγt- GATA-3- T-bet+ cells. 
All bars shown on graphs represent the median value. Data 
representative of (a,b) or pooled from (c-e) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating on CD44hi OTII T cells from WT or CCR7-
/- brachial and axillary LNs, 4 days p.i with alum-ppt NP-OVA. Cells 
are pre-gated on CD3i+ CD4+ T cells and CD45.1 is used for OTII or 
SM1 cell detection. 
b) FACS plots showing gating on ILC populations in WT and CCR7-/- 
control and immunised mice a 4 days p.i. Cells were pre-gated on Lin- 
(CD3/CD5/B220/CD11b/CD11c, CD3i-) IL-7Rα+ ILCs. 
c) Graph showing the total number of CD44hi OTII T cells (circles) and 
SM1 T cells (triangles) per LN in WT (white) and CCR7-/- (grey) mice 
4 days post immunisation with PBS or alum-ppt antigen (D4).  
(n=5,7,5,6). 
d) Graph showing the total number of each ILC subset per LN in WT 
(white triangles) and CCR7-/- (grey triangles) PBS control mice. 
(n=5,5). 
e) Graphs showing the total number of each stated ILC population per 
LN in WT (white triangles) or CCR7-/- (grey triangles) mice 4 days p.i 
with PBS of alum-ppt antigen (D4). Y axis on the left-most graph 











In WT:CCR7-/- mixed BMCs, the ability of LTi-like ILC3 to re-populate inguinal lymph 
nodes was found to be dependent on cell-intrinsic CCR7 signalling, and given the 
similarities between iLN and brachial and axillary LNs already documented it could be 
speculated that this is also true under this circumstance. Although this experiment in 
straight CCR7-/- mice does not rule out a role for CCR7-dependent cell-extrinsic factors, 
such as APC exclusion and the absence of a strong T cell response, it does reveal a 
dependency on CCR7 for ILC accumulation in draining LNs following immunisation. 
5.4 ILC3 DEFICIENCY DOES NOT AFFECT NUMBERS IN PRIMARY CD4+ T CELL 
RESPONSE 
 Chimeric mouse models 
Bone marrow chimeras have been described previously in Chapter 3 as a method to 
remove RORγt-expressing cells in a mouse in which all secondary lymphoid tissue is 
present; with one caveat of straight RORγt-/- mice being impaired LN development (Sun 
et al., 2000). Irradiating WT mice and then reconstituting the haematopoietic 
compartment with RORγt-/- bone marrow has been a useful tool to analyse the potential 
functions of ILC3, given the limited availability of models to genetically delete ILC3 from 
WT hosts. To investigate whether or not primary CD4+ T cell responses within LNs 
depended upon the presence of RORγt-expressing cells, and perhaps more specifically 
group 3 ILCs, the response of antigen-specific CD4+ T cell populations was analysed within 
chimeric WT and RORγt-deficient mice. 
WT:WT and WT:RORγt-/- chimeric mice received an adoptive transfer of 105 SM1 CD4+ T 




ppt FliC peptide. Analysis of chimeras for the presence of each ILC subset revealed that 
although RORγt+ ILC3 were markedly reduced in the mLNs of WT:RORγt-/- mice when 
compared to WT:WT controls, they were not completely depleted (Figure 5.10a,b). The 
discovery that LTi-like ILC3 within the mLN are particularly resistant to irradiation 
(Figure 5.5) highlights a caveat with this method, and anti-CD90.2 antibodies were used 
during the generation of these chimeric mice in an attempt to remove any persisting 
ILC3s. Interestingly WT:RORγt-/- mice had increased numbers of ILC1 and IL2 when 
compared to WT:WT controls, and this was found to be statistically significant (Figure 
5.10b). Analysis of the number of CD44hi SM1 T cells within these mice 7 days p.i revealed 
no significant difference between this primary CD4+ T cell response in WT:WT and 
WT:RORγt-/- chimeras (Figure 5.10c). 
This result was indicative of no notable role for ILC3 in the analysed immune response, 
however we further refined our chimeric mouse model to address the caveat of persisting 
ILC3 within WT:RORγt-/- mice. The discovery that CCR7-/- LNs have significantly fewer 
ILC3 than those from WT mice suggested that these would make better hosts, removing 
the need for anti-CD90.2 antibody depletion which could have effects on cells other than 
ILC3. In keeping with the draining LN models detailed in Chapter 4, we now analysed a 
local draining LN response within the skin-draining bLN and aLNs. Given that we found 
LTi-like ILC3 to be susceptible to irradiation within the peripheral tissue-draining iLN 
(Figure 5.5), irradiation-induced depletion is likely to be more efficient within these LNs.  
 Numbers of antigen-specific CD4+ T cells unaffected by ILC3 absence 
On discovering that CCR7-/- mice have notably fewer ILC3 than WT mice in all LNs 




Figure 5.10 Similar numbers of responding CD4+ T cells detected 
following immunisation in ILC3-deficient chimeric mice  
Chimeras were generated by lethally irradiating WT mice before 
reconstituting with WT or RORγt-/- bone marrow cells. Mice were further 
treated with two doses of anti-CD90.2 antibody (WT:RORγt-/-) or anti-rat 
IgG control (WT:WT) intraperitoneally (i.p) and then left for 6-12 weeks. 
Prior to analysis all mice received 105 SM1 T cells and were immunised 
the following day with 100μg alum-ppt FliC i.p. Chimeras were taken at 
D7 post-immunisation and a cell suspension made from mLNs as 
specified in methods. Samples were analysed by flow cytometry and 
absolute numbers per individual mLN calculated. 
All bars shown on graphs represent the median value.  Data 
representative of (a) or pooled from (b-c) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing gating strategy for ILC populations in WT:WT 
(WT) or WT:RORγt-/- (KO) chimeras 7 days p.i with alum-ppt FliC. 
Cells were pre-gated on host CD45.1- cells. Lin is 
CD3/CD5/B220/CD11b/CD11c.  
b) Graphs showing the number of each ILC subset per WT or KO 
chimeric mLN 7 days p.i with alum-ppt FliC. ILC1 are RORγt- GATA-
3- T-bet+ (n=7,7).  
c) Graphs showing the number of CD44hi SM1 T cells (CD3+ CD4+ 









chimera host. With fewer ILC3 to begin with irradiation of these mice might be sufficient 
to deplete these cells alone, removing the requirement for, non-ILC specific, anti-CD90 
antibodies. CCR7-/- host mice were lethally irradiated and reconstituted with WT or 
RORγt-/- bone marrow, whilst replacing the bone marrow compartment with 
CCR7-sufficient cells should negate any effect of the CCR7-deficient host. All chimeras 
received 105 OTII CD4+ T cells and were immunised in the front paw pads with alum-
precipitated NP-OVA. Mice were taken 6 days p.i and cells from the brachial and axillary 
LNs analysed.  
Analysis of ILC populations in CCR7-/-:WT (WT) and CCR7-/-:RORγt-/- (RORγt-/-) chimeras 
revealed that whilst all three groups of ILCs were present within WT chimeras, very few 
RORγt+ ILC3 could been detected in RORγt-/- brachial and axillary LNs (Figure 5.11a), 
although there was no statistically significant difference in the total number of Lin- IL-
7Rα+ ILCs (Figure 5.11b). Enumeration of each group of ILCs per LN revealed that there 
were statistically significantly fewer ILC3 within RORγt-/- LNs than WT (Figure 5.11c), and 
although some ILC3 were still present within RORγt-/- tissue, the median number of ILC3 
per LN was 91.8% decreased compared to that in WT control LNs (Figure 5.11c; 
calculated from median values). This depletion was therefore more efficient than that 
previously seen in WT:RORγt-/- chimeras, where the median number of ILC3 per LN was 
only 62.4% decreased compared to WT control mice (Figure 5.10b; calculated from 
median values), despite the absence of anti-CD90 treatment. Notably, the loss of ILC3 in 
RORγt-/- chimeras was accompanied by an increase in numbers both ILC1 and ILC2 when 
compared to WT controls (Figure 5.11a,c), and this increase was statistically significant 




Figure 5.11 Using CCR7-/- mice as chimeric mouse hosts results in 
improved ILC3 depletion 
Chimeras were generated by irradiating CCR7-/- (CD45.2+) mice before 
reconstituting hosts with WT or RORγt-/- bone marrow cells. Mice later 
received 105 OTII transgenic CD4+ T cells i.v and were immunised in both 
front paw pads with alum-ppt NP-OVA or PBS the following day. 
Chimeras were taken 6 days p.i and a cell suspension made from brachial 
and axillary LNs, as specified in methods. Samples were analysed by flow 
cytometry and absolute numbers per lymph node calculated. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b-c) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing the gating strategy for ILC populations in CCR7-
/-:WT (WT) or CCR7-/-:RORγt-/- (KO) chimeras 6 days p.i with alum-
ppt NP-OVA. Lin is CD3/CD5/B220/CD11b/CD11c. 
b) Graph showing the number of total Lin- IL-7Rα+ ILCs in WT and KO 
chimeras 6 days p.i with alum-ppt NP-OVA (n=8,11). 
c) Graphs showing the number of each ILC subset in WT and KO 
chimeras 6 days p.i with alum-ppt NP-OVA. ILC1 are RORγt- GATA-3- 










5.10(b). Whether this was as a result of the absence of the transcription factor RORγt in 
general or the specific absence of ILC3 is not clear. 
In order to properly interpret any effect seen in the OTII CD4+ T cell response, it was 
necessary to assess the general phenotype of LN-resident cells within these chimeric 
mice. The total number of CD45.1- ‘host’ T and B lymphocytes was enumerated and CD4+ 
T cells, here excluding adoptively transferred CD45.1+ OTII cells, were analysed for either 
an activated (CD44hi CD62Llo) or Treg (FoxP3+ CD25+) phenotype (Figure 5.12a). There 
was found to be statistically significantly fewer total T cells within RORγt-/- chimeras 
compared to WT, although no statistically significant difference in the number of B cells 
(Figure 5.12b), and this was still the case when restricted to those host T cells expressing 
CD4 (Figure 5.12c). Analysis of CD44 and CD62L expression indicated that a higher 
percentage of CD4+ T cells within RORγt-/- chimeras had a CD44hi CD62Llo ‘activated’ 
phenotype than in WT chimeras (Figure 5.12c). FoxP3+ CD25+ Tregs also constituted a 
higher percentage of total ‘host’ CD4+ T cells within RORγt-/- mice, although this 
corresponded with a statistically significantly lower number of total Tregs than seen in 
WT chimeras (Figure 5.12d). 
Analysis of the OTII CD4+ T cells response, using CD45.1 and VβTCR5.1/5.2 as markers of 
OTII cells (Figure 5.13a), revealed that although the median number of CD44hi OTII cells 
detected in RORγt-/- chimeras was lower than that observed in WT chimeras, the 
difference was not significant (Figure 5.13b). When phenotypic markers were analysed it 
was found that the percentage of total CD4+ OTII cells which had a FoxP3+ CD25+ Treg 
phenotype was negligible (Figure 5.13a), whilst the percentage of total OTII CD4+ T cells 




Figure 5.12 Total T cells are fewer in RORγt-deficient BMCs  
Chimeras were generated by irradiating CCR7-/- (CD45.2+) mice before 
reconstituting hosts with WT or RORγt-/- bone marrow cells. Mice later 
received 105 OTII transgenic CD4+ T cells i.v and were immunised in both 
front paw pads with alum-ppt NP-OVA or PBS the following day. 
Chimeras were taken 6 days p.i and a cell suspension made from brachial 
and axillary LNs, as specified in methods. Samples were analysed by flow 
cytometry and absolute numbers per lymph node calculated. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b-d) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing analysis of the phenotype of CD4+ T cells in 
CCR7-/-:WT (WT) or CCR7-/-:RORγt-/- (KO) chimeras. Cells are pre-
gated on CD45.1- host cells to exclude adoptively transferred OTII 
cells from this analysis.  
b) Graphs showing the total number of T (CD3+ B220-) and B (B220+ 
CD3-) lymphocytes per LN in WT and KO chimeras.  
c) Graphs showing the total number of CD4+ T cells per LN in WT and 
KO chimeras (left), and the percentage of CD4+ T cells which have a 
CD44hi CD62lo phenotype (right). 
d) Graphs showing the total number of CD4+ T cells per LN with a Treg 
phenotype (left, FoxP3+ CD25+), and the percentage of CD4+ T cells 











Figure 5.13 Numbers of responding OTII CD4+ T cells do not differ 
significantly in ILC3-deficient BMCs 
Chimeras were generated by irradiating CCR7-/- (CD45.2+) mice before 
reconstituting hosts with WT or RORγt-/- bone marrow cells. Mice later 
received 105 OTII transgenic CD4+ T cells i.v and were immunised in both 
front paw pads with alum-ppt NP-OVA or PBS the following day. 
Chimeras were taken 6 days p.i and a cell suspension made from brachial 
and axillary LNs, as specified in methods. Samples were analysed by flow 
cytometry and absolute numbers per lymph node calculated. 
All bars shown on graphs represent the median value. Data 
representative of (a) or pooled from (b-c) 2 independent experiments. 
Statistical test used is Mann-Whitney non-parametric, two-tailed test. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
a) FACS plots showing the analysis of the phenotype of CD4+ OTII T cells 
in CCR7-/-:WT (WT) or CCR7-/-:RORγt-/- (KO) chimeras. Cells are pre-
gated on CD45.1+ cells to identify cells which originate from the OTII 
TCR transgenic donor. 
b) Graph showing the total number of CD44hi OTII cells per LN in WT 
and KO chimeras 
c) Graph showing the percentage of total OTII T cells (CD45.1+ CD3+ 
CD4+ Vβ5.1/5.2 TCR+) in WT and KO chimeras which have an 











5.13a,c). These models therefore did not reveal a role for RORγt-expressing cells, 
including ILC3, in the primary CD4+ T cell response analysed, however there were many 
caveats associated with this method of depleting cells and these are discussed below. 
5.5 SUMMARY 
The observation that LTi cells expressed CCR7 mRNA (Kim et al., 2008) indicated that 
these cells might be capable of migrating from the peripheral or mucosal tissues to LNs. 
In this investigation I have shown that numbers of certain ILC subsets are lower in LNs of 
CCR7-/- mice, consistent with impaired entry of ILCs into these tissues in the absence of 
this chemokine receptor. This appeared to be site-dependent, with numbers of all ILC 
subsets found to be lower in CCR7-/- mouse peripheral LNs analysed at steady state, but 
only LTi-like ILC3 in the mLN. Whether or not this reflects different requirements for 
entry into the mLN or other LNs, or differences in the ILCs at these sites is unclear, and it 
is not possible to tell from this investigation whether CCR7-dependent ILC entry into LNs 
is through the afferent lymphatics or circulation.  
Our data in mixed bone marrow chimeras suggests that the phenotype observed in 
CCR7-/- mice is at least in part due to the abrogation of cell-intrinsic CCR7 signalling. 
Within this investigation a proportion of LTi-like ILC3 were found to migrate towards a 
ligand of CCR7, albeit to a lesser extent than CD4+ T cells, indicating functional expression 
of this chemokine receptor by ILC3. Although we struggled to detect CCR7 expression on 
the surface of ILCs—despite a range of methods being used and successful detection on 
CD4+ T cells—CCR7 mRNA has been shown to be expressed by LTi cells (Kim et al., 2008) 
and the protein detected on the surface of NKp46- RORγt+ ILCs from the SI (Klose et al., 




CCR7-dependency for ILC3 in the mLN, whilst ILC2 within this tissue were unaffected, 
although in this study they were able to detect high levels of CCR7 expression by ILC3 
(Kim et al., 2015). Unlike the data presented in this investigation, however, a dependency 
on CCR7 was also described for ILC1 within the mLN and differences in ILC populations 
detected within CCR7-/- SI when compared to WT mice (Kim et al., 2015).  
Further differences between ILC populations in mesenteric and peripheral tissue-
draining LNs were highlighted by our discovery that LTi-like ILC3 within the mLN, but not 
spleen or iLN, are comparably resistant to irradiation. Whether or not this suggests that 
LTi-like ILC3 populations at different sites are in fact fundamentally different remains to 
be seen, but could also be as a result of differences in behaviour caused by ILC interactions 
with LN stromal cells at these sites. For example, stromal cells within the mLN have been 
shown to produce more retinoic acid, which plays an important in the induction of gut-
homing programs on T cells, than those in peripheral LNs (Hammerschmidt et al., 2008). 
Even when transplanted into the mesentery it was found that peripheral LNs were unable 
to perform this role, highlighting the fundamental differences between different LNs 
themselves (Hammerschmidt et al., 2008). There are therefore a number of factors which 
could contribute to the differences in ILC populations which we see, and which could be 
explored further through transplant experiments as outlined above, or by sorting and 
phenotyping ILC populations from different sites.  
The lack of ILC accumulation in draining LNs of CCR7-/- mice could be seen as an indication 
that the accumulation of ILCs in WT LNs undergoing an immune response is due to 
CCR7-dependent trafficking of ILCs from other sites. In this investigation we showed that 




CCR7. Certainly our results from Chapter 4 suggest that accumulation is by a mechanism 
other than proliferation of cells within the LN itself. Our observation in CCR7-/- draining 
LNs does however closely mirror results seen in CD80-/-CD86-/- mice in Chapter 4, where 
the T cell response was similarly abrogated; in CD80-/-CD86-/- mice as a result of lack of 
co-stimulation, and within CCR7-/- mice likely due to impaired DC trafficking. The role of 
CCR7 cell-intrinsic signalling in this process could be investigated by analysing 
accumulation of CCR7-/- ILC subsets in mice where a normal immune response is restored, 
but whether other factors, such as signals from cells undergoing an immune response or 
processes such as lymph node shutdown contribute to ILC accumulation within draining 
LNs is yet to be seen.  
Finally, RORγt-deficient bone marrow chimeras were used to get an insight into whether 
RORγt-expressing cells are required for normal expansion of responding CD4+ T cells 
during a LN primary immune response. Given the many similarities of ILCs with other 
lineages of cells, in transcription factor expression and surface markers, it has proved 
challenging to selectively remove these cells without affecting other cell populations. 
Genetic deletion of group 3 ILCs presents the additional challenge that a deficiency of LTi 
cells prevents the embryonic development of LNs (Sun et al., 2000). Bone marrow 
chimeras allow the deletion of these cells in hosts whose LNs have already formed. This 
model involves the deletion of host cells using irradiation, followed by the reconstitution 
of the haematopoietic compartment with bone marrow cells which lack the expression of 
RORγt, therefore the result is the depletion of all RORγt-expressing cell types, including 
ILC3. The radiation-resistance of LTi-like ILC3 has been shown in this investigation and a 
variety of methods, including the use of depleting antibodies and CCR7-/- mice as hosts, 




resulted in relatively poor depletion of RORγt+ ILCs, and it could not be ruled out that the 
depleting antibodies were having an effect on other CD90+ cells types, despite the fact that 
chimeras were left a number of weeks post-treatment and prior to use. Refinement of this 
method to use irradiated CCR7-/- hosts removed the need for additional antibody 
depletion, as very few ILC3 reside within the LNs in the first place, and resulted in the 
effective removal of more than 90% of ILC3 from brachial and axillary LNs.  
In both chimeric models analysed within this chapter no significant difference was 
detected in the numbers of an antigen-specific population of CD4+ T cells at day 6 or 7. 
Analysis of activation markers also did not reveal a higher level of activation within this 
responding T cell population, which could have been indicative of a dysregulated 
response. There were however differences in the non-OTII populations of T cells analysed 
in CCR7-/-:RORγt-/- chimeras compared to controls, although it is not possible to say from 
this experiment the exact reason why this was the case. These experiments using bone 
marrow chimeras therefore indicate no requirement for RORγt-expressing cells types, 
including ILC3, in the primary CD4+ T cell responses analysed, consistent with previous 
findings in the LTi-deficient spleen (Withers et al., 2012). These bone marrow chimeras 
were however associated with a number of caveats. Many chimeric mice had to be 
removed from these experiments and culled as a result of them reaching clinical end 
points, whilst those used within this investigation showed signs of being unwell; likely 
consistent with these mice having an impaired immune system in the absence of RORγt-
expressing cells and as a result of the high doses of irradiation required to deplete host 
cells. More sophisticated genetic approaches to specifically delete subsets of ILCs are 
increasingly being reported. The use of these models in the future would avoid many of 




CHAPTER 6. DISCUSSION 
 
In this thesis I have robustly characterised populations of ILCs in LNs, defined the location 
of these cells, identified novel mechanisms by which ILCs enter these tissues and explored 
changes upon immunisation. 
6.1 ILC3 ARE ENRICHED IN MUCOSAL TISSUE DRAINING LNS 
The presence of subsets of ILCs in the mLN had been reported previously (Hepworth et 
al., 2013, Price et al., 2010), however less was known about their existence in peripheral 
LNs which drain the skin. This was likely in part due to the difficulties associated with 
isolating rare populations of cells from such small LNs. Our ability to isolate these cells 
from a range of different peripheral and mucosal tissue draining LNs allowed us to 
identify and characterise these cells, revealing that all ILC subsets were present in all LNs 
analysed. This investigation also revealed differences in the proportions of each ILC 
subset found in LNs which drain different sites. While all subsets of ILC are more 
numerous in the mesenteric LN (mLN) than either the skin-draining inguinal (iLN) or 
brachial LNs (bLN), ILC3 are particularly enriched. Similarly, the proportion of ILC3 in 
mediastinal LNs (medLN), which drain the respiratory tract, is notably higher than that 
detected in other LNs, particularly those which drain the skin. This suggests that group 3 
ILCs are enriched in LNs which drain tissues with the highest antigen burden, likely 
indicative of an increased requirement for these cells in LNs which drain mucosal barrier 
sites. The specific enrichment of LTi-like ILC3 within the mLN was particularly interesting 
due to its location draining the ILC-enriched gut, upon which much of ILC research is 




 ILC3 in tolerance to gut-derived antigens 
ILC3 have been shown to be better represented within the small intestine than in the skin 
or lung (Spencer et al., 2014), and have been found to carry out many important functions 
within the gut. IL-22 produced by ILC3s has been shown to be important for the 
maintenance of barrier surface integrity and for the prevention of systemic spread of 
commensal bacteria (Sonnenberg et al., 2012). When properly excluded, intestinal 
commensal bacteria exist symbiotically with their host, providing help with digestion 
(Brestoff and Artis, 2013) and proving crucial in preventing colonisation of the epithelium 
by potentially pathogenic bacterial strains (Kamada et al., 2013). The ability of the host to 
tolerate the presence of microorganisms in numbers as large as those found within the 
gut is due to effective barrier surfaces, the careful maintenance of these surfaces by innate 
cells, and the ability of the immune system to tolerate their presence. In addition to their 
role in maintaining these barrier surfaces, ILC3 have been shown to promote this state of 
tolerance by directly influencing adaptive immune responses (Hepworth et al., 2013, 
Hepworth et al., 2015). 
Induction of immunological tolerance to food and commensal bacterial antigens in the 
periphery is vital.  Despite many levels of regulation during the development of 
lymphocyte populations, there are T and B cells which exist within the periphery that are 
specific for harmless or self-antigens (Walker and Abbas, 2002). Whilst processes, such 
as negative selection and deletion of developing CD4+ T cells which respond to self-
antigen presented in the context of MHCII, help to remove such cells prior to their 
emigration from the thymus (Hogquist et al., 2005), certain antigens, such as those from 
commensal bacteria or food, are not present at this point. As a consequence, CD4+ T cells 




periphery where they could cause detrimental inflammatory immune responses in the 
gut. Although Treg cells have been shown to suppress such immune responses (Ai et al., 
2014) ILC3 are also now known to play a role (Hepworth et al., 2013, Hepworth et al., 
2015). 
LTi cells have already been implicated in the process of negative selection of self-reactive 
naïve T cells in the thymus (Rossi et al., 2007), but recent reports suggest that their 
influence on immune tolerance extends to regulating those T cells which make it to the 
periphery in a process termed intestinal selection (Hepworth et al., 2015). MHCII+ ILC3 
have been shown to reside within the gut and mLN tissue (Hepworth et al., 2013) and in 
this investigation we find that a higher proportion of mLN-resident ILC3 express this 
molecule than their peripheral LN counterparts. Although capable of acquiring, 
processing and presenting antigen these cells were reported to lack expression of the co-
stimulatory molecules CD80 and CD86, rendering them unable to provide the co-
stimulatory signals required to activate CD4+ T cells (Hepworth et al., 2013, Mueller et al., 
1989). Consistent with our understanding of T cell activation, antigen presentation by 
ILC3 to CD4+ T cells would likely render these cells anergic and unable to respond to 
further stimulation (Schwartz, 2003). Antigen presentation by ILC3 in vitro did not result 
in CD4+ T cell proliferation (Hepworth et al., 2013). Indeed, in keeping with a regulatory 
role, mice in which MHCII was selectively deleted from ILC3 (MHCIIΔILC3), but not other 
antigen-presenting cell types, were found to develop spontaneous intestinal inflammation 
resulting from dysregulated CD4+ T cell responses to commensal bacteria (Hepworth et 
al., 2013). The mechanism of ILC3 MHCII-mediated regulation of CD4+ T cell responses 




which react inappropriately to innocuous antigens in a manner which shares many 
similarities to negative selection in the thymus (Hepworth et al., 2015). 
 APC-induced tolerance takes place in the mLN 
Although there is likely to be a contribution of gut-associated lymphoid tissues such as 
the Peyer’s patches (PPs) and isolated lymphoid follicles (ILFs) to the induction of oral 
tolerance, the mLN has been shown to play an important role. For example, LTα-/- mice 
which lack both lymph nodes and PPs lack immune tolerance to oral antigens, yet the 
selective rescue of mLN development in these mice was sufficient to restore induction of 
oral tolerance, even in the absence of PPs (Spahn et al., 2002). A population of CD103+ gut-
resident DCs have been shown to acquire innocuous antigens within the gut and migrate 
to the mLNs, where they present these peptides in the context of MHCII to naïve T cells to 
initiate tolerance (Pabst et al., 2007). The importance of antigen sampling specifically at 
this mucosal site is demonstrated by the fact that DCs are programmed to promote 
tolerance by the production of cytokines and retinoic acid (RA) by gut epithelial cells (Iliev 
et al., 2009). This can then be implemented by the DCs, by rendering those T cells which 
recognise the antigen anergic or by inducing them to become T regulatory cells which 
suppress the immune response (Pabst et al., 2007).  
 Trafficking of ILCs to the mLN 
The location of ILC3-mediated regulation of intestinal CD4+ T cell responses has not yet 
been elucidated. We have published that CCR6+ ILC3 are capable of trafficking from the 
small intestine to the mLN, and this publication is included at the end of this thesis 
(Mackley et al., 2015). Given that migration of DCs to the mLN has been shown to be 




feasible that ILC3 within this LN may be similarly involved. Homing and entry of dendritic 
cells into lymph nodes depends upon their expression of the chemokine receptor CCR7 
(Forster et al., 2008) and the induction of tolerance to oral antigens is impaired in CCR7-/- 
mice (Worbs et al., 2006). In this investigation we demonstrate that, like dendritic cells, 
the ability of ILC3 to enter the mLN is dependent upon signalling through the chemokine 
receptor CCR7. Numbers of LTi-like ILC3 in the mLN of CCR7-/- mice were significantly 
lower than in WT controls, whilst numbers in the spleen did not notably differ. 
Interestingly, within the mLN this applied to the LTi-like ILC3 population alone, with 
populations of ILC1, ILC2 and NCR- ILC3 unaffected by the absence of CCR7. Although we 
could not detect CCR7 expression on the surface of ILC3 with our methods, a recent study 
has detected high levels of expression of this receptor on certain subsets of ILCs and in 
agreement with our investigation has found CCR7 to be important for ILC3, but not ILC2, 
entry into the mLN (Kim et al., 2015). In contrast to our findings, however, was the  
detection of an ILC1 dependency on CCR7 for entry into the mLN, in addition to 
differences in ILC populations within the SI of CCR7-/- mice (Kim et al., 2015) and further 
investigation would be required to address these differences.  
Whilst our experiments in mixed bone marrow chimeras demonstrated that the entry of 
LTi-like ILC3 into the skin-draining iLN appeared to be highly dependent upon 
cell-intrinsic CCR7 signalling, the mechanism of CCR7-dependent entry into the mLN was 
less clear. Although cell-intrinsic CCR7 signalling appeared to be required in part, and 
CCR6+ ILC3 from the mLN were found to be capable of migrating towards CCL21 in a 
CCR7-dependent manner, it is not clear that entry of these cells to the mLN does not also 
require some CCR7-dependent cell-extrinsic factors. The lymph nodes of CCR7-/- mice 




detected fewer CD4+ T cells within the mLN of CCR7-/- mice than in WT mice. Interestingly 
our data in RAG-/- and ZAP70-/- mice revealed that relatively few ILC3 can be detected 
within the mLN of T cell deficient mice, despite being the predominant ILC population in 
the mLN of WT mice. Analysis of T cell deficient iLNs suggested that this observation was 
specific to the mLN, so perhaps the presence of T cells in LNs is, by some unknown 
mechanism, required for ILC3 entry to mLNs in addition to cell-intrinsic CCR7 signalling. 
The data presented in this investigation shows clear similarities between the migratory 
behaviour of ILC3 and DCs. Whilst it is possible to conclude that the increased number of 
ILC3 within the mLN is as a result of trafficking of cells from the ILC3-enriched intestinal 
tissue, it must also be noted that ILC3 make up an even larger proportion of the total ILC 
population in mediastinal LNs (medLN) despite very few ILC3 residing within the lung 
(Spencer et al., 2014). Although these cells could migrate to the medLN from a different 
site—the medLN also drains the intraperitoneal cavity (Kool et al., 2008) for example, 
although it is not known that this area is enriched in ILC3—this perhaps indicates that the 
increased number of ILC3 in mucosal-draining LNs is not as a result of constitutive 
trafficking, or that this is tissue-specific. Either way, it is indicative of an increased 
requirement for these cells within LNs which drain barrier sites. 
It is not yet clear from this investigation whether CCR7-dependent entry of ILC3 into the 
mLN is a result of entry from the blood or lymph. As tissue-resident innate cells, entry of 
ILC3 through the lymph and lymphatic vessels would seem more likely, as has been 
established for DCs (Randolph et al., 2005). ILCs have been detected in human peripheral 
blood, although these are reported to be mostly ILC2 (Mjosberg et al., 2011), and it is 
possible that an ILC3 precursor population circulates in this way. A proportion of ILC3 in 




indicative of an ability of these cells to home to the gut should they enter the circulation 
(Kim et al., 2015). In addition the chemokine receptor CCR6, expressed by the majority of 
ILC3 in the LN, has been shown to be important for the homing of another RORγt-
expressing cell type, Th17 cells, to the small intestine (Esplugues et al., 2011), so it is 
possible that CCR6 may dictate the LN exit of these ILC3. Whether or not ILC3 transport 
antigen to the mLN has also not yet been established, despite their capacity to do so. 
Nonetheless the phenotype of group 3 ILCs within LNs certainly fits with this proposed 
function. Whilst a proportion of ILC3 within the gut express NKp46 (Vonarbourg et al., 
2010) and are classed as NCR+ ILC3, the vast majority of ILC3 in the lymph nodes that we 
analysed were NKp46- LTi-like ILC3, and this is indicative of a specific enrichment of this 
subset within the mLN. It has previously been reported that MHCII expression is found 
solely on those ILC3 which lack expression of NCRs (Hepworth et al., 2013) and as shown 
in our LN analysis a large proportion of LTi-like ILC3 within LNs do express MHCII, with 
the percentage highest in the mLN. Our study of CCR7-/- mLNs revealed that NCR+ ILC3 
did not depend upon signalling via CCR7 for LN entry, suggesting that it is primarily the 
LTi-like ILC3, and therefore the subset capable of expressing MHCII, which traffic in a 
manner similar to DCs. Whether or not migration of these cells is instigated by the 
acquisition of antigen or other signals still needs to be explored. 
Although ILC3 have been shown to regulate CD4+ T cell responses by inducing apoptosis 
in a MHCII-dependent manner (Hepworth et al., 2015) it is possible that ILC3 could also 
carry out this function by additional mechanisms. It is, for example, possible that these 
cells could regulate some CD4+ T cell responses by inducing Tregs. ILC3 have previously 
been shown indirectly promote support of Tregs through their production of CSF2 and 




have been shown to sit within close proximity to FoxP3+ Treg cells (F. McConnell, 
unpublished observations). Although Hepworth et al (2013) did not detect impaired Treg 
function which could account for the dysregulation of T cell responses seen in MHCIIΔILC3 
mice this was not analysed in an antigen-specific manner (Hepworth et al., 2013). Either 
way, from our findings and those of other groups it seems feasible that increased numbers 
of ILC3 reside in LNs which drain mucosal sites so as to limit immune responses to 
harmless antigen. 
 Is the mLN a more favourable environment for ILC3? 
One striking observation made of mLN-resident ILC3 in this study is their resistance to 
irradiation. The radiation-resistance of LTi cells has previously been documented in the 
thymus (Dudakov et al., 2012), but in this study LTi-like ILC3 in the mLN, but not skin-
draining iLN or spleen, were found to be resistant to irradiation. It is feasible that this is 
due to a lack of LTi-like ILC3 proliferation, and certainly data from our group points 
towards these cells having a low rate of turnover (D. Withers, unpublished observations). 
Revealingly this suggests that, despite their similar phenotype, LTi-like ILC3 may have 
different properties depending on their location. Whether or not this reflects differences 
in the ILC population themselves, or is the result of variations in signals received in 
different LNs should be explored further. Some mLN stromal cell populations have been 
reported to be fundamentally different to those found in peripheral LNs. Stromal cells 
within the mLN have been shown to produce more retinoic acid (RA), a metabolite which 
has been shown to contribute to the induction of a gut-homing phenotype on T cells; a 
role that peripheral LNs cannot emulate, even if transplanted into the mesentery 
(Hammerschmidt et al., 2008). Whether or not differences such as this accounts for the 




remains to be seen. RA, for example, has been shown to be important for the maintenance 
of ILC3s in the SI, with numbers of ILC3 diminished in mice where RA signalling is 
inhibited (Spencer et al., 2014). It is possible that increased levels of this molecule within 
the mLN in part contributes to ILC3 persistence at this site. Signalling by RA has also been 
shown to affect the proliferative capacity of ILC3 within the SI, although in this case 
resulting in a higher proportion of ILC3 proliferating (Spencer et al., 2014) and therefore 
does not support our hypothesis of a low rate of turnover providing resistance to 
irradiation. Nonetheless, it is not clear whether this is the case in the mLN. It would 
therefore be of interest to understand more of ILC cross-talk with LN stromal cells, as such 
interactions could affect the properties of ILCs and stromal cells alike. On a separate note, 
this persistence of LTi-like ILC3 even following irradiation may well be beneficial to the 
host following medical interventions such as chemotherapy, where the development of 
intestinal mucositis and loss of epithelial barrier integrity can be a problem (Pico et al., 
1998).  
6.2 LOCATION IN LNS PROVIDES OPPORTUNITIES FOR ILC SUBSETS TO 
INFLUENCE AN ADAPTIVE IMMUNE RESPONSE 
 ILC3 cluster in interfollicular areas and at the B-T interface 
Determining the location of cells in LNs using immunofluorescence microscopy provides 
an invaluable insight into their potential functions. LTi cells have previously been shown 
to cluster in the interfollicular regions of murine mLNs (Withers et al., 2012) and we 
looked at this observation in more detail in this study. Within the mLN clusters of ILC3 
could be detected within interfollicular areas and at the interface between B cell follicles 
and the T cell-dominated area. An possible explanation for their location at these sites has 




which attracts cells to the B cell follicles, and CCR7, which attracts cells to the paracortical 
zone (Lane et al., 2009). We found that a proportion of ex vivo overnight cultured ILC3, 
but not ILC2, expressed CXCR5. CCR7 expression by group 3 ILCs, although not detected 
using our methods, has been previously reported at the mRNA level (Kim et al., 2008). The 
ability of some ILC3 to migrate towards a ligand of CCR7 was demonstrated within this 
study, although to a much lesser extent than CD4+ T cells. It is still not clear whether or 
not these chemokine receptors dictated the location of these cells, however in the absence 
of CCR7 ILC3 do not reside within LN B cell follicles (D. Withers unpublished 
observations), and it is possible instead that the chemokine CCR6, expressed by LTi-like 
ILC3, plays a role.  
It is within these ILC-enriched interfollicular regions and further into the parcortical zone 
that high endothelial venules (HEVs), the vessels which facilitate lymphocyte entry into 
LNs from the blood, can be found. Naïve CD4+ T cells enter LNs through HEVs to sample 
antigens presented by APCs before leaving through the efferent lymph to re-circulate to 
other lymphoid tissues (von Andrian and Mempel, 2003). ILC3 clustering at this site could 
therefore have the opportunity to interact with these cells through MHCII, as discussed 
above, or by other mechanisms. This location also puts ILC3 in a position to interact with 
other lymphocytes, such as re-circulating, long-lived memory CD4+ T cells. When an 
adaptive immune response is initiated a small population of responding lymphocytes will 
persist long after pathogen clearance to become memory cells. These long-lasting cells are 
capable of mounting a rapid but specialised adaptive immune response should the same 
threat be detected again (Sprent, 1997). Although the survival of memory CD4+ T cells is 
thought to be independent of MHCII (Swain et al., 1999), and as a result antigen re-




memory T cell responses (Kassiotis et al., 2002), possibly by serving as a mechanism to 
bring cells together for the provision of other signals. LTi cells have already been shown 
to be important in supporting CD4+ memory T cells in mice (Withers et al., 2012), although 
the mechanism by which they do this is not known, and it would be interesting to explore 
whether memory CD4+ T cell responses are impaired in MHCIIΔILC3 mice.  
This location also provides ILC3 with the opportunity to interact with APCs which enter 
LNs through the afferent lymph (Braun et al., 2011). It is possible that ILCs could influence 
cells of the innate immune system through the release of cytokines or by direct 
interaction, and that this in turn could influence the result of an adaptive immune 
response. Certainly, ILC2-derived cytokine has previously been shown to induce DC 
migration to draining LNs and indirectly promote the generation of a Th2 response (Halim 
et al., 2014). Whether cytokine-mediated effects can be exerted by ILCs residing within 
the LNs is unclear. This striking location therefore provides ILC3 with the opportunity to 
interact with a wide range of different cells, whether of the adaptive immune system or 
the innate. 
 ILC2 and ILC3 co-localise in mLN tissue 
Within this study ILC2 were identified in LN tissue by their expression of GATA-3 and 
ILC2-associated surface markers. ILC2 could be found within the same regions as ILC3, 
although they were comparatively fewer in number within the mLN tissue and this 
analysis did not exclude the possibility that they also located elsewhere. The proximity of 
these two subsets in LNs perhaps provides an opportunity for cross-talk, although this 
has not been demonstrated in this investigation. It is also possible that ILC2 and ILC3 are 




that vitamin A deficiency in mice results in impaired ILC3 responses, but increased 
numbers of ILC2 in the small intestine. This was found to be in part due to an increased 
responsiveness of ILC2 to IL-7 signals (Spencer et al., 2014). Although previously shown 
to be expressed mostly by reticular cells in the T cell zone (Link et al., 2007), IL-7 has also 
been found to be generated by lymphatic endothelial cells (LECs) which are enriched in 
the interfollicular regions of LNs (Onder et al., 2012), so it is possible that these two 
populations of ILCs are in competition for this cytokine. Certainly, during this 
investigation there have been several occasions when a reduction in the number of ILC3 
within LNs has been associated with an increase in the number of ILC2. Very few ILC3 
were detected specifically within the mLNs of RAG-/- and ZAP-70-/- mice, and this was 
accompanied by higher numbers of ILC2 than those seen in WT mice. The same was true 
of RORγt-/- chimeric mice, where mice lacked RORγt-expressing cells and as a result had 
no ILC3. Whilst in bone marrow chimeric mice this could be attributed to differences in 
the development of ILCs from bone marrow progenitor cells in the absence of RORγt, 
RAG-/- mice were found to have similar proportions of ILC2 and ILC3 in iLNs, suggesting 
that this was a mLN-specific effect and not related to development. The reason for a bias 
towards ILC2 in these mice is still unknown, however our data is consistent with there 
being a relationship between numbers of these two subsets. This would be interesting to 
investigate further, particularly if differences in ILC subsets within these areas could have 
an effect on the progression and shaping of an immune response. 
 Interfollicular microenvironment differs between peripheral and mucosal 
draining LNs 
In this study, this interfollicular microenvironment was found to be notably different in 




interfollicular areas of skin-draining peripheral popliteal (popLN) and inguinal LNs (iLN) 
quantitative analysis revealed that, in contrast to the mLN, many of these cells expressed 
CD3 and were therefore T cells. In this study differences were detected in the RORγt+ T 
cell types present in mLNs and pLNs, which may account for this observation, and a 
number of RORγt-expressing T cell populations have been reported in the skin.  Alongside 
ILC3, RORγt+ γδ T cells been shown to be important sources of IL-17 in a murine model of 
psoriasis (Pantelyushin et al., 2012), and populations of RORγt+ invariant NKT (iNKT) 
cells have been shown to reside in the skin whilst a phenotypically similar iNKT cell 
population can be detected in peripheral LNs (Doisne et al., 2009). What is striking is the 
correlation between the expression of the transcription factor RORγt and location of cells 
to the interfollicular area. This can perhaps be explained by an increased requirement for 
IL-7 signalling, as RORγt-expressing cells within the interfollicular areas of LNs in this 
study mostly expressed high levels of IL-7Rα. IL-7 has been shown to be produced by 
LECs, which are enriched in interfollicular areas of LNs and this was proposed to provide 
essential homeostatic survival signals to nearby IL-7Rα+ cells (Onder et al., 2012). 
Certainly LTi cell survival in adult tissue has been shown to be supported by signalling by 
this cytokine (Schmutz et al., 2009), and the importance of this signalling may provide an 
explanation as to why these cells cluster at this location. Another reason could be 
expression of the chemokine receptor CCR6. CCR6 expression by subsets of group 3 ILCs 
is well-established (Klose et al., 2013), and we have shown that ILC3 in LNs are 
predominantly CCR6+. CCR6 expression has also been documented on populations of 
RORγt-expressing T cells, such as CD4+ Th17 cells (Esplugues et al., 2011) and RORγt+ 
iNKT cells (Doisne et al., 2009). Transcriptional profiling of lymph node LECs has shown 




therefore migration towards these sites could be instructed by this, although analysis of 
LNs from CCR6-deficient mice would give further indication. 
6.3 ILC POPULATIONS IN A DRAINING LN 
The position of these cells at the interfollicular regions and interface between B cell 
follicles and T cell zone (B-T interface) of lymph nodes also places them in a position to 
participate in an immune response. One hypothesis for our initial observation of 
numerous ILC3 within the mLN was that this reflected the phenotype of an ‘activated’ LN, 
given that the mLN is likely exposed to a larger amount of antigen than its skin-draining 
counterparts. Draining lymph node models therefore enabled us to analyse whether ILC 
populations of ‘activated’ peripheral LNs increased in number, and to characterise these 
cells to see whether, and by what manner, they could influence this immune response. 
Both group 2 and group 3 ILCs, like DCs, have been shown to express MHCII and be 
capable of presenting peptide to CD4+ T cells (Oliphant et al., 2014, Hepworth et al., 2013, 
von Burg et al., 2014). The immunological result of this presentation is however likely to 
be highly dependent on their expression of the co-stimulatory molecules CD80 and CD86, 
although a potential role for others, such as OX40L and CD30L (Kim et al., 2005), which 
were not analysed in this study should not be excluded. Whilst ILC3 in the mLN have been 
shown to lack expression of CD80 and CD86, and MHCII+ ILC3 in the gut suppress CD4+ T 
cell responses to commensal bacteria (Hepworth et al., 2013), ILC3 derived from the 
spleen and cultured in IL-1β have been shown to be capable of expressing moderate levels 
of CD80 and CD86 and inducing the proliferation of CD4+ T cells in an antigen-specific 
manner (von Burg et al., 2014). Similarly ILC2 expressing MHCII have been shown to be 
able to induce CD4+ T cell proliferation in vitro (Oliphant et al., 2014). Little is known of 




established whether ILCs in these LNs express co-stimulatory molecules at steady state 
or following immunisation. In this investigation we sought to assess the ILC response to 
immunisation in the paw pad by looking at quantitative and phenotypical changes in ILC 
populations in the draining axillary and brachial LNs (aLN, bLN). 
We found ILC3 to constitute a lower proportion of total ILCs within skin-draining inguinal 
and brachial LNs (bLN) than in the mLN or medLN. The discovery of ILCs in the skin is 
relatively recent and comparatively less has been published on their function in this tissue 
compared to the gut, likely in part a result of the difficulties associated with isolating cells 
from the skin. ILC2 have been reported in the skin of both mice and humans (Kim et al., 
2013, Roediger et al., 2013) and these cells have been shown to be enriched in patients 
with a type 2 inflammatory skin disorder (Salimi et al., 2013). Whilst ILC3 have also been 
reported in the skin (Pantelyushin et al., 2012, Villanova et al., 2014) the general ILC bias 
in this tissue is thought to be skewed towards GATA-3+ ILC2 (Spencer et al., 2014).  
Interestingly in this investigation we do not see this ILC2 bias reflected in either the skin-
draining LNs or the medLN—which drains the lung—at steady state, although large 
numbers of ILC2 have been reported to accumulate within the medLNs of mice following 
intranasal administration of IL-33 (Wolterink et al., 2012).  
 ILCs accumulate in a draining LN but are atypical APCs 
Activated DCs have been shown to arrive within a peripheral draining LN (dLN) within 
one day of stimulation of the skin (Tomura et al., 2014) and in our study numbers of both 
ILC2 and LTi-like ILC3 were found to be moderately increased in dLNs at this timepoint 
when compared to controls. Although a proportion of both ILC2 and LTi-like ILC were 




similar percentages observed in both dLNs and control. Although co-stimulatory 
molecules could be detected on the surface of some MHCII+ ILC2 and ILC3, the level of 
expression was notably lower than that detected on professional APCs. Even following 
accumulation, these ILCs were relatively few and the low levels of CD80 and CD86 on their 
surface makes it seem unlikely that these cells could efficiently contribute to the priming 
of naïve CD4+ T cells at this timepoint. This finding fits with the description of these cells 
as atypical APCs (Kambayashi and Laufer, 2014), as opposed to cells which could replace 
the function of DCs. 
ILC number increased most notably at later timepoints analysed, perhaps indicating that 
these cells play a role following the initial establishment of the immune response. 
Deficiency of ILC3 has previously been shown to have no effect of primary CD4+ T cell 
responses in the spleen (Withers et al., 2012), although analysis of numbers of responding 
CD4+ T cells in pLNs of MHCIIΔILC3 mice six days following immunisation has previously 
shown some evidence of dysregulation of T cell responses in the absence of MHCII-
mediated ILC3 signalling (Mackley et al., 2015). Whether or not this increase in the 
number of ILC3 is simply a result of LN expansion or could be related to a role at these 
later timepoints, such as the provision of signals to T cells which will go on to become 
memory cells, was unclear but would be interesting to investigate further. Although there 
was an increase in the number of ILC3 in draining peripheral LNs, it was not clear that 
these now resembled the mLN. Although ILC3 can still be detected within the 
interfollicular areas of draining peripheral LNs (E. Mackley, unpublished observations) it 
was difficult to make any conclusions due to their scarcity in the enlarged LN. Repeated 
exposure of a peripheral LN to antigen would perhaps be a better test of this hypothesis, 




Although we detected an increase in the number of ILCs in a draining LN the number of 
ILC2 detected in the dLNs across the entire timecourse was still low. Despite the adjuvant 
used, aluminium hydroxide, being known to promote a robust type 2 immune response 
(Lindblad, 2004) the increase in number of ILC2 observed in the dLN following 
immunisation with alum-ppt NP-OVA was moderate across all timepoints, yet ILC2 have 
previously been reported to accumulate in the medLNs during an immune response to 
intranasal administration of OVA (Wolterink et al., 2012). It is possible that the mild 
increase seen could be a result of ILC2 not participating in dLN immune responses from 
the skin, or perhaps that our method of immunising was not well targeted to this 
population. 
 Mechanism of ILC accumulation in draining LNs suggests trafficking 
We sought to determine whether the increases in numbers of ILCs could be related to 
trafficking from the tissue, as has been shown in the gut (Mackley et al., 2015). No 
increased proliferation was detected in any population of ILC which could account for the 
increased numbers of ILCs seen, despite ILC2 having previously been shown to proliferate 
in response to T cell-produced IL-2 (Oliphant et al., 2014). This raised the possibility that 
ILCs may traffic into the dLNs from other sites. Unlike in the mLN where, in this study, 
only LTi-like ILC3 displayed a CCR7-dependency, all ILCs are lower in the skin-draining 
iLN of CCR7-/- mice and this was also found to be true in CCR7-/- axillary and brachial LNs 
at steady state. It is not clear that other populations of ILCs in this tissue express high 
levels of CCR7, nor has the expression of this molecule by ILCs been explored at many 
different sites. In keeping with a hypothesis of cell trafficking in a CCR7-dependent 
manner, no accumulation of ILCs was detected in the dLNs of CCR7-/- mice following 




experiments in this study have shown that the inability of CCR7-/- ILC3 to enter the resting 
iLN was at least in part a cell-intrinsic defect, and this likely also applies to the aLN and 
bLN, whether or not cell-intrinsic CCR7 signalling is required for ILC3 entry following 
immunisation still remains to be seen. 
An immunisation experiment in CD80-/-CD86-/- mice gave similar results, with ILCs failing 
to accumulate in the dLN in the absence of CD80 and CD86. Given the low expression of 
these molecules detected on the surface of ILCs in this tissue, it seems unlikely that this is 
a direct effect of loss of CD80 and CD86 expression on these cells. One factor that 
experiments in CCR7-/- and CD80-/-CD86-/- mice had in common was a lack of a T cell 
response within the draining LN. In CCR7-/- mice very little expansion of an adoptively 
transferred antigen-specific population of CD4+ T cells was detected, despite these cells 
themselves being CCR7-sufficient and thus capable of entering the LN. This was most 
likely due to impaired CCR7-/- DC migration to the draining LN (Forster et al., 2008, Braun 
et al., 2011) and the subsequent lack of T cell priming. CD80-/-CD86-/- mice were similarly 
unable to mount a CD4+ T cell response, in this case likely because of the lack of essential 
co-stimulatory signals following antigen-presentation. It is therefore possible that a T cell-
derived signal is required to instruct ILC increase in LNs, and could explain why ILC 
increase was primarily at later timepoints in an immune response. ILC2 have previously 
been shown to respond to T cell-produced IL-2 and cross-talk with T cells has been 
demonstrated to be important for their function. (Oliphant et al., 2014, Mirchandani et al., 
2014). IL-2 has also been shown to induce the proliferation of ILC2 in the spleen of 
RAG-1-/- mice (Roediger et al., 2013), however these findings do not explain the results of 
our study, where no increased ILC proliferation was detected even in the presence of an 




mLN has been discussed previously, and it is possible that the abrogation of a T cell 
response in draining peripheral LNs is responsible for the phenotype seen. It is, however, 
not clear from these studies whether draining LNs in CCR7-/- and CD80-/-CD86-/- mice 
undergo normal processes, such as LN shutdown. Following activation, egress of activated 
lymphocytes is prevented for a period of time (Cyster and Schwab, 2012). It is not clear 
whether or not populations of ILC are also prevented from leaving LNs during this time. 
Should normal LN shutdown not occur in the dLNs of CCR7-/- and CD80-/-CD86-/- mice then 
this could provide further explanation for the lack of ILC accumulation detected.  
6.4 ROLE OF ILC3 IN A PRIMARY CD4+ T CELL RESPONSE 
 ILC3-deficiency does not impair expansion of CD4+ T cells in a primary 
immune response 
Lymph nodes are important for the generation of CD4 T cell responses, confining all cells 
required to mount a response to a defined site and maximising the opportunities for re-
circulating CD4+ T cells to sample a large number of different antigens (von Andrian and 
Mempel, 2003). Data from our group has previously shown that support for populations 
of CD4+ T memory cell is impaired in mice which lack LTi cells, however the effects of 
these cells on CD4+ T cell responses in LNs was not explored (Withers et al., 2012). We 
have shown that ILC3 sit in regions of LNs which are exposed to large numbers of naïve 
CD4+ T cells, as well as CD4+ T cells taking part in an immune response. Additionally we 
have observed that populations of ILC can increase in a draining LN following 
immunisation, potentially indicative of a role in this immune response. A bone marrow 
chimera method was therefore used to investigate whether loss of ILC3 had any impact 




Analysis of an antigen-specific CD4+ T cell response in the absence of RORγt-expressing 
cells following immunisation revealed that CD4+ T cell numbers were similar to those in 
WT controls. In addition to this, no evidence of increased T cell dysregulation, in terms of 
the expression of markers associated with T cell activation, could be found. Whilst these 
data suggest that RORγt-expressing cell types, including ILC3, are not required for the 
mounting of a primary CD4+ T cell response in peripheral LNs, this investigation has not 
explored other elements of a CD4+ T cell response, for example the phenotype of these T 
effector cells. This, and other studies into the function of these cells, would benefit from 
more sophisticated ILC3-depletion models which have recently been developed.  
 Models to analyse ILC function 
Innate lymphoid cells are a part of a fast-growing field of research and, as such, new 
advances are made often. The development of mouse models which enable the effective, 
selective targeting of these populations will revolutionise research into the functions of 
these cells. Up until recently most analysis of immune responses in the absence of ILC 
subsets has had to rely upon the use of bone marrow chimeras or studies in T cell deficient 
mice (Withers et al., 2012). This is largely due the similarity of ILCs to other cell types, in 
their expression of transcription factors and surface markers, and the subsequent 
difficulties in specifically targeting these cells without affecting others. Advances in the 
field have led to the development of elegant mouse models where populations of ILCs, or 
specific molecules on these cells, can be genetically deleted, either constitutively or in an 
inducible fashion.  
MHCIIΔILC3 mice, where only ILC3 lack the expression of MHCII, provide a good example 




recombination technology. By crossing floxed H2-Ab1 mice with those that express a Cre 
recombinase under the control of the Rorc promoter, they created a strain of mice where 
expression of RORγt resulted in the deletion of the gene which results in MHCII expression 
(Hepworth et al., 2013). This ILC3-specific targeting left MHCII expression by other APCs 
comparable to that in controls, and did not affect the embryonic lymphoid tissue inducing 
functions of cells within this group (Hepworth et al., 2013). Using these mice it would be 
of interest to investigate the role of ILC3-expressed MHCII in a range of different LNs, not 
just the mLN, and through all stages of a CD4+ T cell response; from initial priming to the 
maintenance of and response of memory cells.  
Although details of mouse models in which ILC3 are genetically and selectively deleted 
have not yet been published, such models exist for ILC2. Oliphant et al (2014) use an ILC2-
deficient mouse in which a floxed diphtheria toxin (DT) receptor is expressed in the place 
of the gene for inducible T cell co-stimuator (ICOS) protein. This results in those cells 
which ordinarily express ICOS now expressing a receptor for DT, uptake of which results 
in the death of the cell. Although ICOS is also expressed by T cells, and thus ordinarily this 
would result in the DT-mediated deletion of both ILC2 and T cells, the authors 
circumvented this by including a gene for Cre recombinase expression which is activated 
in the event of expression of CD4; therefore those cells in which CD4 expression has been 
switched excise the gene for DT receptor expression and are no longer deleted upon 
administration of DT. As ILC2 do not express CD4, but all T cells will upregulate this 
marker at some stage during development (Germain, 2002) this results in a mouse model 
where ILC2 are selectively deficient (Oliphant et al., 2014). One of the advantages of this 
system is that it can be induced with the administration of the toxin, thereby allowing 




The growing use of photo-convertible fluorescent proteins in mouse models, where cells 
can be ‘tagged’ and their migration analysed (Morton et al., 2014, Tomura et al., 2014), 
could be an effective way to study whether ILCs are recruited from the skin to the LN in 
our draining LN model, and whether they then leave and re-circulate to other sites. 
Indeed, these models have already proved a useful tool in studying ILC3 migration from 
the small intestine to the mLN (Mackley et al., 2015). The tagging of cells could also 
provide answers as to whether ILCs in LNs at different sites are in fact distinct 
populations, or widely re-circulating cells.  The migratory capacity of these cells could also 
be investigated using surgical methods, such as cannulation of lymph, to determine 
whether CCR7-dependent entry of ILCs to LNs is as a result of trafficking through the 
lymph or blood. Additionally, the location of these cells near the exterior of LNs lends itself 
to analysis using multi-photo microscopy methods to reveal specific interactions of ILCs 
within the interfollicular area. 
Most importantly, these methods will enable the role of ILCs in immune responses, and 
the specific mechanisms by which they act, to be elucidated. Discovery of whether or not 
MHCII+ ILC3 carry out their regulation of CD4+ T cell responses in the gut or in the draining 
mesenteric LN will fundamentally contribute to our knowledge of tolerance to commensal 
antigens (Hepworth et al., 2015). Expression of MHCII has been reported on human ILC3 
(Hepworth et al., 2013) and found to be lower on ILC3 from patients with pediatric 
Crohn’s Disease when compared to controls (Hepworth et al., 2015). With a better 
understanding of the role of these cells in tolerance and the prevention of inappropriate 
inflammatory responses in the gut, it is possible that these cells could become future 
therapeutic targets to treat immune-mediated pathologies. Given our observation of 




population could be useful in the treatment of mucositis, and it would be important to 
investigate whether the same phenotype is true of ILC3 within the gut. Finally, it is 
important that we understand the ways in which adaptive immune responses are initiated 
and shaped in order to be able to manipulate them beneficially ourselves.  
6.5 CONCLUDING REMARKS 
Within this investigation I have extensively characterised ILCs within a range of different 
LNs at steady state and following immunisation, which will provide the foundation for 
further experiments which can specifically elucidate their function within these 
structures. The observed enrichment of LTi-like ILC3 in mucosal tissue-draining LNs is 
indicative of an increased requirement for these cells in LNs which drain barrier sites, and 
which are regularly exposed to antigen. Our finding that the majority of ILC3 within the 
mLN express CCR6 and MHCII, and thus resemble those cells shown to regulate CD4+ T 
cell responses in the gut, suggests that ILC3-mediated tolerance could take place in the 
mLN. Consistent with this, we show that LTi-like ILC3 entry to this tissue, like that of DCs, 
is dependent upon CCR7 signalling and that once within mLNs ILC3 cluster in 
interfollicular regions to create a microenvironment which is not detected in peripheral 
tissue-draining LNs. It is therefore feasible that the increased numbers of ILC3 in mucosal 
tissue-draining LNs serves to limit immune responses to commensal microorganisms and 
harmless antigens. 
 Although ILC populations are less numerous in peripheral LNs we show that they 
accumulate in these tissues following local immunisation. The observation that this 
accumulation was not as a result of ILC proliferation within the LN could be seen as 




draining LNs of CCR7-deficient mice suggests that this chemokine receptor is involved, 
although whether this is a cell intrinsic effect or due to extrinsic factors remains to be 
seen. Given that MHCII and low levels of CD80 and CD86 could be detected on the surface 
of some ILCs in peripheral LNs, it seems likely that the role of these cells in adaptive 
immune responses is dependent upon both the site and circumstances of immunisation. 
Nonetheless, it is not clear that these ILCs are comparable antigen-presenting cells to DCs. 
Given their rarity and low level expression of co-stimulatory molecules in the peripheral 
LNs analysed, it seems unlikely that these cells are efficient at priming naïve CD4+ T cells 
during an immune response and, consistent with this, our data indicates that numbers of 
CD4+ T cell cells in a primary LN response are not impaired by a deficiency in ILC3. Further 
experiments, using new mouse models which selectively target ILC function, are however 
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